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 ABSTRACT 
Iron is a critical micronutrient required for nearly all organisms to live.  It is an 
important cofactor in proteins involved in DNA replication, cellular energy production, 
and oxygen transport.  Nonphysiological levels of iron have pathological consequences 
ranging from iron deficiency that affects billions worldwide, to the iron overload disorder 
Hereditary Hemochromatosis that causes debilitating organ failure.  Considering the dual 
nature of iron in healthy and diseased states, organisms have evolved elegant mechanisms 
to regulate iron homeostasis.  This thesis examines the cellular mechanisms involved in 
controlling cellular iron uptake and storage, and highlights the importance of iron in the 
innate immune response and endocrine function of the mammalian pancreas.  
Using C. elegans as a model to study iron metabolism, we show that the nuclear 
receptor, NHR-14, is a potent repressor of intestinal iron uptake through the iron importer 
SMF-3.  In addition to iron import, NHR-14 regulates a transcriptional response to 
bacterial infection that is dependent upon the insulin/IGF-1-like signaling (IIS) pathway 
transcription factor PQM-1. 
In mammals, cellular iron is maintained by the Iron Regulatory Proteins (IRPs).  
Mice lacking Iron Regulatory Protein 2 (IRP2) were shown to develop fasting 
hyperglycemia as a result of defective insulin biosynthesis that likely stems from 
mitochondrial dysfunction and Endoplasmic Reticulum (ER) stress. 
I wish to dedicate this thesis to my parents, Dennis and Pamela, and sister, Paige.  
Through all their unconditional love and encouragement, none of this would have been 
possible.   
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 CHAPTER 1 
AN INTRODUCTION INTO IRON HOMEOSTASIS 
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The first law of thermodynamics states that energy cannot be created nor 
destroyed; energy can only be transferred or changed from one form to another.  
Similarly, for our purposes here on Earth, iron is neither created or destroyed but 
transitions from one oxidation state to another.  Elemental iron on Earth was created 
billions of years ago by large and extremely hot stars through the silicone burning 
process.  Through these celestial processes, iron became the 4th most abundant element 
on Earth and an absolute requirement for life.  Hence, iron is incorporated in 
hemoproteins, Fe-S cluster proteins, and enzyme catalytic sites that are essential for many 
biological processes, including DNA replication, mitochondrial energy production, and 
oxygen transport.   
The biological dependency on iron has not come without evolutionary challenges 
for its regulation.  Iron bioavailability is restricted due to rapid oxidation and hydrolysis 
in the environment, and limited solubility causes problems for acquisition and transport.  
Defects in iron homeostasis can have severe pathological consequences, ranging from 
iron deficient anemia that affects a third of the world’s population to iron overload 
disorders that can cause significant organ failure (Clark, 2008; Papanikolaou and 
Pantopoulos, 2005).  Thus, the dual nature of iron has resulted in the evolution of unique 
mechanisms to acquire, transport, and store iron.  The following is an overview of the 
mechanisms that regulate iron metabolism in both C. elegans and mammals with roles 
that extend into host-pathogen interactions and glucose homeostasis.  Specifically, I 
highlight the conservation of iron metabolism between C. elegans and mammals.  
Readers are directed to Chapters 1 and 3 for detailed reviews on mechanisms of iron 
metabolism in C. elegans and mammals, respectively (Anderson and Leibold, 2014; 
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Anderson et al., 2012).  Several topics that I consider relevant background for Chapters 2 
and 4 will also be discussed in this introduction.  For Chapter 2, this includes nuclear 
receptor signaling, innate immune mechanisms, and the insulin/insulin-like growth factor 
pathway in C. elegans.    Lastly, models of IRP2 deficiency, iron in diabetes, and 
mitochondrial and ER perturbations that lead to impaired glucose metabolism will be 
reviewed as background for Chapter 4. 
 In human adults, approximately 3-4 mg of dietary iron is absorbed at the apical 
membrane of duodenal enterocytes by divalent-metal transporter 1 (DMT1) after being 
reduced by ferrireductases such as duodenal cytochrome B (DCTYB).  Within the cell, 
ferrous iron comprises the labile iron pool where it is utilized as a cofactor in proteins for 
key cellular processes, stored into the iron storage protein ferritin, or transported across 
the basolateral membrane into circulation by ferroportin.  Circulating iron is quickly 
bound by transferrin (Tf) and delivered to cells expressing transferrin receptor 1 (TfR1), 
such as maturing red blood cells.  Tf-Fe-TfR1 complexes are internalized by receptor-
mediated endocytosis.  Acidification of the endosome releases Fe3+ from these complexes 
where it is reduced and exported across the endosomal membrane into the cytoplasm by 
STEAP3 and DMT1, respectively.  
 Since a regulated process of iron excretion has yet to be discovered, sloughing of 
intestinal enterocytes every 3 days is the only mechanism of iron efflux from the body.  
Therefore, precise control of intestinal iron uptake and storage is needed to maintain iron 
homeostasis throughout the body.  It is not surprising due to the importance of iron that 
many genes involved in iron homeostasis are conserved across metazoa.  Indeed, there is 
a high degree of conservation between iron metabolic genes in C. elegans and mammals 
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(Anderson and Leibold, 2014).  The intestine is one of the major organs of C. elegans, 
roughly comprising one third of the entire somatic mass of the worm (Kormish et al., 
2010).  Similar to vertebrates, iron absorption in C. elegans occurs at the basal brush 
boarder of intestinal enterocytes by SMF-3, the principal ferric iron transporter 
(Bandyopadhyay et al., 2009).  The worm also expresses two DMT1-like transporters, 
SMF-1 and SMF-3 that share 55-58% amino acid identity with DMT1.  Their role in iron 
uptake is limited compared to SMF-3, however, they appear to act as key regulators of 
manganese transport and the response to pathogenic bacteria (Au et al., 2009).  The 
transport across the apical membrane to the interstitial space and other organs is not well 
understood.  Worms do however express three ferroportin orthologs (FPN-1.1-1.3) that 
likely transport iron in a similar fashion as mammalian ferroportin. 
 The ferritin orthologs FTN-1 and FTN-2 are responsible for storing ferric iron in 
C. elegans, a form that is unable to generate free radicals.  Interestingly FTN-1 and FTN-
2 both exhibit ferroxidase activity that is a specific feature of the heavy subunit (FTH) of 
mammalian ferritin.  The light subunit (FTL) on the other hand is responsible for iron 
nucleation that results in a core or shell that can store up to 4500 Fe3+ atoms.  Ferritin is 
ubiquitously expressed, and in C. elegans FTN-1 is highly enriched in the intestine while 
FTN-2 is expressed in many tissues that include the pharynx, hypodermis, body-wall 
muscle, and intestine.  Essential for maintaining proper iron balance, uptake, and storage 
are tightly regulated processes and are carried out by very distinct mechanisms in C. 
elegans and mammals.   
 In C. elegans, iron homeostasis is predominantly regulated transcriptionally by 
the basic helix-loop-helix (bHLH) transcription factor hypoxia inducible factor 1 (HIF-1).  
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The lability of hypoxia inducible factors (HIF-1α and HIF-2α in mammals, HIF-1 in C. 
elegans) in response to oxygen tension is well known, however their sensitivity to iron is 
often overlooked.  During iron deficiency, HIFs are stabilized due to reduced activity of 
the oxygen and iron dependent prolyl hydroxylase (PHD) (Peyssonnaux et al., 2007).  
Our lab has shown that stabilized HIF-1 during iron deficiency transcriptionally activates 
SMF-3 while simultaneously repressing FTN-1 and to a lesser degree FTN-2 to increase 
iron uptake and reduce storage (Romney et al., 2008, 2011a).  A similar mechanism 
occurs in mammals, where HIF-2α activates the transcription of DMT1, FPN1, and 
DCYTB in the intestine to increase iron absorption (Mastrogiannaki et al., 2009). 
In mammals, cellular iron metabolism in maintained by Iron Regulatory Proteins 
1 and 2 (IRP1 and IRP2) (Anderson et al., 2012).  The IRPs are RNA binding proteins 
that bind with high affinity to specific stem-loop structures called Iron Response 
Elements (IREs) present in the 5’ and 3’ untranslated regions (UTRs) of target mRNAs 
that mediate their translational efficiency or stability.   IRPs bind to IREs in the mRNAs 
involved in iron uptake (TfR1), sequestration (FtH and FtL) and export (FPN).  During 
iron deficiency the IRPs bind to 5’ IREs in ferritin and ferroportin to repress their 
translation, and to 3’ IREs in TfR1 to stabilize its mRNA.  During normal iron conditions 
the IRPs bind to cognate IREs at a low affinity, which enables enhanced translation of 
ferritin and ferroportin, and mediating TfR1 mRNA instability and degradation.  In 
essence, IRPs are responsible for increasing iron uptake and reducing storage during iron 
deficiency, and vice versa when iron levels are high.  In addition to mRNAs involved in 
iron metabolism, the IRPs regulate expression of mRNAs involved in diverse biological 
processes, all of which rely on proper iron levels.  These IRE containing mRNAs include; 
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aconitase (TCA cycle), erythroid aminolevulinate synthase (heme biosynthesis), HIF-2α 
(hypoxia), MRCKα (cytoskeletal dynamics), and CDC14a (mitosis) (Sanchez et al., 
2011).  IRPs themselves are also iron regulated, but in two distinct ways.  IRP1 contains 
a 4Fe-4S cluster that enables it to perform as a bifunctional protein.  Iron promotes 
assembly of the 4Fe-4S cluster that results in its conversion from an RNA-binding 
protein to a cytosolic aconitase.  IRP2 on the other hand is targeted by a iron-regulated 
ubiquitin ligase (FBXL5) for proteasomal degradation (Salahudeen et al., 2009; Vashisht 
et al., 2009). 
 In Chapter 2, I discuss the identification and characterization of the nuclear 
hormone receptor 14 (NHR-14) as a novel regulator of iron metabolism and innate 
immunity.  Nuclear receptors (NRs) are a hallmark of metazoan evolution that comprises 
a highly specialized family of ligand gated transcription factors.  Family members can 
bind ligands such as vitamins, fatty acids, and steroids; and are tasked with the 
coordination of critical processes that range from xenobiotic metabolism to growth and 
development (Antebi, 2015).  DNA binding domains of NRs consist of two zinc-fingers 
at the N-terminus that facilitate contact with DNA.  At the C-terminus the ligand binding 
domain coordinates ligand binding and interaction with transcriptional coactivators and 
corepressor that dictate NR activity.  There are two classes of NRs: class 1 members are 
activated when bound by their ligand, while class 2 receptors are also ligand activated but 
they also function as transcriptional repressors in the absence of ligand.  Nuclear 
receptors with unidentified ligands are considered to be orphan receptors        
 The C. elegans genome contains 284 NRs, which is remarkable considering only 
48 have been identified in humans (Antebi, 2015).  Out of the 284, 269 are considered to 
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be an expansion by gene duplication of the HNF4 family, while the remainder shares a 
high degree of conservation with mammalian NRs.  To date, less than 10% of NRs have 
been genetically characterized in C. elegans.  Previous to our findings NHR-14 remained 
a relatively uncharacterized NR.  One study demonstrated that NHR-14 was responsible 
for the estrogen dependent activation of vitellogenin-2 (vit-2) (Mimoto et al., 2007).  The 
group went further to show that NHR-14 binds estrogen by surface plasma resonance.  
However a later study showed that nhr-14 RNAi had no affect on vitellogenin expression, 
hence, the role of NHR-14 in estrogen signaling remains to be determined (Fischer et al., 
2012).  I discuss in Chapter 2 that NHR-14 represses iron transport through SMF-3, and 
this mechanism has key implications for C. elegans’ innate immune response.  NHR-14 is 
the first identified NR in C. elegans to regulate iron metabolism and the innate immune 
response.  Notably these two processes are not mutually exclusive.   Rather, the 
regulation of iron availability is a core component of the immune response. 
 Nutritional immunity relies on host mechanisms that limit the acquisition of 
micronutrients such as iron, manganese, and zinc by pathogens (Hood and Skaar, 2012).  
The importance of iron during infections is underscored by enhanced susceptibility with 
iron supplementation and in individuals with the iron overload disease hemochromatosis 
(Khan et al., 2007).  Thus, a combination of systemic and cellular mechanisms has 
evolved to sequester micronutrients away from pathogens.  During an infection in 
mammals, the iron hormone hepcidin is upregulated and secreted by the liver.  Hepcidin 
binds to ferroportin expressed in duodenal enterocytes and macrophages to prevent the 
export of iron into circulation (Nemeth et al., 2004).  As an acute phase reactant, ferritin 
expression also increases in response to infection and is an important factor in 
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intracellular iron withholding.  Overall, these mechanisms lead to hypoferremia and 
anemia of inflammation that comprise an important host defense strategy for limiting iron 
to pathogens.   
 At the other end the spectrum, pathogens acquire host iron through the production 
of small high affinity iron chelating compounds called siderophores.  Siderophores bind 
ferric iron with affinities that exceed host transferrin and lactoferrin, effectively stealing 
iron from the host (Miethke and Marahiel, 2007).  Millions of years of coevolution have 
enabled mammals to develop mechanisms that inhibit siderophore-mediated iron 
acquisition by bacteria.   Lipocalin-2 (also known as, siderocalin, neutrophil gelatinase-
associated lipocalin, or 24p3) is the most abundant antimicrobial secreted by epithelial 
cells and neutrophils in response to intestinal and respiratory infections.  Specifically, 
lipocalin-2 is able to bind and sequester siderophores thus limiting iron bioavailability 
(Flo et al., 2004).  Due to the intense molecular arms race between hosts and pathogens, it 
is not surprising that pathogens have evolved ways to evade lipocalin-2.  Certain 
pathogens including Salmonella enterica and uropathogenic E. coli synthesize 
siderophore derivatives that cannot be bound by lipocalin-2, which enables their iron 
uptake (Muller et al., 2009).   
 The vast majority of data regarding nutritional immunity has come from 
mammalian studies with very little contribution from C. elegans.  However, regulating 
micronutrient availability is an important factor for potential hosts, and C. elegans is no 
exception.  Worms grown in high iron conditions are more susceptible to Salmonella 
infection (Kortman et al., 2015), and smf-3 mutants with disrupted iron and manganese 
homeostasis have decreased survival compared to wild-type when infected with 
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Staphylococcus aureus (Bandyopadhyay et al., 2009).  These studies introduce important 
aspects of C. elegans that make them useful models for studying host-pathogen 
interactions and the innate immune response.  Most importantly, human pathogens such 
as P. aeruginosa, S. enterica, and S. aureus have been shown to infect and elicit a highly 
specific immune response in C. elegans that rely on conserved signaling pathways 
including, FOXO transcription factors, β-catenin, and p38 mitogen-activated protein 
kinase (MAPK) (Miyata et al., 2008; Roberts et al., 2010; Troemel, 2006).  These 
signaling pathways function in parallel to induce overlapping expression of antimicrobial 
effectors, including c-type lectins, ShK toxins, lysozymes, sapposins, and genes involved 
in iron metabolism (Cohen and Troemel, 2015).  In Chapter 2, we identify a 
transcriptional profile in nhr-14 mutants that significantly overlaps with transcriptional 
responses seen during infection with Pseudomonas, Salmonella, and other various 
pathogens.  This signature also correlates with DAF-16/FOXO dependent transcription, 
which is the primary transcription factor in the insulin/insulin-like growth factor 
signaling pathway in C. elegans.  
 Coordination of nutrient availability with development, metabolism, and the stress 
response is a conserved process among vertebrates and C. elegans that is mediated by 
insulin/insulin-like (IIS) growth factor signaling.  The insulin pathway is activated by 
insulin and insulin-like growth factors that bind to tyrosine kinase receptors (DAF-
2/IGFR-1), leading to the phosphorylation of the Forkhead Box, Class O transcription 
factor (DAF-16/FOXO) (Lin et al., 2001).  Phosphorylated DAF-16/FOXO is retained in 
the cytoplasm, thus preventing activation of its transcriptional targets.  Conversely during 
nutrient starvation or stress, DAF-2/IGFR-1 is not activated and DAF-16 does not 
10 
 
become phosphorylated, which allows for nuclear translocation and activation of genes 
involved in metabolism, stress response, and innate immunity.   
Mutants lacking daf-2 were shown to have constitutively active DAF-16/FOXO 
and an upregulation of DAF-16/FOXO target genes, designated Class 1 genes that are 
important in the stress response.  The gene subset downregulated in these mutants are 
designated as Class 2 genes, and are considered to be important for growth and 
development.  It was shown that Class 1 gene promoters contain a DAF-16 binding 
element (DBE) important for DAF-16/FOXO binding and activation, while Class 2 
promoters contain a DAF-16 associated element (DAE) (Murphy et al., 2003).  A recent 
study discovered that the transcription factor PQM-1 activated Class 2 genes through 
their DAE (Tepper et al., 2013).  The study also demonstrated that nuclear localization of 
DAF-16 and PQM-1 was mutually antagonistic.  For instance, when DAF-16 is nuclear 
localized, PQM-1 remains in the cytoplasm and vice versa.  PQM-1 was originally 
discovered to be upregulated in response to paraquat-induced oxidative stress, and is 
considered to be a stress response transcription factor (Tawe et al., 1998).  This is 
inconsistent however with its role in activating Class 2 genes that are thought be 
important for growth and development.  In fact, Class 2 genes have a higher correlation 
with genes involved in the innate immune response, and pqm-1 RNAi is shown to 
enhance susceptibility to bacterial infection (Kawli and Tan, 2008).   Further research is 
needed to better understand the dynamics between DAF-16/FOXO and PQM-1, and how 
they balance stress responses with growth and development signals.   
 In Chapter 4, I discuss defects in glucose homeostasis resulting from a loss of 
IRP2.  To date there have been several global and tissue specific deletions of IRP2, which 
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are discussed in the next section.  In mice, whole body deletion of IRP2 results in 
microcytic anemia, erythropoietic protoporphyria, altered body iron distribution, and 
neurological defects (Galy et al., 2005a; LaVaute et al., 2001; Zumbrennen-Bullough et 
al., 2014).  Iron content is elevated in intestine and liver and is associated with increased 
ferritin expression and decreased TfR1 expression, while iron is reduced in splenic 
macrophages and is associated with decreased ferritin expression.  In comparison, IRP1 
deficient mice have no overt phenotype while deletion of both IRP1 and IRP2 results in 
embryonic lethality.  IRP2 has been conditionally ablated in several cell types that 
include splenic and bone marrow macrophages, hepatocytes, and duodenal enterocytes 
(Ferring-Appel et al., 2009; Galy et al., 2005b, 2008).  One of the most severe 
phenotypes was observed in mice with intestinal-specific deletion of both IRP1 and IRP2, 
where 80% of the animals died shortly after weaning (Galy et al., 2008).  IRP deficient 
enterocytes from these mice displayed less structured duodenal crypts and villi, and 
intestinal enterocytes exhibited mitochondriopathy along with increased apoptosis. 
Ferritin and ferroportin levels were profoundly increased, and TfR1 and DMT1-IRE 
isoform mRNAs and protein were decreased.   
 It is well established that elevated iron levels pose as a major risk factor for 
developing Type 2 diabetes (T2D).  Readers are directed to an in depth review by Simcox 
and McClain that covers iron and diabetes risk (Simcox and McClain, 2016).  Risk 
association was first identified in patients suffering from iron overload disorders 
including hereditary hemochromatosis (HH), beta-thalassemia, and transfusional iron 
overload (Fernández-Real et al., 2002).  Insulin deficiency is commonly observed in 
these pathological states; interestingly however, HH individuals have increased insulin 
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sensitivity rather than insulin resistance seen with tranfusional iron overload.  Similarly, 
mouse models of HH exhibit reduced insulin secretion stemming from elevated oxidative 
stress, reduced glucose sensitivity, and increased beta cell apoptosis (Huang et al., 2011).  
Further evidence linking iron with diabetes comes from observations that showed 
improvements in insulin secretion capacity with phlebotomy and chelation therapy.  
Elevated iron stores measured by serum ferritin is also positively correlated with T2D 
risk, and high ferritin enhances risk for metabolic syndrome and cardiovascular disease.   
 At the other end of the spectrum, there is a high prevalence of iron deficiency in 
obese individuals, where obesity is a major predisposing factor for T2D (Hotamisligil, 
2006).  Evidence suggests that low iron in these individuals is caused by anemia of 
inflammation rather than iron-poor diets.  Chronic inflammation is associated with 
increased hepcidin and ferritin expression, and is a hallmark of obesity.  Studies show 
that inflammatory markers such as serum ferritin and C Reactive Protein are better 
predictors of iron deficiency in obese individuals than dietary iron levels (Jehn et al., 
2004).  In Chapter 4, I discuss iron deficiency as a major consequence of IRP2 
deficiency.  Unlike the examples discussed above, these animals do not suffer from 
chronic inflammation and obesity.  Instead these mice are leaner than wild-type 
littermates and have normal insulin sensitivity.  Our observations indicate that 
hyperglycemia stems from insulin deficiency that is caused by defects in insulin 
processing.  Despite data associating iron with diabetes, very little is known about the 
role of iron in insulin processing.  Discussed below is the process of producing mature 
insulin, and potential iron-dependent mechanisms that perturb this process.  The 
production and secretion of mature insulin is a highly complex process that involves the 
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tight coordination of transcriptional, ER, and vesicular trafficking machinery.  
Transcription of the ins1 and ins2 genes in mice results in the insulin precursor, 
preproinsulin, that is cleaved and folded into proinsulin in the ER.  Proinsulin transits to 
Golgi vesicles where it is further cleaved by the prohormone convertases PC1/3, PC2, 
and Carboxypeptidase E to form mature insulin.  Within Golgi vesicles, mature insulin 
utilizes Zn2+ to crystalize into dense core granules that are ready to be secreted in 
response to glucose.  Defects in ER maintenance (Zhang et al., 2006), proinsulin 
processing enzymes (Zhu et al., 2002), and proinsulin structure itself can ultimately lead 
to reduced insulin production and often times an accumulation of proinsulin that wreaks 
havoc on the ER and Golgi.  In fact, elevated serum proinsulin has become a marker of 
prediabetes and an early indicator of β-cell dysfunction (Pfützner et al., 2004).   
The relationship between oxidative protein folding in the ER and mitochondrial 
metabolism is becoming more appreciated (Simmen et al., 2010).  The exchange of 
calcium, ATP, and metabolites such as flavin adenine dinucleotide (FAD) has shown to 
be important for chaperone function and protein disulfide isomerase (PDI) activity that is 
responsible for disulfide bridge formation and proper folding of nascent polypeptides 
(Inaba et al., 2010).   
Besides ATP production, mitochondria are best known for Fe-S cluster 
biogenesis, and defects in this process can have dramatic pathological consequences.  
Defects in Fe-S cluster machinery, for example, results in Friedrich’s Ataxia (FA), 
Sideroblastic anemia, and myopathy; all of which exhibit reduced activity of Fe-S cluster 
containing proteins and increased mitochondrial iron deposition (Rouault, 2015).  The 
link between Fe-S cluster metabolism and diabetes is not well understood.  Incidence of 
14 
 
diabetes in individuals with FA is high, and β-cell specific deletion of Frataxin causes 
glucose intolerance and reduced β-cell mass in mice (Ristow et al., 2003).  CISD2 and 
CDKAL1 are Fe-S cluster containing proteins that have also been implicated in diabetes.  
Mutations in CISD2 cause Wolfram Syndrome, a neurodegenerative disorder 
characterized by optic atrophy, deafness, and diabetes (Chen et al., 2009).  Cdkal1 is 
consistently associated with T2D risk across heterogeneous populations, and mutations 
have been associated with reduced insulin secretion (Dehwah et al., 2010).  More 
recently, Cdkal1 was shown to be responsible for the methylthiolation of tRNALys(UUU) 
that is important for accurate translation of AAA and AAG codons in proinsulin (Wei et 
al., 2011).  β-cells lacking Cdkal1 have a reduction in insulin secretion and are glucose 
intolerant, defects resulting from improper proinsulin synthesis.   
In summary, like diabetes itself, the etiology of iron in diabetes is multifaceted.  
Levels outside the normal physiological range have severe consequences at the cellular 
and organismal level, thus additional research is needed to better understand these 
consequences in disease contexts.  Improved understanding of iron’s role in the processes 
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Iron is involved in many biological processes essential for sustaining life. In excess,
iron is toxic due to its ability to catalyze the formation of free radicals that damage
macromolecules. Organisms have developed specialized mechanisms to tightly regulate
iron uptake, storage and efflux. Over the past decades, vertebrate model organisms have
led to the identification of key genes and pathways that regulate systemic and cellular
iron metabolism. This review provides an overview of iron metabolism in the roundworm
Caenorhabditis elegans and highlights recent studies on the role of hypoxia and insulin
signaling in the regulation of iron metabolism. Given that iron, hypoxia and insulin signaling
pathways are evolutionarily conserved, C. elegans provides a genetic model organism that
promises to provide new insights intomechanisms regulatingmammalian ironmetabolism.
Keywords: ferritin, DMT1, SMF-3, iron deficiency, hypoxia, hypoxia-inducible factor, insulin signaling, C. elegans
INTRODUCTION
Iron is essential due to its presence in proteins involved in key
metabolic processes such as DNA synthesis, mitochondrial respi-
ration, and oxygen transport. Regulation of cellular iron content
is crucial as excess iron catalyzes the generation of reactive oxygen
species that damage DNA and proteins, while cellular iron defi-
ciency causes cell cycle arrest and cell death. Disruption of iron
metabolism, by iron excess or iron deficiency, leads to common
hematological, neurodegenerative, and metabolic diseases (Flem-
ing andPonka,2012). As a consequence, organismshavedeveloped
strategies to sense, transport and store this metal.
Our understanding of the mechanisms that regulate iron
metabolism has advanced through the use of model organ-
isms. Physiological and genetic studies in transgenic mice have
revealed the mechanism regulating systemic iron metabolism by
the ferroportin–hepcidin axis. Saccharomyces cerevisiae have been
used to unravel the complex pathways involved in Fe-S cluster
synthesis (Lill and Muhlenhoff, 2008), while zebrafish have been
critical in the identification of genes involved in hematopoiesis
(Shafizadeh and Paw, 2004). More recently, the soil nematode
Caenorhabditis elegans has emerged as amodel of ironmetabolism.
The advantages of C. elegans include a short generation time
and life span, the feasibility of genetic screens and the oppor-
tunity to study physiological processes in a whole organism
context. C. elegans orthologs have been identified formany human
genes (Shaye and Greenwald, 2011) and many of the key genes
and pathways regulating mammalian iron metabolism are con-
served in C. elegans. The genetic tractability of C. elegans can
provide a complementary approach to mammalian systems to
identify novel genes and unravel complex pathways involved in
iron metabolism. This review provides an overview of our cur-
rent understanding of iron metabolism in C. elegans, how iron
metabolism integrates with oxygen and insulin signaling, and
how this genetic model can provide insights in mammalian iron
metabolism.
CONSERVATION OF IRON METABOLISM IN C. ELEGANS
All organisms must maintain cellular iron content within a nar-
row range to avoid the adverse consequences of iron depletion
or excess. This is accomplished in vertebrates by precise mech-
anisms that regulate iron uptake, storage and efflux (Andrews
and Schmidt, 2007; Zhang and Enns, 2009; Figure 1). Mam-
mals acquire iron solely from the diet. Dietary non-heme iron
is reduced by membrane bound ferrireductases (e.g. DCYTB,
also known as CYBRD) and transported across the apical mem-
brane of intestinal enterocytes by divalent-metal transporter 1
(DMT1, also known as NRAMP2, SLC11A2 and DCT1; Macken-
zie and Garrick, 2005; Shawki et al., 2012). Iron is released into
a cellular labile iron pool thought to consist of low molecular
weight iron complexes. This pool is kept small due to the abil-
ity of iron to catalyze the production of reactive oxygen species.
Iron is utilized by the mitochondria for Fe-S cluster and heme
biosynthesis, and by iron-containing proteins in the cytosol and
nucleus. Iron is exported across the basolateral membrane into
the circulation by ferroportin (FPN1, also known as SLC40A1,
IREG1 and MTP1) in concert with its oxidation by the multi-
copper oxidase hephaestin (HEPH). Iron enters the circulation
where it binds with high affinity to transferrin for delivery to cells
expressing transferrin receptor 1 (TfR1, also known as TFRC).
TfR1-transferrin-Fe(III) complexes are internalized by receptor
mediated endocytosis. Iron is released from transferrin, reduced
to Fe(II) by the ferrireductase STEAP3 and transported across
the endosomal membrane to the cytoplasm by DMT1. Thus,
DMT1 is essential in intestinal non-heme iron absorption as
well as transport of endosomal iron released by transferrin into
the cytoplasm. Although most cell types express TfR1, erythroid
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precursors are dependent on Tf-TfR1-DMT1 for iron uptake as
disruption of Tfrc gene in mice (Levy et al., 1999) or mice with
reduced transferrin (Trenor et al., 2000) developed severe ane-
mia. DMT1 mutations in humans (Shawki et al., 2012), the mk
mouse (Fleming et al., 1997), and the Belgrade rat (Fleming et al.,
1998) also cause a severe microcytic hypochromic anemia, under-
scoring the importance of DMT1 in intestinal and erythroid iron
acquisition.
Mammals can also acquire iron by the intestinal absorption of
heme iron that comes primarily from animal sources. Although
several heme importers have been identified (Yuan et al., 2013),
the mechanism regulating intestinal heme import is not well
understood. It is likely that heme oxygenase 1 releases iron from
dietary heme, which is then exported by ferroportin into the
circulation.
When body iron stores are high, cytosolic iron is not exported,
and is instead sequestered in ferritin in an inert form unable to
catalyze free radical formation (Harrison and Arosio, 1996; Torti
and Torti, 2002; Theil, 2011). After 3 days, iron in ferritin is lost
by enterocyte sloughing into the intestinal lumen. The regula-
tion of intestinal ferritin is crucial as it serves as a cellular iron
“sink” to limit efflux of iron into the circulation (Vanoaica et al.,
2010; Galy et al., 2013). Because there is no regulated mechanism
for iron excretion, precise regulation of intestinal iron uptake
and storage is required. Given the fundamental nature of iron
metabolism, it is not surprising that many proteins involved in
intestinal iron uptake, storage and export are highly conserved
between C. elegans andmammals. C. elegans express orthologs for
DMT1 (SMF-3), ferritin (FTN-1, FTN-2), and ferroportin (FPN-
1.1, FPN-1.2, FPN-1.3; Figure 1). The C. elegans genome also
encodes potential orthologs for DCYTB ferrireductase and hep-
haestin multicopper oxidase. The intestinal anatomy in C. elegans
is similar to vertebrates in that they contain an apical brush border
facing the lumen and a basolateral membrane facing the intersti-
tial space (circulation in mammals) (McGhee, 2013) (Figure 1).
The intestine serves as the major site for absorption of dietary
nutrients and a defense against xenobiotics and pathogens. C.
elegans lack adipose tissue, liver, and pancreas and the intes-
tine fulfills these functions by serving as a major site of lipid
and glucose metabolism. Unlike mammals, C. elegans are heme
auxotrophs and are dependent on acquiring heme from the envi-
ronment (Rao et al., 2005; Hamza and Dailey, 2012; Yuan et al.,
2013).
SMF-3 is the principal intestinal Fe(II) transporter in C.
elegans. Consistent with its role in intestinal iron transport,
SMF-3 is highly expressed at the apical membrane of intestinal
epithelium (Au et al., 2009; Bandyopadhyay et al., 2009), tran-
scriptionally activated during irondeficiency (Romney et al., 2011)
and loss of SMF-3 expression leads to reduced iron content in
smf-3(ok1035) null mutants (Romney et al., 2011). SMF-3 also
transports Mn(II) as demonstrated by reduced Mn content in
smf-3(ok1035)mutants (Romney et al., 2011), increased tolerance
of smf-3(ok1035) mutants to Mn overload (Au et al., 2009) and
Mn-mediated reduction in smf-3 mRNA and SMF-3 protein in
intestine (Au et al., 2009; Settivari et al., 2009). Like SMF-3, DMT1
transports Mn(II), which competes with Fe(II) uptake (Gunshin
et al., 1997; Illing et al., 2012). The DMT1-deficient Belgrade rat
FIGURE 1 | Conservation of intestinal iron metabolism in mammals
and Caenorhabditis elegans. C. elegans anatomy is shown in the left
panel. The body plan of C. elegans is made up of two concentric tubes
separated by the interstitial space (pseudocoelum). The inner tube consists
of the intestine and the outer tube consists of cuticle, hypodermis, muscle
and nervous tissue. The digestive tract is an epithelial tube containing the
mouth, pharynx (foregut) and intestine (midgut). Right panel, an intestinal
epithelial cell is shown with an apical brush border membrane facing the
lumen and a basolateral membrane facing the interstitial space or blood in
mammals. Mammalian proteins (black) and C. elegans orthologs (red) are
indicated. Dietary non-heme iron is reduced by ferrireductases (e.g.
DCYTB1) and transported across the apical intestinal membrane by
SMF-3/DMT1. Cytosolic iron is incorporated in iron-containing proteins and
transported to mitochondria for Fe-S cluster biosynthesis and heme
biosynthesis in mammals. C. elegans are heme auxotrophs and are
dependent on acquiring heme from the environment (Rao et al., 2005). Iron
is also exported across the basolateral membrane into the interstitial space
(blood in mammals) by FPN-1.1, FPN-1.2, FPN-1.3/ferroportin. Ferroportin is
the sole iron exporter in mammals, whereas C. elegans express three
orthologs whose specific functions in iron export are not well understood.
Iron export by ferroportin is coupled to the oxidation of iron by the
multicopper oxidase hephaestin (HEPH). The C. elegans genome harbors
putative DCYTB and HEPH homologs. Iron not utilized or exported is
stored in FTN-1, FTN-2/ferritin. Iron deficiency stabilizes C. elegans HIF-1
and mammalian HIF-2α, leading to the transcriptional activation of
smf-3/DMT1 to increase iron absorption. Mammalian DCYTB and
ferroportin are also activated by HIF-2α during iron deficiency. HIF-1
regulation of C. elegans DCYTB and FPN-1-1, FPN1.2, and FPN-1.3
orthologs remains to be determined. Iron deficiency reduces ferritin
abundance in C. elegans and mammals by different mechanisms: C.
elegans lack the IRP-IRE network and ferritin is transcriptionally repressed
by HIF-1, whereas mammalian ferritin is translationally repressed by IRPs.
displays impaired Mn uptake in intestine and erythroid precur-
sors consistent with a physiological role forDMT1 inMnuptake in
mammals (Chua andMorgan,1997). In excess,manganese is toxic,
and in humans chronic occupational nasopulmonary exposure to
Mn causes a neurological disease known as manganism (Roth and
Garrick, 2003). Because Mn(II) and Fe(II) compete for DMT1
transport, this suggests that iron deficiency may be an important
factor in the predisposition toMn toxicity. Consistent with this are
Frontiers in Pharmacology | Drug Metabolism andTransport May 2014 | Volume 5 | Article 113 | 2
28 
Anderson and Leibold Iron metabolism in Caenorhabditis elegans
studies showing that iron deficiency is associated with increased
Mn content in the brain of rats (Chua and Morgan, 1996; Erikson
et al., 2002), in the olfactory epithelium of the DMT1-deficient
Belgrade rat (Thompson et al., 2007) and in serum of humans
with anemia or an iron deficient diet (Davis et al., 1992; Rahman
et al., 2013).
Caenorhabditis elegans also express DMT1-like proteins SMF-
1 and SMF-2 that share about 55–58% amino acid identity
with DMT1 (Settivari et al., 2009). SMF-1 is widely expressed,
but showed high expression in the apical intestinal membrane
(Au et al., 2009; Bandyopadhyay et al., 2009), whereas SMF-2 is
mainly cytoplasmicwith high expression in pharyngeal epithelium
(Au et al., 2009). smf-3 and smf-1 are transcriptionally induced
upon exposure to pathogenic Staphylococcus aureus, and smf-
3(ok1035), and smf-1(ok1748) mutants showed hypersensitivity
to this pathogen, indicating a role for these proteins in innate
immunity (Bandyopadhyay et al., 2009). Like smf-3, exposure to
high Mn reduces smf-1 and smf-2 mRNA levels, suggesting that
reduced expression of these transporters may be a mechanism to
reduce Mn toxicity (Settivari et al., 2009). This is consistent with a
study showing that SMF-1 expression in dopamine neurons con-
tributes to Mn2+-mediated neuronal death (Settivari et al., 2009).
The roles of SMF-1 and SMF-2 in iron metabolism are not well
understood; however, unlike smf-3mutant worms, iron and man-
ganese content were not significantly reduced in smf-1 and smf-2
mutants compared to wildtype worms consistent with a promi-
nent role of SMF-3 in iron and manganese transport (Romney
et al., 2011).
The mechanism regulating basolateral transfer of iron to the
interstitial space and to tissues inC. elegans is not known. Inmam-
mals, ferroportin is the sole exporter of iron to the circulation.
C. elegans express three ferroportin orthologs, FPN1.1, FPN-1.2,
and FPN-1.3, but their specific roles in iron export remains to be
determined.
Caenorhabditis elegans express genes orthologous tohuman fer-
ritin heavy subunit (FTH) and ferritin light subunit (FTL) genes.
Ferritin is a ubiquitously expressed protein that stores iron in a
form that is unable to generate free radicals. Mammalian ferritin
is composed of a mixture of 24 FTL and FTH subunits that form a
shell containing up to 4500 iron atoms (Theil, 2013). FTH exhibits
ferroxidase activity that facilitates oxidation of iron, while FTL
participates with FTH in the nucleation of iron (Bou-Abdallah,
2010; Liu and Theil, 2005). C. elegans FTN-1 and FTN-2 are more
similar to human FTH than to FTL and both FTN-1 and FTN-2
contain ferroxidase active-site residues (Gourley et al., 2003). ftn-1
is highly expressed in intestine whereas ftn-2 is expressed in many
tissues such as pharynx, body-wall muscle, hypodermis and intes-
tine (Gourley et al., 2003; Kim et al., 2004). ftn-1, and to a lesser
extent ftn-2, are induced by high iron exposure (Gourley et al.,
2003; Kim et al., 2004). Only ftn-1 mutants are iron sensitive and
have reduced lifespanswhen exposed to high iron (Kim et al., 2004;
Valentini et al., 2012).
Iron induces ferritin expression in mammals and in C. elegans,
but the mechanism regulating ferritin differs in these organisms.
In mammals, ferritin is primarily regulated at the translational
level by iron-regulatory proteins 1 and 2 (IRP1 and IRP2) (Hentze
et al., 2010; Anderson et al., 2012). During iron deficiency, IRPs
bind to an RNA stem-loop known as the iron-responsive element
(IRE) in the 5′ untranslated regions of FTH and FTL mRNAs to
repress ferritin synthesis. When cellular iron increases, IRP1 is
converted to its Fe-S cluster aconitase form concomitant with loss
of RNA-binding activity, while IRP2 is targeted for ubiquitination
and proteasomal degradation causing ferritin synthesis to increase
(Salahudeen et al., 2009; Vashisht et al., 2009). C. elegans lack the
IRP-IRE system, but express a cytosolic aconitase (ACO-1; Gourley
et al., 2003; Kimet al., 2004). ACO-1 is homologous tomammalian
IRP1 and its aconitase activity is regulated by iron, but unlike
IRP1, it lacks RNA-binding ability. Despite lacking IRP-IRE reg-
ulation, C. elegans have evolved unique mechanisms to regulate
iron storage.
HIF-1 REGULATES IRON UPTAKE AND STORAGE DURING
IRON DEFICIENCY
InC. elegans, hypoxia signaling is the predominantmechanism for
regulating iron metabolism (Romney et al., 2011; Ackerman and
Gems, 2012). Hypoxia signaling is a highly conserved process that
conditions organisms to lowoxygen and iron environments by reg-
ulating diverse biologic processes, including glucose metabolism,
angiogenesis and iron metabolism (Semenza, 2007; Kaelin and
Ratcliffe, 2008). During iron deficiency in mammals, hypoxia-
inducible factor 2α (HIF-2α, also known as EPAS1) activates
the transcription of DMT1, FPN1 and DCYTB genes in the
intestine to increase iron absorption (Taylor et al., 2011; Mastro-
giannaki et al., 2009; Shah et al., 2009). Hypoxia-inducible factors
(HIF-1 and HIF-2) are basic helix-loop-helix (bHLH) transcrip-
tion factors that consist of oxygen-regulated α subunits (HIF-1α
and HIF-2α) and a constitutively expressed β subunit (HIF-1β,
also known as aryl hydrocarbon nuclear translocator or ARNT)
(Semenza, 2007; Kaelin and Ratcliffe, 2008; Kaluz et al., 2008).
Under normal conditions, in the presence of oxygen and iron,
HIF-α subunits are hydroxylated by prolyl hydroxylase (PHD2,
also known as EGLN1) whose activity is dependent upon oxy-
gen and iron. Hydroxylated HIF-α is targeted for proteasomal
degradation by the E3 ubiquitin ligase von Hippel Lindau tumor
suppressor protein (VHL) (Ivan et al., 2001). During hypoxia or
iron deficiency, PHDs are inactive, thus allowing HIF-α sub-
units to translocate to the nucleus, dimerize with HIF-1β and
recruit coactivators to activate target gene expression in pathways
such as erythropoiesis, iron metabolism, glucose metabolism and
angiogenesis (Semenza, 2007; Kaelin and Ratcliffe, 2008; Kaluz
et al., 2008). HIF-1α and HIF-2α regulate overlapping, but dis-
tinct sets of target genes (Kaluz et al., 2008). For example, only
HIF-2α is responsible for the coordinate upregulation of DMT1,
DCYTB and FPN1 in intestine during iron deficiency (Mastro-
giannaki et al., 2009; Shah et al., 2009; Taylor et al., 2011). HIF-2α
regulation of intestinal iron metabolism during iron deficiency
ensures that sufficient iron is absorbed and delivered to the
bone marrow for production of red blood cells (Shah and Xie,
2014).
TheHIF signaling pathway is conserved inC. elegans. C. elegans
express HIF-1, AHA-1, VHL-1, and EGL-9, which are orthologs
of HIF-1α/HIF-2α, HIF-1β, VHL and PHD, respectively, in verte-
brates (Epstein et al., 2001; Jiang et al., 2001). Unlike mammals,C.
elegans express a single hif-1 gene that shares homology to HIF1α
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FIGURE 2 | Model for HIF-1 iron-dependent activation and inhibition of
intestinal iron uptake and storage in C. elegans. Iron sufficiency : ELT-2
binds to GATA binding sites located in the ftn-1 and ftn-2 IDEs. We
propose that ELT-2 cooperates with an unidentified transcriptional activator
(ACT) that binds to the hypoxia-response elements (HREs) to regulate
transcription. As HREs resemble E-box elements, which are binding sites
for bHLH transcription factors, it is possible that a bHLH transcription
factor serves this role. smf-3 is transcribed at basal levels during iron
sufficiency to limit iron absorption. HIF-1 is expressed during normal
growth conditions, but at low levels. Iron deficiency : HIF-1 accumulates
and dimerizes with AHA-1. HIF-1/AHA-1 (denoted by HIF-1) displaces the
transcriptional activator ACT binding to the ftn-1 and ftn-2 HREs and
inhibits transcription. Another possible mechanism for HIF-1 mediated ftn-1
repression is the displacement of ELT-2 by HIF-1. HIF-1/AHA-1 binds to the
smf-3 HREs, recruits coactivators (CoA) and cooperates with ELT-2 to
activate smf-3 transcription. Whether ELT-2 is bound to the ftn-1 GATA
sites during iron deficiency and to the smf-3 GATA sites during iron
sufficiency has not been determined. (Adapted from Romney et al., 2011).
andHIF2α (Jiang et al., 2001). HIF-1 functions in a variety of bio-
logical processes ranging from stress response, innate immunity,
neuronal development, ageing and iron metabolism as discussed
below (Shen et al., 2005; Chang and Bargmann, 2008; Pocock and
Hobert, 2008; Luhachack et al., 2012; Jones et al., 2013).
During iron deficiency, ftn-1 and ftn-2 transcription is
repressed and is dependent upon a cis-regulatory element termed
the iron-dependent enhancer (IDE) located in the ftn-1 and ftn-
2 promoters (Kim et al., 2004; Romney et al., 2008) (Figure 2).
Basal expression of ftn-1 and ftn-2 is mediated by the intestinal
GATA transcription factor ELT-2 that binds GATA sites located in
ferritin IDEs (Romney et al., 2008). Further studies revealed that
HIF-1 binds to hypoxia response elements (HREs) located in the
IDEs of ftn-1 and ftn-2 to repress transcription during iron defi-
ciency (Romney et al., 2011;Ackerman andGems,2012). Intestinal
iron uptake through SMF-3 is also regulated by HIF-1 during
iron deficiency. Similar to ftn-1 and ftn-2 IDEs, smf-3 contains
an IDE in its promoter that contains HRE binding sites that con-
fer HIF-1 dependent activation during iron deficiency (Romney
et al., 2011) (Figure 2). Romney et al. (2011) also showed that hif-1
(ia04)mutants have reduced iron and manganese content and are
developmentally delayed when grown in iron deficient conditions.
Notably, development of hif-1(ia04) mutants was restored when
the cellular iron pool was increased by RNAi depletion of ftn-
1 and ftn-2. It is not known whether the ferroportin homologs
fpn-1.1, fpn-1.2 and fpn-1.3 and DCYTB homologs are regulated
by hypoxia. These studies show that regulation of iron uptake
and storage by HIF-1 is crucial for ensuring proper growth and
development during iron deficiency.
HIF-1 is well known as a transcriptional activator but less is
known about its role as a transcriptional repressor. The ques-
tion arises regarding the mechanism of HIF-1 transcriptional
repression of ftn-1 and ftn-2. Chromatin immunoprecipitation
analysis and electrophoretic mobility gel assays showed direct
HIF-1 binding to the ftn-1 IDE (Romney et al., 2011; Acker-
man and Gems, 2012). Another study showed that mutations
of all three HREs in the ftn-1 IDE abolished expression of a
pftn-1::gfp transcriptional reporter, suggesting that an activator
may bind the HREs during normal conditions (Romney et al.,
2011; Figure 2). HREs resemble E-box elements and it is pos-
sible that this activator may be a member of the basic helix
loop helix (bHLH) transcription factor family that can bind to
non-canonical E-boxes (Kewley et al., 2004). A MAD-like tran-
scription factor MDL-1 was identified in an RNAi screen as a
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transcriptional activator of ftn-1 expression (Ackerman andGems,
2012).mdl-1 encodes a bHLH transcription factor that bind E-box
sequences as a dimer with MXL-1 to regulate target genes(Yuan
et al., 1998). MDL-1 transcriptional regulation of ftn-1was shown
to be iron independent (Ackerman and Gems, 2012), suggest-
ing the possibility that MDL-1 may bind to the ftn-1 and ftn-2
HREs when iron is sufficient, but is displaced by HIF-1 when
iron is low. Alternatively, it is possible that during iron deficiency
the displacement of ELT-2 from its GATA binding sites by HIF-1
results in decreased ftn-1 and ftn-2 transcription. Further work
is required to define this mechanism. In mammals, ferritin has
not been reported to be regulated by HIF-2α; however, hypoxia
regulates ferritin expression by altering IRP1 RNA binding activ-
ity and IRP2 protein abundance (Schneider and Leibold, 2003;
Meyron-Holtz et al., 2004; Salahudeen et al., 2009; Vashisht et al.,
2009).
FERRITIN REGULATION BY THE INSULIN/INSULIN-LIKE
GROWTH FACTOR SIGNALING PATHWAY
Ferritin is regulated by the insulin/insulin-like (IIS) growth factor
signaling pathway in C. elegans. The IIS pathway is a con-
served pathway in vertebrates and C. elegans that coordinates
nutrient availability with development, metabolism and stress
responses (Accili and Arden, 2004; Figure 3). When nutrients
are available, insulin and insulin-like growth (IGF) factors acti-
vate tyrosine kinase receptors DAF-2/IGFR1, triggering a kinase
cascade that leads to the phosphorylation of the Forkhead box,
Class O (FOXO) transcription factor DAF-16/FOXO and its cyto-
plasmic retention and inhibition. When IIS is reduced during
nutrient deprivation, DAF-16/FOXO phosphorylation is reduced,
promoting DAF-16/FOXO translocation to the nucleus where it
regulates the expression of target genes involved in stress resis-
tance, metabolism, and innate immunity (Murphy and Hu, 2013).
A recent study showed that ftn-1 expression was elevated in daf-2
mutants compared to daf-16;daf-2 mutants, indicating that DAF-
16 activated ftn-1 expression (Ackerman andGems, 2012). Further
genetic studies showed that hif-1 and daf-16 act in parallel path-
ways to regulate ftn-1 and that DAF-16 regulation of ftn-1 was
not iron dependent (Ackerman and Gems, 2012). Less is known
about the role of IIS in smf-3 regulation. One study showed
that glucose treatment induced the smf-3 expression, suggesting
a potential role for IIS and DAF-16 in smf-3 downregulation (Lee
et al., 2009). Reduced IIS leads to DAF-16 dependent upregulation
and downregulation of a diverse set of genes, which are desig-
nated as class 1 and class II genes, respectively (Lee et al., 2003;
McElwee et al., 2003; Oh et al., 2006). More recently, the tran-
scription factor PQM-1 was discovered to regulate class II genes
by binding to the DAF-16 associated element (DAE) located in
the promoter of these genes, whereas DAF-16 regulates class 1
genes by binding to the DAF-16 binding element (DBE; Tepper
et al., 2013). The smf-3 promoter contains both DBE and DAE
binding sites, but whether DAF-16 or PQM-1 regulates smf-3
awaits future studies. Taken together, these studies suggest that
DAF-16 activation of ftn-1 during reduced IIS provides C. elegans
with a mechanism to increase iron storage, thereby limiting iron
toxicity during stress conditions (Figure 3). When IIS is stim-
ulated, DAF-16 is inhibited and ftn-1 transcription is reduced,
FIGURE 3 | Pathways regulating cellular iron metabolism in C. elegans.
Iron deficiency-HIF-1 pathway : this pathway is activated in response to iron
deficiency or hypoxia and results in HIF-1 dependent repression of ftn-1 and
ftn-2 and activation of smf-3. This leads to reduced iron storage and
increased iron uptake, ultimately increasing the cellular iron pool and
promoting survival during iron limitation. Insulin/insulin growth factor-1
(IGF-1) signaling (IIS) pathway : the IIS pathway is a conserved pathway in
worms, flies and in vertebrates that regulates the transcription factor
DAF-16/FOXO. DAF-16/FOXO regulates genes in essential processes, such
as metabolism, stress resistance, pathogen defense and lifespan
extension. Activated IIS initiates a phosphorylation cascade that leads to
the cytoplasmic retention of DAF-16/FOXO and inhibits its function. Nutrient
deprivation reduces IIS leading to the nuclear localization of DAF-16 to
activate ftn-1. Glucose upregulates smf-3 expression, but whether DAF-16
directly regulates smf-3 remains to be determined. This pathway provides a
mechanism to increase cellular iron by reducing ftn-1 when nutrients are
abundant to promote growth and to reduce cellular iron during stress by
increasing ftn-1 to limit iron-catalyzed oxidative stress.
increasing the availability of iron required for development and
growth
Insulin signaling and FOXO regulation of mammalian ferritin
has not been reported. However, mammalian ferritin is transcrip-
tionally activated by oxidative stress (Thimmulappa et al., 2002;
Pietsch et al., 2003a,b; Hintze and Theil, 2005) and repressed
by oncogenes, providing a mechanism to sequester iron during
stress and to increase iron availability during cell proliferation
(Tsuji et al., 1993, 1995; Wu et al., 1999). Similarly, several studies
have shown that ferritin depletion stimulates cell proliferation by
increasing available iron, whereas sequestration of iron by ferritin
overexpression slows cell proliferation (Cozzi et al., 2000; Kakhlon
et al., 2001; Cozzi et al., 2004; Baldi et al., 2005). Like C. elegans,
changes in ferritin expression in response to environmental stimuli
are essential for survival during stress and growth during normal
conditions.
OTHER REGULATORS OF FERRITIN EXPRESSION
ftn-1 transcription has also been shown to be repressed by theREF-
1-like proteinHLH-29 (Quach et al., 2013) andUNC-62 amember
of the TALE family of homeobox transcription factors (Catoire
www.frontiersin.org May 2014 | Volume 5 | Article 113 | 5
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et al., 2011; Ackerman and Gems, 2012). HLH-29 is homologous
to the HairyVEnhancer of Split (HES) transcription factors that
regulate embryonic development through Notch-dependent and
independent pathway (Fischer and Gessler, 2007). HLH-29 was
recently shown to bind promoter sequences upstream of the ftn-1
IDE and repress its transcriptional expression independent of the
iron responsive HIF pathway (Quach et al., 2013). Additionally,
hlh-29mutants have elevated levels of ftn-1 and are resistant to per-
oxide stress. Further studies are needed to define the mechanism
and significance of this regulation.
unc-62 encodes the mammalian ortholog of MEIS1 that has a
crucial role innormal development and in leukemia (Azcoitia et al.,
2005; Argiropoulos et al., 2007). MEIS1 has also been identified as
a Restless Leg Syndrome (RLS) predisposing gene (Winkelmann
et al., 2007; Xiong et al., 2009; Spieler et al., 2014). RLS is a sensori-
motor disorder that is associated with iron insufficiency in brain,
but the role of iron in RLS is not well understood (Clardy et al.,
2006; Allen and Earley, 2007; Catoire et al., 2011). It is of inter-
est that ftn-1 expression is significantly decreased in C. elegans
treated with unc-62 RNAi (Ackerman and Gems, 2012), suggest-
ing that dysregulation of MEIS-1/MEIS can lead to altered iron
metabolism.
Ferritin regulation spans beyond iron and nutrient stress. For
instance, ftn-2, but not ftn-1, was shown to be necessary for proper
innate immune response to pathogenic S. aureus (Simonsen et al.,
2011). During infection, ftn-2 was also transcriptionally upregu-
lated along with several DAF-16 targets. It is likely that DAF-16
activates ftn-2 to protect C. elegans from bacterial infection by
limiting iron availability.
CONCLUDING REMARKS
We have highlighted recent studies showing the potential of C.
elegans as a useful genetic platform to explore mechanisms inte-
grating iron and oxygen metabolism. Future genomic studies are
needed to identify additional target genes of HIF-1 that are spe-
cific to hypoxia or iron deficiency and the unique HIF-1 partner
proteins that coordinate these responses. A better understanding
of how iron and insulin signaling are coordinated in C. elegans
could provide new knowledge about the role of iron in glucose
metabolismand in the pathogenesis of diabetes in humans. Finally,
these studies have set a foundation for the development of genetic
screens to identify novel regulators that are involved in iron sens-
ing, uptake, storage and utilization. C. elegans holds promise as a
system to decipher complex pathways regulating iron metabolism
that can be followed up in mammals.
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 CHAPTER 3 
THE NHR-14 NUCLEAR RECEPTOR COORDINATES IRON 
UPTAKE INNATE IMMUNITY IN C. ELEGANS 
35 
Abstract 
Iron metabolism in Caenorhabditis elegans is maintained by the regulation of iron 
uptake and storage through a HIF-1-dependent transcriptional mechanism. We previously 
showed that defective iron uptake in hif-1(ia4) mutants grown in low iron conditions 
results in delayed larval development.  In this study, we performed a genetic screen to 
identify novel genes involved in iron metabolism that would rescue the developmental 
delay of hif-1(ia4) mutants.  This screen led to the isolation of nuclear hormone receptor-
14 (NHR-14), a homolog of mammalian hepatocyte nuclear factor 4α (HNF4α).  We 
found that NHR-14 regulates iron uptake and innate immunity through the transcription 
factor PQM-1, a components of the insulin/IGF-like (IIS) pathway that controls the 
response of C. elegans to Pseudomonas aeruginosa and Salmonella enterica infection.  
Importantly, we showed that regulation of iron uptake by NHR-14 in C. elegans is a 
conserved process, in that the mammalian iron importer DMT1 is repressed by HNF4α.  
These data underscore the interplay between iron metabolism and innate immunity during 
host-pathogen interactions, and provide insight into how C. elegans and potentially 
mammals utilize nuclear receptor and insulin/IGF-1-like (IIS) signaling to sense and 
respond to pathogenic stress.     
Introduction 
Iron is an essential micronutrient required by nearly all organisms for biological 
processes including DNA replication, mitochondrial respiration, and oxygen transport 
(Anderson, 2013).  As a redox active element, iron also plays an important role in the 
production of reactive oxygen species (ROS) through the Fenton reaction, which can be 
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deleterious to cellular proteins, DNA and membranes.  Iron deficiency impacts billions of 
individuals per year worldwide that results in a variety of health issues ranging from 
impaired neurological development in infants to anemia in adults (Functioning and 
Beard, 2001; Ward et al., 2014).  Meanwhile, iron overload leads to cirrhosis, 
cardiomyopathy, and diabetes mellitus, and is associated with neurodegenerative diseases 
(Ganz and Nemeth, 2011; Huang et al., 2011).  Given the dual nature of iron in healthy 
and diseased states, it is critical for organisms to maintain cellular iron concentration in a 
tight physiological range.   
C. elegans is a useful model for studying iron metabolism (McElwee et al., 2004; 
Pocock  Oliver, 2008; Romney et al., 2008).  In addition to its genetic tractability and 
ease of maintenance, key proteins involved in mammalian iron uptake, storage and efflux 
are conserved in C. elegans. C. elegans express genes orthologous to the intestinal iron 
transporter divalent-metal transporter 1 or DMT1 (SMF-3), the iron-storage protein 
ferritin (FTN-1 and FTN-2) and the iron export protein ferroportin (FPN-1.1-3).  In C. 
elegans, iron is transported across the apical enterocyte membrane by SMF-3. Iron is 
used for the metallation of iron-containing proteins and by mitochondria for the 
biosynthesis of Fe-S clusters and heme (Lill and Muhlenhoff, 2008).   Iron not utilized is 
stored in FTN-1 and FTN-2 within the enterocyte or exported across the basolateral 
enterocyte membrane by FPN-1.1-3 into the interstitial space.  Like mammals, intestinal 
iron absorption is upregulated during iron deficiency by hypoxia-inducible factor (HIF) 
transcriptional activation of smf-3/DMT1 (C. elegans, HIF-1; mammals, HIF-2α) 
(Ackerman and Gems, 2012; Anderson et al., 2012; Romney et al., 2011a).  One 
difference between iron homeostasis in C. elegans and mammals is that during iron 
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deficiency, HIF-1 represses ftn-1 and ftn-2, whereas in mammals, ferritin is 
translationally repressed by iron-regulatory proteins (IRPs) (Anderson et al., 2012).  In 
addition to iron, ftn-1 is upregulated by DAF-16/FOXO transcription factor during stress 
(Ackerman and Gems, 2012) and ftn-2 is upregulated in C. elegans exposed to 
Staphylococcus aureus (Simonsen et al., 2011). The regulation of smf-3 and ftn-1 and ftn-
2 by HIF-1 provides a mechanism to elevate the intracellular iron pool by increasing iron 
uptake and reducing iron storage. This is consistent with our study showing that hif-
1(ia4) mutants are developmentally delayed when grown under low iron conditions 
(Romney et al., 2011).   
Iron is critical in the establishment of bacterial infections as pathogens synthesize 
and release siderophores that are responsible for acquiring iron from the host.  As a 
consequence, mammalian enterocytes have evolved specialized mechanisms to limit iron 
availability that include the secretion of iron chelators such as lipocalins and increasing 
iron storage by ferritin induction (Hood and Skaar, 2012; Miethke and Marahiel, 2007; 
Torti, 2002; Wessling-Resnick, 2010). C. elegans do not have an adaptive immune 
system and rely exclusively on innate immune mechanisms for sensing and resolving 
bacterial infections (Cohen and Troemel, 2015; Irazoqui et al., 2010). Human pathogens, 
such as S. enterica and P. aeruginosa, cause lethal intestinal infections in C. elegans.  In 
C. elegans, smf-3 mutants are susceptible to S. aureus infections (Bandyopadhyay et al., 
2009), and loss of HIF-1 has been reported to enhance susceptibility to P. aeruginosa 
through an iron-dependent hypoxic death mechanism (Kirienko et al., 2013). 
Accordingly, C. elegans has emerged as an important model for identifying virulence 
factors involved in pathogenesis and novel effectors of the host innate immune response 
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(Aballay et al., 2000; Tan et al., 1999). 
The expansion of nuclear receptors (NRs) in C. elegans has widely diversified 
their biological function, spanning from sex determination and molting to xenobiotic 
response and metabolic control (Jones et al., 2013; Taubert et al., 2011).  The C. elegans 
genome contains 284 NRs, of which 269 are related to mammalian hepatic nuclear factor 
4 (HNF4) (Antebi, 2015).  The majority of C. elegans NRs have not been analyzed, and 
those that have are related to conserved homologs in higher eukaryotes.  For instance, 
nhr-49 is a homolog of mammalian Hepatic Nuclear Factor 4 (HNF4) family of NRs and 
is controls fatty acid metabolism and longevity (Van Gilst et al., 2005; Pathare et al., 
2012).  As a class of transcription factors, NRs contain a conserved N-terminal zinc 
finger DNA-binding domain and a more divergent C-terminal ligand-binding domain 
(LBD).  Small lipophilic ligands are generally associated with regulating NR function 
(Yuan et al., 2009), but in C. elegans most NR ligands have not been identified.  In 
addition to binding ligands, the LBD can coordinate binding of corepressor and 
coactivator complexes to regulate gene expression (Antebi, 2015).   
Here, we identify NHR-14, a previously uncharacterized NR, as a novel regulator 
of iron uptake and the innate immune response. We found that NHR-14 represses iron 
uptake through smf-3 in a manner dependent on the transcription factor PQM-1, a 
coregulator that cooperates with DAF-16/FOXO in the IIS pathway.  Finally, the 
regulation of smf-3 by NHR-14 is a conserved process in part wherein HNF4α, a 
mammalian homolog of NHR-14, transcriptionally represses the iron importer DMT1 in 
intestinal enterocytes.  
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Materials and methods 
Worms were grown on nematode growth medium (NGM) agar plates seeded with 
Escherichia coli OP50 at 20 °C unless otherwise noted.  For iron experiments, worms 
synchronized by hypochlorite treatment at the L4 to young adult stage were grown 
overnight on NGM plates and then transferred to NGM plates supplemented with 6.6 
mg/ml ferric ammonium citrate (FAC) or 0.1 mM 2,2’-dipyridyl (BP, iron chelator) and 
grown overnight.   
The expression pattern of NHR-14 was determined using transgenic animals 
expressing a fosmid (40 kb) encoding a NHR-14::FLAG::GFP transgene 
(TransgeneOme) (Sarov et al., 2012). This fosmid contains the entire nhr-14 locus as well 
as large amounts of flanking DNA that are critical for endogenous nhr-14 expression. 
The fosmid was injected into ttTi5606;unc-119 worms and three independent lines were 
established.   
Human HT29 colorectal cells (ATC HT-38) were maintained in McCoy’s 5a 
medium (Life Technologies) supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin at 37 oC with 5% CO2.  For HNF4α shRNA knockdown, the 
hairpin targeting sequence was cloned into the pLL3.7 (Addgene) vector that was co-
transfected into EBNA 293 T-cells with pVSVG and pGag-Pol for viral production.  
Lentivirus containing empty vector (EV) shRNA or HNF4α shRNA was used to 
transduce HT29 cells, where puromycin was used for selecting clones.  HT29 cells (70% 
confluency) were treated with 50 uM deferoxamine (DFO, iron chelator) or 50 ug/ul FAC 
for 18 h.  Mouse duodenum, jejunum, ileum and colon isolated from intestinal epithelial 
cell-specific HNF4α mice (Hnf4αrIEpC) and control floxed mice (Hnf4αF/F) were 
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generously provided by Dr. Frank Gonzalez (NCI) (Ahn et al., 2008). 
 Ethyl methanesulfonate (EMS) mutagenesis was performed as previously 
described (Brenner, 1974).  Briefly, L4 stage hif-1(ia4) worms were treated with 50 mM 
EMS in M9 buffer (22 mM KH2PO4, 42 mM Na2HPO4, 86 mM NaCl), for 4 h.  
Mutagenized worms were then washed five times to remove excess EMS and then plated 
on NGM plates and grown till gravid.  Gravid F1s were then bleached, and F2 eggs 
plated on NGM plates.  Gravid F2 worms were transferred to 25 uM BP plates and 
removed after laying F3 eggs.  F3 progeny that rescued the low iron phenotype of hif-
1(ia4) mutants (determined by body length measurements in ImageJ) were scored as 
suppressors and collected for whole genome sequencing (WGS).  SNP mapping to 
identify the causative mutation was performed as previously described (Doitsidou et al., 
2010).  Our Bristol hif-1 mutant strain was outcrossed to the polymorphic Hawaiian strain 
CB4856 six times.  Suppressor mutants were crossed with hif-1(ia4) mutant Hawaiian 
strain worms and F1 progeny were moved to fresh NGM plates.  Gravid F1 adults were 
allowed to lay eggs overnight on NGM plates containing 25 uM BP.  Adults were 
removed the next day and ~50 F2 recombinants that reached adulthood within five days 
were isolated and DNA from their F3 and F4 progeny was purified using the PureLink 
Genomic DNA Mini kit (Invitrogen).  WGS was performed using an Illumina HiSeq 
sequencer.  Hawaiian SNP positions were mapped on the genomes of suppressor mutants 
E17 and V2B using the single-step SNP-mapping pipeline CloudMap (Minevich et al., 
2012).   
Five gravid adults from each strain were picked to either NGM or NGM 
containing 25 uM BP plates and allowed to lay eggs overnight.  Adults were removed the 
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following day and progeny were incubated for five days at 20 °C after which images 
were collected using a Leica M205 FA microscope and Leica DFC 310 FX camera (Leica 
Microsystems).  Progeny were scored based on length using Image J.  
 For indicated conditions and time-points, worms were washed off the plate with 
M9 buffer washed three times to remove external bacteria, and rocked for 2 h in M9 
buffer to clear bacteria from the gut.  RNA was extracted using TRIzol Reagent 
(Invitrogen) according to manufacturer’s protocol. cDNA synthesis was performed using 
SuperScript III First-Strand Synthesis SuperMix (Invitrogen).  After reverse transcription, 
qPCR was performed using TaqMan Gene Expression Assays (Applied Biosystems) and 
analyzed using an Applied Biosystems 7900 HT thermocycler.  Similar methods were 
used for qRT-PCR analysis of Hnf4αrIEpC and Hnf4αF/F intestinal tissue except that 
Power SYBR Green detection (Invitrogen) was used.  For HT29 cells, qRT-PCR was 
performed using TaqMan Gene Expression Assays and primers..   
The smf-3(-1500)::GFP-his reporter line (Romney et al., 2011) was synchronized 
by hypochlorite treatment and arrested L1 larvae were grown on 10 cm NGM plates 
containing nhr-14 RNAi or EV RNAi for 48 h. Worms were washed in M9 buffer and 
transferred to nhr-14 RNAi or EV RNAi plates supplemented with either 100 µM BP or 
6.6 mg/mL FAC and grown overnight.  Worms were collected by centrifugation and 
washed several times in M9 buffer to remove bacteria and debris.  Worms were analyzed 
using COPAS Biosort where L4 to young adult worms were gated based on extinction 
and time of flight parameters (TOF). Extinction and TOF parameters were held constant 
for subsequent GFP fluorescence acquisition throughout all conditions.  GFP 
fluorescence for 1000 worms was analyzed using FlowJo.   
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RNAi clones nhr-14 (T01B10) and pqm-1 (F40F8.7) were obtained from the 
ORFeome-based RNAi library (Reboul et al., 2001) and empty vector (L4440) was used 
as a control.  RNAi clones were verified by sequencing. Five hif-1(ia4) gravid adults 
were allowed to lay eggs overnight on NGM or NGM-BP plates (supplemented with 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 100 µg/ml ampicillin) seeded 
with bacteria expressing dsRNA corresponding to nhr-14 or L4440.  The following day 
adults were removed and progeny scored for rescue against BP as described above. 
 Eggs were obtained by treating gravid adults from each strain with alkaline 
hypochlorite. Eggs were allowed to hatch overnight in Egg Buffer (118 mM NaCl, 48 
mM KCl, 2 mM CaCl2, 2 mM MgCl2, and 25 mM HEPES) and arrest in the L1 stage.  
Synchronized L1 worms were grown on NGM plates seeded with OP50 until reaching 
the L4 stage.  Worm were washed extensively with M9 buffer and incubated in M9 buffer 
at room temperature for 2 h to allow for purging of the gut followed by three rinses with 
ddH2O.  Worms were pelleted and dried, and metal content determined by ICP-OES 
(Children’s Hospital Oakland Research Institute (CHORI) Elemental Analysis Facility).  
Empty tubes were run in parallel to serve as controls.  Iron and manganese content was 
normalized to sulfur content. 
 Images of NHR-14::GFP expression were captured using an Olympus FV1000 
confocal microscope and camera using Olympus FV10-ASW 3.1 confocal imaging 
software.  Images of smf-3(-1500)::GFP-his and PQM-1::GFP were captured using a 
Leica DM6000B.  Following acquisition, images were rotated, cropped and sized using 
Adobe Photoshop. 
 At indicated time points, worms were washed off the plate with ddH2O and 
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washed three times to remove bacteria. Worms were resuspended in lysis buffer (20 mM 
HEPES pH 7.5, 25 mM KCl, 0.5% NP-40) and disrupted by two 5-sec pulses using an 
Ultrasonic Processor (Sonics) at 50% amplitude.  Protein concentrations were determined 
using Coomassie Plus Protein Assay Reagent (Thermo Scientific).  Protein samples were 
incubated for 10 min at 95 °C in NuPage LDS Sample Buffer (Invitrogen) containing 10 
mM DTT then subjected to electrophoresis using NuPage 4-12% Bis-Tris gels 
(Invitrogen) and transferred to Amersham Hybond ECL nitrocellulose (GE Healthcare).  
Antibody treatments were carried out in 1x TBS (0.01% Tween-20) containing 5% nonfat 
dry milk. Horseradish peroxidase-conjugated secondary antibodies (Jackson 
Laboratories) were visualized using Western Lighting Plus-ECL Chemiluminescence 
Substrate (Perkin Elmer).  HT29 cells were lysed in Triton Buffer (20 mM HEPES pH 
7.5, 25 mM KCl, and 0.01% Triton X-100) and protein was analyzed by NuPage 4-12% 
Bis-Tris gels as described above.  Primary antibodies used in this study are: mouse 
monoclonal antiFLAG (Sigma, 1:2000); mouse antitubulin (MP Biomedical, 1:2000); 
rabbit antiHNF4α (Novex, 1:2000) and rabbit antiβ-actin (Ambion, 1:2000). 
Densitometry analysis was performed using Image J (National Institutes of Health).   
N2 wild-type and nhr-14(tm1473) L1 worms were grown on NGM plates seeded 
with OP50 and harvested at L4 stage (48 h at 22 oC).  Worms were collected by 
centrifugation and washed with M9 buffer to remove bacteria and RNA was extracted 
using a modified TRIzol procedure. Briefly, the aqueous phase was mixed with an equal 
volume of 70% EtOH and added to RNeasy spin columns (Qiagen).  RNA concentration 
and quality were determined using a NanoDrop spectrophotometer followed by further 
quality control with the Bioanalyzer RNA 9000 Nano Chip. Library construction was 
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performed using the Illumina TruSeq RNA Sample Preparation Kit v2 (RS-122-2001 and 
RS-122-2002) and was sequenced with the Illumina HiSeq (50 cycle, single-end).  
Sequenced reads were aligned to the Ce10 (WormBase Build 220) transcriptome index 
using Novoalign, and differential expression was determined using Useq 8.7.4 (Nix et al., 
2008).  Transcripts with a log2 ratio of 1 or higher at a false discovery rate (FDR) ≤ 0.05 
were considered differentially expressed.  Gene enrichment analysis was performed using 
GOrilla (Eden et al., 2009), which determines enriched GO terms at the top of a ranked 
list of genes.  The overlap of upregulated genes in nhr-14(tm1473) mutants with those in 
previously reported pathogen infection studies was determined as previously described 
and significance was calculated using exact hypergeometric probability (Hwang et al., 
2014).  BioProspector was used for de novo motif finding with the width parameter set to 
16.  Consistent motifs were identified using 1000 bp upstream of up- and downregulated 
genes.     
Bacterial lethality studies were performed as previously described (Tan et al., 
1999).  Briefly, 20-30 gravid adult worms were transferred to slow-killing (SK) plates 
containing lawns of S. enterica or P. aeriguinosa (PA14).  Worms that failed to respond 
to light prodding were scored as dead and removed.  Live worms were transferred to 
fresh plates to prevent interference from progeny.     
Worms were grown on NGM or pathogen formulated plates supplemented with 
75 µM 5-Fluoro-2’-deoxyuridine (FUDR) to prevent egg hatching.  Approximately 30 of 
L4 synchronized N2 wild-type, nhr-14(tm1473) and smf-3(ok1035) worms were placed 
on the plates and incubated for 24 h at 22 oC. Life span analysis began at the L4 larval 
stage (t = 0).  Worms were scored as dead if they did move, pump, or respond to 
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prodding.  Worms that died of a bursting vulva (gonad extruding through the vulva) or 
had crawled off the plate were censored from analysis. Experiments were performed at 
least three times.   
 Colony forming assay was performed as previously described (Garsin et al., 
2001).  Briefly, L4 staged N2 wild-type and nhr-14(tm1473) worms were transferred to 
SK plates containing lawns of S. enterica and allowed to feed for 8, 24, and 48 h.  At the 
indicated time points, five worms were transferred to NGM agar plates containing 100 
ug/ml gentamicin and washed two times in 4 µl drops of M9 buffer containing 25 mM 
levamisole.  Washed worms were transferred to tubes containing 20 µl of M9 lysis buffer 
(1% Triton in M9 buffer) and disrupted with a pestle.  Lysate volume was brought up to 
50 µl with M9 lysis buffer, serially diluted, and plated on MacConkey agar plates for S. 
enterica selection or LB agar plates for P. aeuroginosa selection.   
 Results are displayed as the mean ± SE, and comparisons between two groups 
were performed using a Student’s t-test. For each variable, at least three independents 
experiments were carried out.  Survival comparisons were made using the Mantel-Cox 
log-rank test.  All data were evaluated at the significance level p ≤ 0.05 and analyzed 
using Prism 6 (Graphpad).   
 
Results 
 We previously showed that hif-1(ia4) mutant worms are developmentally delayed 
when grown under iron limiting conditions using the iron chelator, 2,2-dipyridyl (BP) 
(Romney et al., 2011).  To discover novel genes involved in iron homeostasis, a 
suppressor screen was performed to identify mutations that rescued the low iron 
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phenotype observed in hif-1(ia4) animals. This screen led to the isolation of six 
suppressor mutants, two of which (E17 and V2B) were identified as strong suppressors of 
the hif-1(ia4) low iron phenotype (Figure 3.1A).  The causative mutation within these 
lines was determined using whole genome sequencing and Hawaiian strain SNP mapping 
(see Materials and Methods).  Both E17 and V2B displayed a similar ~1 Mb region of the 
X chromosome that have a Hawaiian/Bristol reads ratio of close to zero (Figure 3.1B). 
Sequence analysis revealed that suppressors E17 and V2B possess distinct mutations 
within the nuclear hormone receptor gene nhr-14 (T01B10.4).  E17 contains a G>A 
substitution that changes Trp33 to a STOP codon and V2B contains a G>A substitution 
that changes Gly49 to Arg. Double mutant hif-1(ia4);nhr-14(tm1473) worms develop 
normally under iron limited conditions (Figure 3.1C), confirming that mutations within 
nhr-14 are responsible for the rescue observed in lines E17 and V2B.   
Given that NHR-14 was identified in a screen for hif-1 mutants that enabled 
normal development under low iron conditions, we questioned whether nhr-14 was 
regulated by changes in iron status.  N2 wild-type worms displayed no change in nhr-14 
transcript levels when grown under low or high iron conditions compared to NGM 
conditions (Figure 3.2A).  To determine whether NHR-14 protein levels are affected by 
iron status, we generated a transgenic line carrying an nhr-14 fosmid transgene that 
utilizes the endogenous cis-elements and promoter of nhr-14 to drive the expression of 
NHR-14 tagged with 3xFLAG and GFP. We validated NHR-14::FLAG::GFP as a 
functional replacement for endogenous NHR-14 by injecting nhr-14(tm1473);hif-1(ia4) 
double mutants with the nhr-14 fosmid transgene and showing that these worms 
displayed the hif-1(ia4) delayed developmental phenotype when grown under low iron 
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conditions (Figure S3.1).  NHR-14::FLAG levels did not change with low or high iron 
treatment compared to worms grown on NGM (Figure 3.2B).  Furthermore, fluorescent 
imaging revealed that NHR-14::FLAG::GFP is predominately expressed within the 
nuclei of intestinal cells as well as cells in the head, and that this pattern was not affected 
by iron (Figure 3.2C).  
To determine the mechanism by which nhr-14(tm1473) mutants rescued the low 
iron phenotype of hif-1(ia4) mutants, we compared the transcription profiles of L4 stage 
nhr-14(tm1473) mutants with N2 wild-type animals using RNAseq.  We identified 676 
differentially expressed genes, 458 of which were upregulated and 218 downregulated in 
nhr-14(tm1473) mutants that changed at least two-fold compared to N2 wild-type 
animals at a 5% false discovery rate (FDR) (Table 3.1).  We also identified smf-3, which 
encodes the intestinal iron transporter, as one of the most highly upregulated genes in 
nhr-14(tm1473) mutants.  This observation suggested increased iron uptake as a possible 
mechanism to explain rescue of hif-1(ia4) mutants.   
We first confirmed upregulation of smf-3 in nhr-14(tm1473) mutants and in hif-
1(ia4);nhr-14(tm1473) double mutants compared to N2 wild-type animals and hif-1(ia4) 
mutants by qPCR (Figure 3.3A).  Consistent with increased smf-3 expression, content of 
iron (and manganese) was increased in nhr-14(tm1473) mutants compared to N2 wild-
type animals (Figure 3.3B).  We also found that nhr-14(tm1473);hif-1(ia4);smf-
3(ok1035) triple mutants failed to grow on low iron, indicating that  upregulation of smf-3 
in nhr-14(tm1473) mutants is required for the rescue of hif-1(ia4) mutants (Figure 3.3C).  
Taken together, these data revealed that NHR-14 negatively regulates smf-3 expression 
and that loss of NHR-14 rescues the hif-1(ia4) low iron phenotype through smf-3-
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dependent iron uptake.  
We next questioned whether NHR-14 directly regulates smf-3 expression using 
transgenic worms expressing a GFP-his transcriptional reporter containing the 123-bp 
IDE located in the smf-3 promoter. This element contains hypoxia response motifs 
(HREs) critical for HIF-1 binding, and are required for smf-3 activation in the intestine 
during iron deficiency (Romney et al., 2011). The IDE also contains three DAE motifs 
that are associated for PQM-1 occupancy (modENCODE) (Figure 3.4A).  
Transgenic worms expressing smf-3(1500)::GFP-his were fed control RNAi or nhr-14 
RNAi and grown under normal, low iron (BP) or high iron (FAC) treatments. Consistent 
with our previous study (Romney et al., 2011), GFP expression increased with BP and 
decreased with FAC treatment in worms fed control RNAi, reflecting HIF-1 regulation 
(Figure 3.4B).  In nhr-14 RNAi fed worms, GFP expression was further increased under 
normal, BP and FAC treatments, suggesting that NHR-14 acts in parallel to the HIF-1 
pathway (Figure 3.4B).  These data showed that the smf-3 123-bp IDE is important for 
NHR-14 regulation; however, we did not observe a direct interaction between NHR-14 
and the IDE by electrophoretic mobility gel shift assays or ChIP assays (data not shown), 
suggesting that NHR-14 indirectly regulates smf-3.    
Given the presence of DAE motifs in the smf-3 IDE and the modENCODE PQM-
1 ChIP-seq data, we tested the hypothesis that PQM-1 directly regulates smf-3. We found 
that GFP expression in smf-3(-1500)::GFP-his transgenic worms fed pqm-1 RNAi was 
reduced compared to control RNAi (Figure 3.4C).  Strikingly, mutating the DAE 1, 2, or 
3 motifs from TGATAAG to TCATAAG abolished GFP expression in untreated and BP-
treated worms compared to control smf-3(-1500)::GFP-his worms (Figure 3.4D).  
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Consistent with smf-3 transgenic reporter studies, endogenous smf-3 expression in pqm-
1(ok485) mutants was reduced by 50% compared to N2 wild-type worms (Figure 3.4E).  
PQM-1 as an activator of smf-3 was also evidenced by a low iron developmental delay 
seen in pqm-1(ok485) mutants (Figure 3.5F). Importantly, the ability of nhr-14(tm1473) 
mutants to rescue the low iron developmental defect in hif-1(ia4) mutants was reduced as 
a result of diminished smf-3 expression when nhr-14(tm1473) mutants were grown on 
pqm-1 RNAi (Figure 3.4G and 3.4H).  Since pqm-1 expression is not altered in nhr-
14(tm1473) mutants, we wanted to determine whether PQM-1 nuclear localization is 
affected.  L3 worms expressing a PQM-1::GFP fosmid that were fed nhr-14 RNAi had 
significantly more nuclear GFP staining compared to worms fed control RNAi (Figure 
3.4I).  Collectively, these data provide strong evidence that PQM-1 activates smf-3 
expression by binding to DAE motifs in the smf-3 promoter and that NHR-14 acts 
upstream of PQM-1 to inhibit its nuclear translocation and transcriptional activity.  
In addition to intestinal iron uptake, nhr-14 regulates innate immune and 
antimicrobial genes.  Of the 458 upregulated genes in nhr-14(tm1473) mutants versus N2 
wild-type, 38 genes are involved in the innate immune response (Figure 3.5A).  Gene-set 
enrichment analysis using DAVID (Huang et al., 2009) showed that over-represented 
functional categories within this dataset included C-type lectin (carbohydrate  binding 
proteins), CUB-domain proteins (extracellular and membrane proteins), peptidases, 
glutathione S-transferases (xenobiotic metabolism), lysozymes, metridin-like Shk toxin, 
and collagens, all of which are part of a core immune response program in C. elegans 
(Simonsen et al., 2012) (Figure 3.5B).  Genes that are upregulated in nhr-14(tm1473) 
mutants include classical immune response genes such as; lysozymes (lys-7, 2, and 1) 
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(Alper et al., 2007), downstream of daf-16 (dod-24, 19, 22, and 17) (Murphy et al., 2003), 
C-type lectins (clec-86, 41, 62, and 66) (Schulenburg et al., 2008), antimicrobial peptides 
(spp-18 and 3) (Hoeckendorf and Leippe, 2012), and glutathione S-transferase (gst-38 
and 22) (Figure 3.4C).  Ferritin (ftn-2), a known innate immune gene (Simonsen et al., 
2011), was also induced nhr-14(tm1473) mutants (Figure 3.5C).  We verified nhr-14-
dependent upregulation of eight genes within the immune response group by qPCR 
(Figure 3.5D). Among the downregulated genes, there was enrichment in genes involving 
cellular organization and body morphogenesis including; dpy-3, noah-1, ptr-4, and mlt-8.    
Given that the transcriptional profile of nhr-14(tm1473) mutants is enriched for 
immune response genes, we examined the overlap between nhr-14 upregulated genes and 
previously published genes that are induced by infection to various pathogenic bacteria.  
We found significant overlap between genes upregulated in nhr-14(tm1473) mutants and 
genes upregulated in response to P. aeruginosa (Shapira et al., 2006; Troemel, 2006), 
Pseudomonas luminescens (Wong et al., 2007), Enterococcus faecalis (Wong et al., 
2007) and Staphylococcus aureus (Visvikis et al., 2014) (Table 3.2). These genes include 
lysozymes, c-type lectins, and antimicrobial peptides that were identified in nhr-
14(tm1473) mutants.  Interestingly, we did not observe an overlap between nhr-14 
upregulated genes with Serratia marscens (Wong et al., 2007). This is likely due to the 
considerable variation with transcriptome profiling between infection studies (Mallo et 
al., 2002; Simonsen et al., 2012; Wong et al., 2007).   
The pathogen response in C. elegans is controlled through three distinct signaling 
pathways that converge on inducing a highly specific innate immune transcriptional 
program (Cohen and Troemel, 2015; Irazoqui et al., 2010).  We compared our nhr-14 
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RNAseq dataset with p38-MAPK (Troemel, 2006), TGF-β (Roberts et al., 2010)  and 
DAF-2/DAF-16 (Murphy et al., 2003) innate immune pathway datasets, and found 
significant gene expression overlap. There was significant overlap (R.F.= 6.4, p-
value=4.1e-12) with pmk-1-dependent genes (p38-MAPK); however, an increase in 
phosphorylated PMK-1 (p38), which is an indicator of activation, was not observed in 
nhr-14(tm1473) mutants (Figure S3.2).  This does not rule out the possibility that the 
terminal transcription factors in the p38-MAPK cascade, AFT-7 and SKN-1, are 
transcriptionally active independent of PMK-1 phosphorylation.  The highest degree of 
overlap (R.F.= 6.5, p-value =2.4e-22) occurred with the DAF-2/DAF-16 Class 2 subset of 
genes that include the downstream-of-daf-16 (dod) gene group (Murphy, 2003) and 
classic antimicrobial genes such as lys-7, spp-1 and spp-12 (Figure S3.2B).  Similarly, 
PMK-1 dependent genes also show considerable overlap with Class 2 genes and 
essentially no overlap with Class 1 genes, which are activated by DAF-16/FOXO 
(Troemel, 2006).  These genes are characterized as being repressed by DAF-16/FOXO 
and contain a GATA-like DAF-16-associated element (DAE), T/CTTATCA or 
TGATAAG/A, which is targeted by the transcriptional activator PQM-1 (Tepper et al., 
2013).  Troemel’s group had also shown pqm-1 to be induced by approximately 4-fold in 
response to P. aeruginosa infection.  This led us to question whether genes upregulated in 
nhr-14(tm1473) mutants contain DAEs, and are potential targets of PQM-1.  Among the 
upregulated genes in nhr-14(tm1473) mutants, the DAE was present in 288 of 457 
promoters tested (p-value = 5.4e-45), including three tandem TGATAAG/A motifs in the 
smf-3 promoter.  Analysis of chromatin-immunoprecipitation-seq (ChIP-seq) data from 
modENCODE (Niu et al., 2011) revealed significant PQM-1 binding within 16 out of the 
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top 25 upregulated genes in nhr-14(tm1473) mutants, while only 4 out of 25 for the 
downregulated subset One of the most prominent PQM-1 signals was observed in the 
smf-3 IDE (IV: 2618542..2619063; qValue 1.7e-32), suggesting PQM-1 might be involved 
in the activation of smf-3 in nhr-14(tm1473) mutants.     
Considering PQM-1’s role in pathogen resistance (Kawli and Tan, 2008; Lee et 
al., 2013) and the induction of innate immune genes in nhr-14(tm1473) mutants, we 
questioned whether nhr-14(tm1473) mutants were more resistant to pathogenic infection.  
To test this, we infected N2 wild-type and nhr-14(tm1473) mutant worms with P. 
aeruginosa PA14 and S. enterica, and measured survivability over time.  Compared to 
N2 wild-type worms, nhr-14(tm1473) mutants were more resistant to both PA14 and S. 
enterica infection (Figure 3.6A and F).  In addition to increased resistance, PA14 and S. 
enterica colonization is significantly reduced in nhr-14(tm1473) mutants after 24 h or 12 
h, respectively, of infection (Figure 3.6B and F).  Analysis of nhr-14 expression after 
PA14 infection (24 h) or S. enterica infection (72 h) revealed reduced nhr-14 mRNA 
with a corresponding increase in smf-3 mRNA levels (Figure 3.6C and G and H).  This 
was also observed for NHR-14 protein content over the same time period in transgenic 
worms expressing NHR-14::GFP::FLAG that were infected with PA15 or S. enterica 
(Figure 3.6D and H).  Since iron is an important factor in bacterial infections where both 
host and pathogen have evolved unique mechanisms to control its availability (Hood and 
Skaar, 2012), it appears that reduced NHR-14 expression during infection could be a 
mechanism to limit iron in the intestinal lumen by increasing cellular import through 
SMF-3.  Along these lines, a previous study showed that smf-3(1035) mutants are 
sensitive to S. aureus infection (Bandyopadhyay et al., 2009).  We questioned whether 
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the resistance of nhr-14(tm1473) mutants to PA14 was partly dependent on the increased 
expression of smf-3.   We found that smf-3(ok1035) mutants are more susceptible to 
PA14 infection compared to N2 wild-type worms and nhr-14(tm1473) mutants (Figure 
3.5I).  A role for smf-3 was further evidenced by the observation that nhr-
14(tm1473);smf-3(ok1035) mutants were more susceptible to infection compared to nhr-
14(tm1473) mutants (Figure 3.5I).  Survival of nhr-14(tm1473) mutants infected with 
PA14 was reduced when slow killing plates were supplemented with 6.6 mg/mL FAC 
(Figure 3.5J).  
By implicating a role for nhr-14 in regulating iron uptake through smf-3, we 
questioned whether a similar mechanism was conserved in mammals.  Amino acid 
sequence alignment between NHR-14 and mammalian HNF4α revealed a 65% identity 
within the N-terminal Zn finger DNA-binding domain and a 29% identity within the C-
terminal ligand-binding domain (Figure 3.7A).  Recent studies have shown that HNF4α 
regulates several iron-related genes in hepatocytes, including hepcidin (Hamp) and 
transferrin receptor 2 (Tfr2) (Matsuo et al., 2015; Truksa et al., 2009).  In mammals, 
dietary iron is absorbed by intestinal enterocytes through apically localized DMT1 
(Canonne-Hergaux et al., 1999), which is the SMF-3 ortholog. Due to the sequence 
similarities between NHR-14 and HNF4α and the role of HNF4α in iron metabolism, we 
wondered whether HNF4α regulates DMT1 expression. HT29 human colorectal cells 
were stably transduced with an shRNA targeting HNF4α (shHNF4α) to deplete HNF4α 
or empty vector (EV) (Figure 3.7B). Cells were then treated with the iron chelator 
desferrioxamine (DFO) or FAC, and HNF4α protein and DMT1 mRNA levels were 
assessed.  In EV cells treated with DFO, HNF4α levels were unexpectedly reduced 
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compared to untreated cells, and were further reduced in shHNF4α cells (Figure 3.7B).  
DMT1 mRNA expression was unchanged in untreated shHNF4α cells, but increased ~2-
fold in shHNF4α cells treated with DFO compared to EV cells (Figure 3.7C). These data 
suggested that loss of HNF4α correlates with reduced DMT1 expression in colorectal 
cells, and that unlike NHR-14, HNF4α expression is regulated by iron.  
To further examine the regulation of HNF4α on DMT1 expression in intestine, we 
assessed DMT1 protein and mRNA in the small and large intestine of intestinal-epithelial 
cell specific Hnf4α null mice (Hnf4αrIEpC) and control floxed mice (Hnf4αF/F) (Ahn et 
al., 2008).  Dmt1 mRNA was significantly increased in the duodenum, jejunum, and 
colon of Hnf4αrIEpC mice compared to Hnf4αF/F mice (Figure 3.7D). DMT1 protein 
levels were only modestly increased in colonic lysates from Hnf4αrIEpC compared to 
Hnf4αF/F mice (Figure 3.7E).  Together these data suggest a role for HNF4α in the 
regulation of DMT1 in the mammalian intestine.  
Discussion 
Using a genetic suppressor screen to rescue the low iron developmental delay 
phenotype of hif-1(ia4) mutants, we found that the HNF4α homolog, NHR-14, is a 
repressor of iron uptake through smf-3 in C. elegans.  In determining a mechanism for 
smf-3 regulation we showed that the IIS transcription factor PQM-1 is necessary for the 
upregulation of smf-3 in nhr-14(tm1473) mutants. While uncovering a role for nhr-14 in 
iron metabolism, we also unexpectedly identified nhr-14 to be a regulator of the innate 
immune response.  Genome wide expression profiling in nhr-14(tm1473) mutants 
revealed an induction of immune response genes that are likely to be responsible for the 
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resistance of nhr-14(tm1473) mutants to P. aeruginosa and S. enterica infection.  Out of 
the 284 NRs in C. elegans, our study has identified NHR-14 as the first NR to be 
involved in iron metabolism and immunity. 
Only about 7% of NRs have been characterized in C. elegans and this is likely a 
consequence of no observable phenotype for the vast majority of NRs.  Known functions 
of NRs include sex determination, xenobiotic metabolism, fatty acid metabolism, and 
neural differentiation.  NHR-14 adds to this list due its involvement in iron metabolism 
and the immune response.  Hallmarks of NR structure are a conserved N-terminal DNA 
binding domain and a C-terminal ligand-binding domain, so it was surprising NHR-14 
would regulate smf-3 transcription indirectly through PQM-1.  Originally discovered to 
be induced in response to paraquat-mediated stress, PQM-1 has recently been shown to 
be responsible for the activation of the Class 2 subset of IIS genes.  It has been known for 
some time that reduced IIS leads to the upregulation of Class 1 (stress) and down- 
regulation of Class 2 (development) genes.  DAF-16/FOXO directly activates Class 1 
genes through the DAF-16 binding element (DBE), however the mechanism activating 
Class 2 genes containing the DAF-16 associated element (DAE) remained unknown 
(Murphy, 2003). Tepper et al. (2013) showed that PQM-1 activates Class 2 genes through 
the DAE, and antagonizes DAF-16/FOXO nuclear localization when the DAF-2 insulin 
receptor is active (Tepper et al., 2013).  Many of the upregulated genes in nhr-
14(tm1473) mutants contain the T/CTTATCA DAE and are potential targets of PQM-1.  
Of those, smf-3, was an obvious candidate for PQM-1 activation in nhr-14(tm1473) 
mutants.  As a Class 2 gene, smf-3 was reported to rank relatively weak, but our results 
suggest otherwise.  The observation that smf-3 is highly induced in worms treated with 
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glucose, which activates the DAF-2 insulin receptor, provides further evidence that smf-3 
is a strong Class 2 gene (Lee et al., 2009).  The question of how NHR-14 regulates PQM-
1 is thought provoking.  Since PQM-1 targets are upregulated and its nuclear localization 
enhanced in nhr-14(tm1473) mutants, its reasonable to suggest that NHR-14 inhibits 
PQM-1.  The phosphorylation of DAF-16/FOXO by DAF-2 signaling causes DAF-
16/FOXO to be retained in the cytoplasm, thus allowing nuclear translocation of PQM-1.   
The mechanism by which DAF-16/FOXO antagonizes PQM-1 is unknown, as is 
the signal(s) that retains PQM-1 in the cytoplasm.  It is possible that NHR-14 prevents 
PQM-1 nuclear localization directly through a protein-protein interaction or indirectly 
through an unknown pathway.  Another interesting observation is the upregulation of ins-
7 in nhr-14(tm1473) mutants.  INS-7 is one of the 40 insulin-like peptides in C. elegans 
and has been shown to be a strong DAF-2 agonist (Murphy et al., 2007).  It is 
entertaining to speculate a feed-forward mechanism by which the de-repression of PQM-
1 in nhr-14(tm1473) mutants is amplified by INS-7 autocrine signaling, where INS-7 
would activate the DAF-2 insulin receptor causing a cytoplasmic to nuclear shift in 
PQM-1 localization.  Another issue that remains unanswered deals with the reverse 
complement of the DAE motif, TGATAAG/A, which is important for binding of the 
intestinal specific GATA transcription factor ELT-2 (McGhee et al., 2007).  ELT-2 is 
considered to be the predominant transcription factor in the intestine that is responsible 
for differentiation and function of enterocytes (Kormish et al., 2010; McGhee et al., 
2007).  The functional diversity of ELT-2 also includes the response to environmental 
toxins, pathogenic infection, and regulating the downstream signals of the IIS pathway.  
ELT-2 is thought to be constitutively localized to the nucleus, which is consistent with its 
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role in regulating basal expression of intestinal genes throughout larval development.  
ELT-2 has been shown to bind the DAE element of dod-8 (Zhang et al., 2013), and a 
recent ChIP-seq study showed ELT-2 occupancy of the smf-3 promoter (Mann et al., 
2016).  However, another ELT-2 ChIP-seq study failed to show interaction with smf-3 
(Wiesenfahrt et al., 2016).  Importantly, smf-3 expression was not affected by elt-2 RNAi 
in L1 or L4 larva (Mann et al., 2016), but this could be a consequence of redundancy with 
ELT-7.  The data suggest a model where ELT-2 is important for basal levels of intestinal 
expression, where PQM-1 adds an inducible switch that is controlled by NHR-14, in 
response to bacterial infection for example.  We cannot ignore the possibility that the 
regulatory network between NHR-14 and PQM-1 includes a role for ELT-2.       
The upregulation of Class 2 genes in nhr-14(tm1473) mutants was also 
complemented with an enrichment of genes involved in the innate immune response.  
This was unexpected as Class 2 genes are regarded as important in growth and 
development, whereas Class 1 genes are though to be involved in the stress response (Lee 
et al., 2003; Murphy, 2003).  Additionally, the increased activity of DAF-16/FOXO in 
daf-2 mutants is thought to confer resistance to infection (Miyata et al., 2008).  How this 
occurs is still debatable, because DAF-16/FOXO has never been shown to be nuclear 
localized during infection, and PQM-1 RNAi enhances susceptibility to P. aeruginosa 
(Kawli and Tan, 2008).  This is also confounded by the observations that show virtually 
no overlap between targets of DAF-16/FOXO and p38/MAPK, the primary immune 
response pathway in C. elegans.  In fact, p38/MAPK targets have more overlap with 
Class 2 genes (Troemel, 2006).  Having a primed immune response, we hypothesized that 
nhr-14(tm1473) had a resistance phenotype when grown on pathogenic bacteria.  As 
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expected, we saw increased survival of nhr-14(tm1473) mutants infected with P. 
aeruginosa and S. enterica.  However, the loss of NHR-14 and the induction of smf-3 
during infection were unexpected.  The degradation of NHR-14 in response to infection 
gives us clues into potential ligands for NHR-14.  Since iron didn’t seem to affect NHR-
14, at in least protein levels or nuclear localization, pathogen associated molecular 
patterns (PAMPs) and other bacterial metabolites are interesting ligand possibilities that 
may modulate NHR-14 activity.   
It is well established, that iron is an essential nutrient for pathogens, and is the 
basis for the evolution of mechanisms to acquire and sequester iron from the host and 
pathogen, respectively.  In line with this, the iron chelator ciclopirox olamine (CPX) was 
recently identified to inhibit PA14 pathogenesis in a C. elegans liquid killing assay and 
that PA14 virulence was dependent upon the siderophore, pyoverdin, where loss of HIF-1 
exacerbated pathogenesis (Kirienko et al., 2013).  Since HIF-1 is important for the 
activation of smf-3, one could predict that smf-3 induction would be important during 
PA14 infection.  To date however, a change in smf-3 has not been observed in expression 
profiling studies involving C. elegans’ response to pathogenic bacteria.  However, it has 
been shown that smf-3(ok1035) mutants are susceptible to S. aureus (Bandyopadhyay et 
al., 2009), which is consistent with our findings that smf-3 is important for the increased 
survival of nhr-14(tm1473) mutants infected with P. aeruginosa.  Together these data 
suggest that the regulation of smf-3 by NHR-14 is part of the innate immune response to 
potentially regulate iron availability during infection.  Since the death rate between wild-
type and nhr-14 mutants appears to be the same when infected with Salmonella and 
Pseudomonas, it appears that increased survival of nhr-14 mutants is due to a delay in 
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initial pathogen colonization of the gut lumen.  This is likely a result of having a primed 
immune response that is composed of an increased production of antimicrobial effectors 
and minimal iron bioavailability in the gut.  The very nature of an innate immune 
response in C. elegans is broad and nonspecific; therefore, it is unlikely that a single gene 
attributes to the resistance seen in nhr-14 mutants and rather the result of an immune 
response gene repertoire that protects the organism from initial infection.   
Of the 284 NRs in C. elegans, only 17 (6%) are conserved in humans; and among 
these 17, NHR-14 is considered to be a homolog of HNF4α.  Tissue distribution of 
HNF4α includes the liver, kidney, intestine, and the colon; and activates expression of 
genes involved in glucose, fatty acid, and xenobiotic metabolism (Gonzalez, 2008).  
Various studies have also shown that HNF4α plays a role in controlling iron metabolism, 
specifically through the activation and repression of transferrin and hepcidin gene 
expression (Truksa et al., 2009).  More recently HNF4α was shown to be important for 
the hepatic expression of transferrin receptor 2 (Tfr2), and mice lacking HNF4α in the 
liver developed hypoferremia (Matsuo et al., 2015).  Genome wide association studies 
have also implicated HNF4α in inflammatory bowel disease and ulcerative colitis, and 
mice with an intestinal deletion of HNF4α overexpress inflammatory cytokines including 
IL-1β, TNFα, IFNγ, and CCR2 (Babeu and Boudreau, 2014).  In mice with an intestinal 
deletion of Hnf4α (Hnf4αrIEpC), we found that the mammalian ortholog of smf-3, Dmt1, 
was significantly up regulated and this was most notable in the colon.  Highest DMT-1 
expression is found in the duodenum, which is the primary site of dietary iron absorption, 
and this is in contrast to the colon where Dmt1 expression is minimal.  Given that HNF4α 
regulates DMT-1 to a greater extent in the colon, combined with our data showing a role 
60 
for nhr-14 in innate immunity, it is possible that the suppression of Dmt1 by HNF4α is a 
way to control iron in an innate immune context similar to what we observed in C. 
elegans.  Mutations in the DMT-1 family member, natural resistance associated 
macrophage protein-1 (NRAMP-1) were found to confer susceptibility to several 
different pathogens in mice (Nevo and Nelson, 2006).  It is also known that NRAMP-1 is 
induced by cytokines and is important in the nitric oxide and proinflammatory response 
in macrophages.  Similarly, iron uptake by DMT-1 in monocytes is stimulated by 
cytokines (Govoni et al., 1997). Whether Hnf4αrIEpC mice are more resistant to 
gastrointestinal pathogens is an area for future investigation.  Additional experiments are 
also needed to identify how HNF4α regulates DMT-1.  Is it a direct mechanism, or 
indirect similar to what occurs with NHR-14 in C. elegans?   
In summary, nhr-14 adds a new layer of regulation in a manner dependent on IIS 
that integrates iron metabolism with the innate immune response.  This study also 
highlights the conserved nature of NRs between C. elegans and mammals, with NHR-14 
and HNF4α being prime examples.  Importantly, our data underscores the power of C. 
elegans as a model organism with respect to understanding host-pathogen interactions 
and identifying novel regulators of metabolic pathways mammals.    
61 
References 
Abad P. 2008. Genome sequence of the metazoan plant-parasitic nematode Meloidogyne 
incognita. Nat. Biotechnol. 26, 909–915. 
Ackerman D, Gems D. 2012. Insulin/IGF-1 and hypoxia signaling act in concert to 
regulate iron homeostasis in Caenorhabditis elegans. PLoS Genet 8, e1002498. 
Anderson CP, Leibold EA. 2014. Mechanisms of iron metabolism in Caenorhabditis 
elegans. Front Pharmacol. 5. 
Anderson CP, Shen M, Eisenstein RS, Leibold E a. 2012. Mammalian iron metabolism 
and its control by iron regulatory proteins. Biochim. Biophys. Acta. 1823, 1468–83.. 
Anderson GJ. 2013. Encyclopedia of Metalloproteins. In (eds. R.H. Kretsinger, V.N. 
Uversky, and E.A. Permyakov), pp. 985–995, Springer New York, New York, NY. 
Au C, Benedetto A, Anderson J, Labrousse A, Erikson K, Ewbank JJ, Aschner M. 2009. 
SMF-1, SMF-2 and SMF-3 DMT1 orthologues regulate and are regulated differentially 
by manganese levels in C. elegans. PLoS One 4, e7792. 
Bandyopadhyay J, Song H-O, Park B-J, Singaravelu G, Sun JL, Ahnn J, Cho JH. 2009. 
Functional assessment of Nramp-like metal transporters and manganese in 
Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 390, 136–141. 
Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics 77, 71-94. 
Cohen LB, Troemel ER. 2015. Microbial pathogenesis and host defense in the nematode 
C. elegans. Curr. Opin. Microbiol. 23, 94–101. 
Doitsidou M, Poole RJ, Sarin S, Bigelow H, Hobert O. 2010. C. elegans mutant 
identification with a one-step whole-genome-sequencing and snp mapping strategy. PLoS 
One 5, e15435. 
Dowen RH, Breen PC, Tullius T, Conery AL, Ruvkun G. 2016. A microRNA program in 
the C. elegans hypodermis couples to intestinal mTORC2/PQM-1 signaling to modulate 
fat transport. Genes Dev.  30, 1515–1528. 
Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. 2009. GOrilla, a tool for discovery 
and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48. 
Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. 2012. Identification of a binding 
motif specific to HNF4 by comparative analysis of multiple nuclear receptors. Nucleic 
Acids Res. 40, 5343–5356.  
Fleming RE, Ponka P. 2012. Iron overload in human disease. N. Engl. J. Med. 366, 348–
62 
359. 
Ganz T, Nemeth E. 2011. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 
62, 347–60.  
Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh K V, Murray BE, Calderwood SB, 
Ausubel FM. 2001. A simple model host for identifying Gram-positive virulence factors. 
Proc. Natl. Acad. Sci. U. S. A. 98, 10892–10897.  
Ghedin E, Wang S, Spiro D, Caler E, Zhao Q, Crabtree J, Allen JE, Delcher AL, Guiliano 
DB, Miranda-Saavedra D, et al. 2007. Draft genome of the filarial nematode parasite 
Brugia malayi. Science 317, 1756–1760.  
Gonzalez FJ. 2008. Regulation of hepatocyte nuclear factor 4 alpha-mediated 
transcription. Drug Metab. Pharmacokinet. 23, 2–7. 
Gourley BL, Parker SB, Jones BJ, Zumbrennen KB, Leibold EA. 2003. Cytosolic 
aconitase and ferritin are regulated by iron in Caenorhabditis elegans. J. Biol. Chem. 
278, 3227–3234.  
Hentze MW, Muckenthaler MU, Galy B, Camaschella C. 2010. Two to tango, regulation 
of mammalian iron metabolism. Cell 142, 24–38.  
Hood MI, Skaar EP. 2012. Nutritional immunity, transition metals at the pathogen-host 
interface. Nat. Rev. Microbiol. 10, 525–537.  
Huang DW, Sherman BT, Lempicki R a. 2009. Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57.  
Hwang AB, Ryu E-A, Artan M, Chang H-W, Kabir MH, Nam H-J, Lee D, Yang J-S, 
Kim S, Mair WB, et al. 2014. Feedback regulation via AMPK and HIF-1 mediates ROS-
dependent longevity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 111, 
E4458-67.  
Irazoqui JE, Urbach JM, Ausubel FM. 2010. Evolution of host innate defence, insights 
from Caenorhabditis elegans and primitive invertebrates. Nat. Rev. Immunol. 10, 47–58. 
Kawli T, Tan M-W. 2008. Neuroendocrine signals modulate the innate immunity of 
Caenorhabditis elegans through insulin signaling. Nat. Immunol. 9, 1415–1424. 
Kim Y-I, Cho JH, Yoo OJ, Ahnn J. 2004. Transcriptional regulation and life-span 
modulation of cytosolic aconitase and ferritin genes in C. elegans. J. Mol. Biol. 342, 421–
433. 
Kirienko N V, Kirienko DR, Larkins-Ford J, Wählby C, Ruvkun G, Ausubel FM. 2013. 
Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a 
63 
hypoxic response and death. Cell Host Microbe 13, 406–16. 
Kormish JD, Gaudet J, McGhee JD. 2010. Development of the C. elegans digestive tract. 
Curr. Opin. Genet. Dev. 20, 346–54.  
Kortman GAM, Mulder MLM, Richters TJW, Shanmugam NKN, Trebicka E, Boekhorst 
J, Timmerman HM, Roelofs R, Wiegerinck ET, Laarakkers CM, et al. 2015. Low dietary 
iron intake restrains the intestinal inflammatory response and pathology of enteric 
infection by food-borne bacterial pathogens. Eur. J. Immunol. 45, 2553–2567.  
Laftah AH, Sharma N, Brookes MJ, McKie AT, Simpson RJ, Iqbal TH, Tselepis C. 2006. 
Tumour necrosis factor α causes hypoferraemia and reduced intestinal iron absorption in 
mice. Biochem. J. 397, 61–67.  
Lee S-H, Wong R-R, Chin C-Y, Lim T-Y, Eng S-A, Kong C, Ijap NA, Lau M-S, Lim M-
P, Gan Y-H, et al. 2013. Burkholderia pseudomallei suppresses Caenorhabditis elegans 
immunity by specific degradation of a GATA transcription factor. Proc. Natl. Acad. Sci. 
U.S.A.  110, 15067–15072.  
Lee S-J, Murphy CT, Kenyon C. 2009. Glucose shortens the life span of c. elegans by 
downregulating DAF-16/FOXO activity and aquaporin gene expression. Cell Metab. 10, 
379–391.  
Liu X, Brutlag DL, Liu JS. 2001. BioProspector, discovering conserved DNA motifs in 
upstream regulatory regions of co-expressed genes. Pac. Symp. Biocomput. 127–138. 
Mann FG, Van Nostrand EL, Friedland AE, Liu X, Kim SK. 2016. Deactivation of the 
GATA transcription factor ELT-2 is a major driver of normal aging in C. elegans. PLoS 
Genet. 12, e1005956. 
Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. 2009. HIF-
2α, but not HIF-1α, promotes iron absorption in mice. J. Clin. Invest. 119, 1159–1166.  
Matsuo S, Ogawa M, Muckenthaler MU, Mizui Y, Sasaki S, Fujimura T, Takizawa M, 
Ariga N, Ozaki H, Sakaguchi M, et al. 2015. Hepatocyte nuclear factor 4α controls iron 
metabolism and regulates transferrin receptor 2 in mouse liver. J. Biol. Chem. 290, 
30855-30865.  
McGhee JD, Sleumer MC, Bilenky M, Wong K, McKay SJ, Goszczynski B, Tian H, 
Krich ND, Khattra J, Holt RA, et al. 2007. The ELT-2 GATA-factor and the global 
regulation of transcription in the C. elegans intestine. Dev. Biol. 302, 627–45.  
Minevich G, Park DS, Blankenberg D, Poole RJ, Hobert O. 2012. CloudMap, A cloud-
based pipeline for analysis of mutant genome sequences. Genetics 192, 1249–1269.  
Murphy CT. 2003. Genes that act downstream of DAF-16 to influence the lifespan of 
64 
 
Caenorhabditis elegans. Nature 424, 277–283. 
Murphy CT, Lee S-J, Kenyon C. 2007. Tissue entrainment by feedback regulation of 
insulin gene expression in the endoderm of Caenorhabditis elegans. Proc. Natl. Acad. 
Sci. U. S. A. 104, 19046–19050.  
Murphy CT, McCarroll S a, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, 
Kenyon C. 2003. Genes that act downstream of DAF-16 to influence the lifespan of 
Caenorhabditis elegans. Nature 424, 277–283.  
Niu W, Lu ZJ, Zhong M, Sarov M, Murray JI, Brdlik CM, Janette J, Chen C, Alves P, 
Preston E, et al. 2011. Diverse transcription factor binding features revealed by genome-
wide ChIP-seq in C. elegans. Genome Res 21, 245–254.  
Nix DA, Courdy SJ, Boucher KM. 2008. Empirical methods for controlling false 
positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics 9, 1–9.  
Quach TK, Chou HT, Wang K, Milledge GZ, Johnson CM. 2013. Genome-wide 
microarrray analysis reveals roles for the REF-1 family member HLH-29 in ferritin 
synthesis and peroxide stress response. PLoS One 8, e59719. 
Reboul J, Vaglio P, Tzellas N, Thierry-Mieg N, Moore T, Jackson C, Shin-i T, Kohara Y, 
Thierry-Mieg D, Thierry-Mieg J, et al. 2001. Open-reading-frame sequence tags (OSTs) 
support the existence of at least 17,300  genes in C. elegans. Nat. Genet. 27, 332–336.  
Roberts AF, Gumienny TL, Gleason RJ, Wang H, Padgett RW. 2010. Regulation of 
genes affecting body size and innate immunity by the DBL-1/BMP-like pathway in 
Caenorhabditis elegans. BMC Dev. Biol. 10, 1–10.  
Robinson-Rechavi M, Maina C, Gissendanner C, Laudet V, Sluder A. 2005. Explosive 
lineage-specific expansion of the orphan nuclear receptor hnf4 in nematodes. J. Mol. 
Evol. 60, 577–586.  
Romney SJ, Newman BS, Thacker C, Leibold EA. 2011. HIF-1 regulates iron 
homeostasis in Caenorhabditis elegans by activation and inhibition of genes involved in 
iron uptake and storage. PLoS Genet. 7, e1002394. 
Romney SJ, Thacker C, Leibold EA. 2008. An iron enhancer element in the ftn-1 gene 
directs iron-dependent expression in Caenorhabditis elegans intestine. J. Biol. Chem.  
283, 716–725.  
Rouault TA. 2015. Mammalian iron-sulphur proteins, novel insights into biogenesis and 
function. Nat. Rev. Mol. Cell. Biol. 16, 45–55. 
Sarov M, Murray JI, Schanze K, Pozniakovski A, Niu W, Angermann K, Hasse S, 
Rupprecht M, Vinis E, Tinney M, et al. 2012. A genome-scale resource for in vivo tag-
65 
based protein function exploration in C.  elegans. Cell 150, 855–866. 
Settivari R, Levora J, Nass R. 2009. The divalent metal transporter homologues SMF-1/2 
mediate dopamine neuron sensitivity in Caenorhabditis elegans models of manganism 
and parkinson disease. J. Biol. Chem. 284, 35758–35768.  
Shah YM, Matsubara T, Ito S, Yim S-H, Gonzalez FJ. 2009. Intestinal hypoxia-inducible 
transcription factors are essential for iron absorption following iron deficiency. Cell 
Metab. 9, 152–164.  
Shapira M, Hamlin BJ, Rong J, Chen K, Ronen M, Tan M-W. 2006. A conserved role for 
a GATA transcription factor in regulating epithelial innate immune responses. Proc. Natl. 
Acad. Sci. U. S. A. 103, 14086–91.  
Siggs OM, Beutler B. 2012. The BTB-ZF transcription factors. Cell Cycle 11, 3358–
3369. 
Simcox JA, McClain DA. 2016. Iron and diabetes risk. Cell Metab 17, 329–341. 
Simonsen KT, Gallego SF, Færgeman NJ, Kallipolitis BH. 2012. Strength in numbers,  
“Omics” studies of C. elegans innate immunity. Virulence 3, 477–484.  
Simonsen KT, Møller-Jensen J, Kristensen AR, Andersen JS, Riddle DL, Kallipolitis BH. 
2011. Quantitative proteomics identifies ferritin in the innate immune response of C. 
elegans. Virulence 2, 120–130. 
Stehling O, Lill R. 2013. The role of mitochondria in cellular iron–sulfur protein 
biogenesis, mechanisms, connected processes, and diseases. Cold Spring Harb Perspect 
Biol 5, a011312.  
Stuart LM, Paquette N, Boyer L. 2013. Effector-triggered versus pattern-triggered 
immunity, how animals sense virulent pathogens. Nat. Rev. Immunol. 13, 199–206. 
Tan MW, Mahajan-Miklos S, Ausubel FM. 1999. Killing of Caenorhabditis elegans by 
Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc. Natl. 
Acad. Sci. U.S.A. 96, 715–720. 
Taubert S, Ward JD, Yamamoto KR. 2011. Nuclear hormone receptors in nematodes, 
evolution and function. Mol. Cell Endocrinol. 334, 49–55.  
Tawe WN, Eschbach ML, Walter RD, Henkle-Duhrsen K. 1998. Identification of stress-
responsive genes in Caenorhabditis elegans using RT-PCR  differential display. Nucleic 
Acids Res. 26, 1621–1627. 
Tepper RG, Ashraf J, Kaletsky R, Kleemann G, Murphy CT, Bussemaker HJ. 2013. 
PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-mediated 
66 
development and longevity. Cell 154, 676–690. 
Troemel ER. 2006. p38 MAPK regulates expression of immune response genes and 
contributes to longevity in C. elegans. PLoS Genet. 2, e183. 
Truksa J, Lee P, Beutler E. 2009. Two BMP responsive elements, STAT, and 
bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and 
HJV responsiveness. Blood 113, 688–695.  
Visvikis O, Ihuegbu N, Labed SA, Luhachack LG, Alves A-MF, Wollenberg AC, Stuart 
LM, Stormo GD, Irazoqui JE. 2014. Innate host defense requires TFEB-mediated 
transcription of cytoprotective and antimicrobial genes. Immunity 40, 896–909.  
Wang X, Garrick MD, Yang F, Dailey LA, Piantadosi CA, Ghio AJ. 2005. TNF, IFN-
gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells. Am. J. 
Physiol. Lung Cell Mol. Physiol. 289, L24-33.  
Ward D, Kaplan J. 2012. Ferroportin-mediated iron transport, expression and regulation. 
Biochim. Biophys. Acta. 1823, 1426–1433.  
Wessling-Resnick M. 2010. Iron Homeostasis and the Inflammatory Response. Annu 
Rev Nutr. 30, 105–122.  
Wessling-Resnick M. 2015. Nramp1 and Other Transporters Involved in Metal 
Withholding during Infection. J. Biol. Chem.  290, 18984–18990.  
Wiesenfahrt T, Berg JY, Osborne Nishimura E, Robinson AG, Goszczynski B, Lieb JD, 
McGhee JD. 2016. The function and regulation of the GATA factor ELT-2 in the C. 
elegans endoderm. Development 143, 483–491.  
Wong D, Bazopoulou D, Pujol N, Tavernarakis N, Ewbank JJ. 2007. Genome-wide 
investigation reveals pathogen-specific and shared signatures in the response of 
Caenorhabditis elegans to infection. Genome Biol. 8, R194. 
67 
Figure 3.1.  Mutations in nhr-14 rescue the low iron developmental delay in hif-1(ia4) 
mutants.  A) Representative images of N2 wild-type worms and hif-1(ia4) mutants grown 
on NGM plates containing 20 uM BP (iron chelator) after 5 days.  Quantification of 
worm length from panel A as a percentage of hif-1(ia4) length (n = 50).  B) CloudMap 
SNP Mapping are shown as XY-scatter plots where the ratio of Hawaiian SNPs to Bristol 
SNPs is represented for the E17 and V2B mutants. C) Representative images of N2 wild-
type and hif-1(ia4) mutants, and hif-1(ia4);nhr-14(tm1473) double mutants grown in 
NGM 25 uM BP after 5 days.  Quantification of worm length from panel D after 5 days 
growth in NGM or NGM-25 uM BP (n = 15) and calculated as a percentage of N2 wild-


































   









































































Figure 3.2.  NHR-14 is expressed within the nucleus of intestinal cells and is unaltered by 
changes in iron availability.  A) nhr-14 expression measured by qRT-PCR in N2 adults 
grown in NGM, NGM-BP, and NGM-FAC and normalized to N2 worms on NGM (n = 
3).  B) Representative western blot of NHR-14::GFP::FLAG protein in noninjected 
worms (unc-119) versus injected transgenic worms grown in NGM, NGM-BP or NGM-
FAC.  C) Subcellular localization of NHR-14::GFP::FLAG by confocal microscopy in 



















































Figure 3.3. NHR-14 is a repressor of the intestinal iron importer smf-3.   A) smf-3 
expression measured by qRT-PCR in N2 wild-type, hif-1(ia4), nhr-14(tm1473), and hif-
1(ia4);nhr-14(tm1473) double mutants grown in NGM (n = 3).  B) Total iron and 
manganese content of N2 wild-type worms, and nhr-14(tm1473) and hif-1(ia4) mutants 
grown in NGM (n = 3) quantified by ICP-OES.  C) Representative images of nhr-
14(tm1473), smf-3(ok1035), and nhr-14(tm1473);hif-1(ia4);smf-3(ok1035) mutants 
grown in NGM-25 uM BP for 5 days. Worm length was quantified after 5 days growth in 
NGM or NGM-25 uM BP  (n = 15) and calculated as a percentage of worms grown in 



































































































































Figure 3.4.  PQM-1 is downstream of NHR-14 and is an activator of smf-3.  A) 
Illustration of the smf-3(-1500bp)::GFP-his transcriptional reporter containing 1500 bp 
of 5’ regulatory sequences of  smf-3 (-105 to -228 bp relative to the putative ATG 
initiator  encompassing the 123-bp IDE containing putative DAE sites.  B) GFP intensity 
in smf-3(-1500bp)::GFP-his worms fed control RNAi (grey bars) or nhr-14 RNAi (red 
bars) in NGM, NGM-BP or NGM-FAC plates (n = 1000 worms per treatment) was 
quantified using the COPAS Biosorter.  C) Representative images of smf-3(-1500)::GFP-
his transgenic worms grown on either control (empty vector) or pqm-1 RNAi.  D) GFP 
intensity in smf-3(-1500)::GFP-his transgenic worms with a single nucleotide mutation in 
each of the DAE motifs grown on NGM or 100 µM BP-NGM.  E) Endogenous smf-3 
gene expression in N2 wild-type versus pqm-1(ok485) mutants grown on NGM.  F) 
Length of N2, hif-1(ia4), and pqm-1(ok485) mutants grown on NGM or BP treated plates.  
G) smf-3 expression in N2 wild-type and nhr-14(tm1473) mutants grown on EV or pqm-1
RNAi.  H) Length of N2, hif-1(ia4), and nhr-14(tm1473);hif-1(ia4) mutants grown on 25 
µM BP and treated with EV or pqm-1 RNAi. I) Representative images of L3 PQM-
1::GFP worms fed control or nhr-14 RNAi along with quantification of the percentage of 
worms with nuclear GFP localization. Values are the mean ± SEM; *p < 0.05, **p < 0.01 




















































































   




































































































Figure 3.5.  NHR-14 regulates an innate immune transcriptional program. A) Gene 
ontology analysis of genes that were upregulated in nhr-14(tm1473) mutants compared to 
N2 wild-type worms.  B) DAVID functional category analysis of upregulated genes in 
nhr-14(tm1473) mutants compared to N2 wild-type worms.  C) Selection of innate 
immune genes that are upregulated in nhr-14(tm1473) mutants.  D) qRT-PCR 
confirmation of select innate immune genes that are upregulated in nhr-14(tm1473) 
mutants (n = 3).  E) Motif enrichment analysis for upregulated and downregulated genes 
in nhr-14(tm1473) mutants.  Values are the mean fold-difference compared to N2 wild-
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Figure 3.6.  NHR-14 is downregulated in response to P. aeruginosa PA14, and loss of 
NHR-14 confers resistance to PA14 infection.  A) Survival curves of N2 wild-type and 
nhr-14(tm1473) mutants infected with P. aeruginosa on standard SK medium. Data 
represent three independent experiments. Values are the mean ± SEM; *p < 0.05 and 
***p < 0.001 relative to N2 (Log-rank Mantel-Cox test).  B) P. aeruginosa PA14 
colonization of N2 wild-type and nhr-14(tm1473) worms after 24 h of infection.  C) smf-
3 and nhr-14 mRNA expression after 24 h on E. coli OP50 or P. aeruginosa PA14 
measured by qRT-PCR (n = 3).  D) NHR-14::GFP::FLAG immunoblots after 24 h on E. 
coli OP50 or P. aeruginosa PA14 (n = 3).  Tubulin is a loading control. Values in B and 
C are the mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001.  E) Survival curve of N2 
wild-type and nhr-14(tm1473) worms infected with S. enterica. Values are presented as 
the mean ± SEM; ***p < 0.001 (Log-rank Mantel-Cox test).  F) S. enterica colonization 
of N2 wild-type and nhr-14(tm1473) worms after 72 h of infection.  G) smf-3 and nhr-14 
expression after 72 h on E. coli OP50 or S. enterica measured by qRT-PCR (n = 3).  H) 
NHR-14::GFP::FLAG immunoblot after 72 h on E. coli OP50 or S. enterica (n = 3).  I) 
Survival curve of nhr-14(tm1473), smf-3(ok1035), and nhr-14(tm1473);smf-3(ok1035) 
worms infected with P. aeruginosa PA14 on standard SK medium, and J) Survival curves 
of nhr-14(tm1473) mutants infected with P. aeruginosa on standard SK medium or FAC-
supplemented SK medium. Data represent 3 independent experiments. Values are 
presented as the mean ± SEM; *p < 0.05 and ***p < 0.001 relative to N2 NGM, (Log-
rank (Mantel-Cox) test).  Values for F-H are the mean ± SEM; *p <0.05 (Student’s t-
test).  
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Figure 3.7. HNF4α, the mammalian ortholog of NHR-14, regulates DMT-1 expression in 
the intestinal epithelia.  A) Protein alignment of the DNA binding domains for HNF4α 
and NHR-14 with locations of the E17 and V2B mutations.  B) HNF4α immunoblot 
indicating shRNA knockdown in HT29 colorectal cells treated overnight with DFO or 
FAC.  C) Expression of DMT-1 in EV shRNA or shHNF4α transformed HT29 cells 
grown under normal iron conditions or DFO chelation.  D) DMT-1 immunoblot of WT 
and HNF4αVillin/Cre lysates from colonic epithelial scrapings.  E) Expression of DMT-1 
in intestinal tissues of WT and HNF4αVillin/Cre mice.  Values are presented as the mean 
± SEM; *p < 0.05, **p < 0.01, and ***p < 0.0001.   
CVVCGDKAIGKHYGAVACNGCKGFFRRSVWQNLQYTCRFNKQCNIDKDHRNACRYCRFQKCLADGM
CAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGM












































































Figure S3.1.  NHR-14::GFP::FLAG functions similarly to endogenous NHR-14.  The 
functionality of NHR-14::GFP::FLAG was tested by its ability to downregulate smf-3 
transcript levels, as well as replace endogenous NHR-14.  A) To test transcriptional 
regulation of smf-3, smf-3 and nhr-14 mRNAs were measured by qRT-PCR in 
noninjected worms (unc-119) versus NHR-14::GFP::FLAG; ttTi5606; unc-119 
transgenic worms (n = 3).  nhr-14 mRNA levels increased and smf-3 mRNA levels 
decreased in NHR-14::GFP::FLAG transgenic worms compared to noninjected 
ttTi5606;unc-119 worms.  B) To test for functional replacement of NHR-14, mutations in 
hif-1 and nhr-14 genes were introduced into the unc-119 double mutant and then injected 
with the NHR-14::GFP::FLAG expressing fosmid.  Relative worm length of strains 
grown under normal (white bars) or low iron (black bars) conditions was determined (n = 
15).  Note that unc-119; hif-1; nhr-14 triple mutants expressing NHR-14::GFP::FLAG 
displayed the hif-1-dependent developmental delay as compared to hif-1(ia4); nhr-
14(tm1473) mutants, indicating that NHR-14::GFP::FLAG is functional.  C) Lifespan 
was determined for N2 wild-type and nhr-14(tm1473) mutants grown in NGM or NGM-
25 uM BP; *p < 0.05 (log-rank Mantel-Cox test).  Values are presented as the mean ± 

























































































Figure S3.2. NHR-14 is induced during heat stress.  A) nhr-14 expression in N2 wild-
type worms grown at 20 oC or 25 oC for 6, 12, and 24 h.  B) NHR-14::GFP::FLAG 
expression in transgenic worms grown at 20 oC or 25 oC for 6, 12, and 24 h.  C) Percent 
survival of N2 wild-type and nhr-14(tm1473) mutants grown at 25 oC. Values are the 
mean ± SEM, *p < 0.05 (Student’s t-test). Log-rank (Mantel-Cox) test was used to 
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Figure S3.3. Analysis of transcriptional overlap between innate immune pathways and 
nhr-14(tm1473) mutants.  A) Venn diagram of gene expression overlap between up- 
regulated genes in nhr-14(tm1473) mutants and genes activated in the p38-MAPK (pmk-
1), TGFβ (dbl-1), and DAF-2/DAF-16 (daf-2) pathways. B) Hypergeometric probabilities 
for the gene expression overlap in A. C) Immunoblot for p38 (PMK-1) phosphorylation 
in N2 wild-type and nhr-14(tm1473) mutants treated with M9 or M9 plus 5 mM sodium 
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Table S3. Expression profile comparisons between nhr-14tm1473 mutants and published 
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Table 3.1   Differentially expressed genes in nhr-14(tm1473) mutants 
Table 1. Differentially expressed genes in nhr-14(tm1473) mutants 
A. Top 25 up-regulated genes B. Top 25 down-regulated genes
Gene Name log2 Description 
B0024.4 5.69 Unknown 
F26A1.8 5.55 Unknown 
dod-21 4.25 Epoxide Hydrolase 
T19C9.8 3.91 Epoxide Hydrolase 
asp-17 3.77 Aspartic Peptidase 
dod-24 3.56 Epoxide Hydrolase 
C32H11.9 3.48 Epoxide Hydrolase 
col-129 3.31 Surfactant Protein 
Y47H10A.5 3.27 Exoribonuclease 
clec-41 3.25 C-type Lectin 
lys-7 3.19 Lysozyme 
tsp-2 3.16 Tetraspanin 
dod-23 3.12 Unknown 
dod-19 3.12 Unknown 
col-139 3.03 Cuticle  
smf-3 3.00 Divalent Metal Ion Transporter 
col-81 2.98 Cuticle 
tsp-1 2.82 Tetraspanin 
Y37H2A.14 2.82 Unknown 
ZK6.11 2.81 Unknown 
T27D12.6 2.78 Unknown 
oac-14 2.78 Acyl Transferase 
C14C6.5 2.73 Metridin-like ShK Toxin 
C49C3.9 2.67 Epoxide Hydrolase 
oac-20 2.64 Acyl Transferase 
Gene Name log2 Description 
R09D1.12 -4.51 Kinase 
cpt-6 -4.28 Carnitine Palmitoyltransferase 
H20E11.2 -3.80 Unknown 
str-25 -3.69 Transmembrane Receptor 
H34I24.3 -3.65 TRP Channel Like  
fmi-1 -3.59 Cadherin  
smg-5 -3.50 Nonsense Mediated Decay 
C06B8.3 -3.35 Hydroxysteroid Dehydrogenase 
F33H12.8 -3.27 Unknown 
C28G1.6 -3.21 Ret Finger Protein 
tag-244 -3.19 Unknown 
Y46D2A.8 -3.16 Unknown 
Y47H10A.6 -3.10 Unknown 
cyp-35D2 -3.09 Cytochrome P450 
ZK484.6 -3.04 Unknown 
Y54G2A.10 -2.96 Unknown 
clec-187 -2.94 C-type Lectin 
R10D12.10 -2.92 Tau Tubulin Kinase 
spp-4 -2.89 Saposin  
C51E3.11 -2.84 Unknown 
mys-4 -2.82 Histone Acetyltransferase 
C14C6.3 -2.76 Fucosyltransferase 
acr-12 -2.67 Acetylcholine Receptor 
acd-1 -2.66 Sodium Channel 
fbxa-159 -2.59 F-box A Protein 
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Table 3.2   Overlap between the 457 upregulated genes in nhr-14 (tm1473) mutants and genes 
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Cellular iron homeostasis is maintained by iron regulatory proteins 1 and 2 (IRP1 and IRP2). IRPs bind to
iron-responsive elements (IREs) located in the untranslated regions of mRNAs encoding protein involved
in iron uptake, storage, utilization and export. Over the past decade, signiﬁcant progress has been made
in understanding how IRPs are regulated by iron-dependent and iron-independent mechanisms and the
pathological consequences of IRP2 deﬁciency in mice. The identiﬁcation of novel IREs involved in diverse
cellular pathways has revealed that the IRP–IRE network extends to processes other than iron homeostasis.
A mechanistic understanding of IRP regulation will likely yield important insights into the basis of disorders
of iron metabolism. This article is part of a Special Issue entitled: Cell Biology of Metals.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Iron is required by most organisms as it serves as a prosthetic group
for proteins involved in central cellular processes, including respiration,
DNA synthesis and oxygen transport. In excess, cellular iron catalyzes
the generation of free radicals that damage protein, DNA and lipids,
whereas cellular irondeﬁciency impairs cellular proliferation. In humans,
with the inherited diseases hemochromatosis, excess cellular iron can
result in cirrhosis, cardiomyopathy and diabetes mellitus (reviewed
in [1]). Excess iron content in the brain is associated with several
inherited neurodegenerative diseases, including neurodegeneration
with brain iron accumulation (NBIA) and Friedreich's ataxia (FA), as
well as common neurodegenerative disorders such as Parkinson's
and Alzheimer's diseases (reviewed in [1–3]). On the other hand,
iron deﬁciency affects billions of people worldwide, and results in
cognitive defects in children and anemia in adults. Cellular iron content
must therefore be maintained within a narrow range to avoid the
adverse consequences of iron deﬁciency or excess. Maintenance
of cellular iron homeostasis is accomplished by the coordinated
regulation of iron uptake, storage and export by iron-regulatory
proteins 1 and 2 (IRP1 and IRP2, also known as ACO1 and IREB2).
This review focuses on advances in IRP regulation of iron metabolism
focusing on the past 6 years. We direct readers to several excellent
reviews on IRPs [4–7] and to chapters in this volume on systematic
iron homeostasis, iron–sulfur (Fe–S) cluster biogenesis, iron trafﬁck-
ing, and SKP1–CUL1–FBXL5 structure and function.
2. Overview of systemic and cellular iron metabolism
2.1. Systemic iron metabolism
Approximately, 1–3 mg of iron is absorbed by humans each day, in
order to replace iron losses in the urine, sweat and from desquamated
enterocytes. As mammals lack a regulated physiological mechanism
for iron excretion, intestinal iron absorption is a highly regulated pro-
cess. Dietary non-heme ferric iron is absorbedby enterocytes by divalent
metal transporter 1 (SLC11A2, also known as DMT1 and NRAMP2) after
reduction by membrane bound ferrireductases (such as duodenal cyto-
chrome b (CYBRD1, also known as DCYTB)) (Fig. 1). Heme iron is also
taken up by enterocytes by an undeﬁned mechanism. Cellular iron is
translocated through the enterocyte and is exported into the circulation
by the basolateral exporter ferroportin (SLC40A1). Iron export is depen-
dent on the oxidation of iron by the membrane bound multicopper
oxidase hephaestin enabling it to bind to plasma transferrin (Tf).
Diferric Tf (Tf-Fe(III) is the major form of iron for most cells with ery-
throid precursors being the major user as iron is required for heme syn-
thesis. Tf-Fe(III) binds to cell surface transferrin receptor 1 (TFRC, also
known as TfR1) followed by internalization of the Tf-Fe(III)–TfR1 com-
plex by clathrin-mediated endocytosis. On acidiﬁcation of the endosome,
ferric iron is released from Tf and reduced by STEAP3, and exported into
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the cytosol by DMT1. Cytosolic iron is used for the formation of iron-
containing proteins and by the mitochondria for biosynthesis of Fe–S
clusters and heme. When body iron stores and erythropoiesis are ade-
quate, iron export from enterocytes is reduced by hepcidin-mediated
internalization and degradation of ferroportin, and instead iron is stored
in ferritin. Iron in ferritin is lost after 3 days by desquamation of intestinal
cells.
The small amount of iron (1–3 mg) absorbed by humans each
day represents only a fraction of the total body iron, and most of
the circulating iron comes from the recycling of heme from senescent
erythrocytes by reticuloendothelial macrophages. The iron released
from heme is exported into the circulation by ferroportin where it
binds to apoTf for delivery to bone marrow for hemoglobin synthesis.
Elevated hepatic iron stores and inﬂammation increase hepcidin
production, which mediates ferroportin degradation in intestinal cells
and in reticuloendothelial macrophages, leading to reduced plasma
iron levels.
2.2. IRPs are the principal cellular iron regulators in vertebrates
Maintaining cellular iron content requires precise mechanisms for
regulating its uptake, storage and export. IRP1 and IRP2 are the principal
regulators of cellular iron homeostasis in vertebrates. IRPs are cytosolic
proteins that bind to iron-responsive elements (IREs) in the 5′ or 3′
untranslated regions of mRNAs encoding proteins involved in iron
uptake (TfR1, DMT1), sequestration (H‐ferritin subunit (FTH1) and
L‐ferritin subunit (FTL)) and export (ferroportin) (Fig. 2). When
cells are iron deﬁcient, IRPs bind to 5′ IREs in ferritin and ferroportin
mRNAs with high afﬁnity to repress translation, and to 3′ IREs in TfR1
mRNA to block its degradation. When iron is in excess, IRPs do not
bind to IREs, increasing synthesis of ferritin and ferroportin, while
promoting the degradation of TfR1 mRNA. The coordinated regulation
of iron uptake, storage and export by the IRPs ensures that cells acquire
adequate iron for their needs without reaching toxic levels.
IRPs also regulate other mRNAs that contain 5′ IREs, including
mitochondrial aconitase (ACO2, also known as m-acon, tricarboxylic
acid cycle (TCA)), erythroid aminolevulinate synthase (ALAS2, also
known as eALAS, heme biosynthesis), hypoxia-inducible transcription
factor-2α (EPAS1 also known as HIF-2α, hypoxia adaptation) and
amyloid beta precursor protein (APP, Alzheimer's disease), and 3′ IREs,
including DMT1 (metal transport), CDC14A (mitotic phosphatase),
CDC42‐binding protein kinase α (also known as MRCKα, cytoskeletal
dynamics) and hydroxyacid oxidase 1 (HAO1, peroxisomal enzyme)
[8–17]. More recently, a transcriptome-wide approach was utilized to
identify 35 novel putative IRE-containing mRNAs, some of which have
exclusivity for IRP1 or IRP2 [18]. While these mRNAs each contain an
IRE, the roles of many of these IREs in vivo remain to be determined.
The presence of IREs in a variety of mRNAs indicates that IRP regulation
extends to processes other than iron homeostasis.
Fig. 1. Control of mammalian cellular iron homeostasis by the IRE–IRP regulatory network. A generic mammalian cell depicting roles of proteins encoded by IRE-containing mRNAs
(red lettering). Transferrin bound to two iron atoms (Tf-[Fe(III)2) binds to TfR1 on the cell surface where the Tf-[Fe(III)2–TfR1 complex is endocytosed. Acidiﬁcation of the endosome
causes the release of Fe(III) (red balls) from Tf where it is reduced to Fe(II) (orange balls) by the STEAP3 oxidoreductase before export by DMT1 (divalent metal transporter 1).
ApoTf/TfR1 complex is returned to the cell surface where it dissociates and initiates another round of iron uptake. Tf-bound iron is taken up by most cells, but it is especially im-
portant in erythroid precursors where it is the primary source of iron for heme synthesis. DMT1 is also localized on the apical membrane of duodenal enterocytes where it trans-
ports Fe(II) after reduction by membrane reductases, such as DCYTB. Iron taken up by either TfR1 or DMT1 enters a cytosolic free labile iron pool thought to consist of Fe(II) bound
to small molecular weight molecules. IRPs sense iron in this pool and regulate the translation of 5′ IRE-containing mRNAs (H-ferritin and L-ferritin, eALAS (erythroid
aminolevulinate synthase), mitochondrial (m)-aconitase and ferroportin) or the stability of 3′ IRE-containing mRNAs (TfR1 and DMT1). eALAS serves as the rate-limiting enzyme
in heme synthesis in erythroid precursors. Mitochondrial aconitase is an enzyme in the TCA cycle that requires a [4Fe–4S] cluster for activity. Iron that is not utilized or stored in
ferritin is exported by ferroportin. Export of iron from cells is coupled to the oxidation of iron by membrane-bound hephaestin or serum multicopper oxidase ceruloplasmin (CP).
Modiﬁed from Wallander et al. [4].
Fig. 2. IRPs regulate translation and stability of IRE-containing mRNAs. IRPs bind to IREs
located in either the 5′ or 3′ untranslated regions of speciﬁc mRNAs. When iron is limited,
IRPs bindwith high afﬁnity to 5′ IREmRNAs and repress translation, and to theﬁve 3′ IREs
in TfR1mRNA and to the single IRE in DMT1mRNA and stabilize thesemRNAs.When iron
is abundant, IRPs do not bind IREs, resulting in the translation of 5′ IRE-containingmRNAs
and degradation of TfR1 mRNA. Iron mediates the conversion of the IRP1 RNA binding
form into the [4Fe–4S] cluster c-aconitase form and the ubiquitination and targeted
proteasomal degradation IRP2 by FBXL5 E3 ligase. IRE-containing mRNAs indicated are
those that have been shown to be functional in vivo.
Modiﬁed fromWallander et al. [4].
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3. Recent advances in IRP1 regulation
Although IRP1 and IRP2 share approximately 64% identity, bind
RNA and are regulated by iron, they differ in several ways. First, IRP1
is a bifunctional protein serving either as a high afﬁnity IRE binding
protein in its apoprotein form or the cytosolic isoform of the iron–
sulfur (Fe–S) enzyme aconitase (c-acon) (Fig. 3). Formation and loss
of the [4Fe–4S] cluster regulates RNA binding and provides unique
links between IRP1 and cellular Fe–S cluster biogenesis. Second, IRP1
has distinctive roles in the adaptive response to oxygen availability as
well as in sensing reactive oxygen species (ROS) or reactive nitrogen
species (RNS). Third, IRP1 is controlled by multiple iron-dependent
mechanisms, including targeted protein degradation to limit accumula-
tion of the RNA binding form of IRP1 [19]. Fourth, phosphorylation of
IRP1 at serine 138 dictates the mechanism of its regulation by iron.
Unlike IRP1, IRP2 lacks a [4Fe–4S] cluster and aconitase activity, and
functions as an RNA binding protein. IRP2 is primarily regulated by
iron-mediated degradation. Thus, IRP1 responds to iron-dependent
and iron-independent signals that control its function throughmultiple
mechanisms in order to maintain IRE-binding activity within a range
that permits the optimal maintenance of cellular iron homeostasis.
3.1. Regulation of IRP1 RNA binding activity by the 4Fe–4S cluster
The key role of the [4Fe–4S] cluster in IRP1 in controlling RNA
binding activity provides ameans for linking cellular pathways involved
in formation of these cofactors to cellular iron status. In recent years,
many studies have focused onunraveling themechanismand pathways
of Fe–S biogenesis in model organisms and their dysfunction in human
disease [20–23] [see also Lill et al. in this volume]. In brief, the evidence
indicates that the major pathway for biogenesis of Fe–S clusters and
their insertion into cytosolic proteins, such as IRP1, ﬁrst involves
targeting of iron to the mitochondria where it is imported through the
action of mitoferrin [24] [see also Paw et al. in this volume]. A transient
Fe–S cluster is formed on the scaffold protein ISCU through the action of
iron, the iron binding protein frataxin and sulﬁde derived from cysteine
via the cysteine desulfurase NFS1 and its partner ISD11 [25–30]. The
Fe–S cluster on ISCU, or in some cases other scaffold proteins [31], is
donated to apoprotein targetswith the assistance of protein chaperones
(e.g. HSCB in humans) and electron donors (e.g. FDX, ferredoxin) [21].
Activities of the mitochondrial Fe–S cluster biogenesis machinery
alongwith the exportmachinery components (e.g. ABCB7) are required
for activation of the cytosolic Fe–S cluster assembly (CIA) pathway.
Genetic approaches using IRP1 expressed in yeast led to discovery
of the ﬁrst CIA factor, Cfd1 [32]. Additional elegant studies primarily
in yeast led to identiﬁcation of Nbp35 that together with Cfd1 forms the
initial Fe–S scaffold for cytosolic cluster formationwith the assistance of
DRE2 and TAH18 [30,32–36]. Transfer of the labile cluster from Cfd1/
Nbp35 to some apoprotein targets requires the Nar1/Cia1 heteromer
while for others Nbp35 sufﬁces (reviewed in [22]). Interestingly, recent
studies have begun to identify “speciﬁcity factors” that target speciﬁc
apoFe–S proteins (e.g. complex 1) [37,38]. Whether or not separate
pathways for Fe–S cluster biogenesis exist for sensory and regulatory
roles of Fe–S proteins in mammalian cells, such as IRP1, remains to be
determined.
Primarily through the use of RNAi-based knockdown approaches,
the activity of the Fe–S biogenesis pathways have been shown to
inﬂuence cellular iron sensing and distribution in mammalian cells.
Disruption of components of the mitochondrial Fe–S biogenesis
pathway, including the cysteine desulfurase NFS1 and its partner ISD11
[25,39], the Fe–S scaffolds ISCU [40] and ISCA [41], the iron binding
protein frataxin [27,42], glutaredoxin 5 [43], protein chaperone
HSC20 [44,45] and electron donors ferredoxins 1 and 2 [39,46], impairs
the activity of both mitochondrial, cytosolic, and presumably nuclear
Fe–S proteins in mammalian cells. The ensuing reduction in c-acon
activity is reﬂected in IRP1 activation that is associatedwith an increase
in TfR1 and reduction in ferritin expression. That IRP2 is stabilized
suggests a general cytosolic iron deﬁciency [39,43,44,47,48]. While
the increase in TfR1 and repression of ferritin induced by IRP activation
may reﬂect a compensatory mechanism to combat cytosolic iron
deﬁciency, failure to prevent further inappropriate iron accumulation
in the face of excess iron reﬂects an inability to downregulate IRP activ-
ity that could be cytotoxic [40]. There is also evidence of cellular iron
maldistributionwith abnormal cellular iron deposits andmitochondrial
overload coupled with cytosolic iron deﬁciency when mitochondrial
Fe–S biogenesis is impaired [40,43,47]. Similar changes have been ob-
served in yeast [49–53]. While these studies conﬁrm the concept that
cytosolic Fe–S cluster biogenesis is dependent on active mitochondrial
cluster formation in mammalian cells, they also demonstrate that the
impact of impaired mitochondrial Fe–S biogenesis may in part involve
indirect effects on IRPs or IRP targets. Future studies should address
questions concerning what pathways of Fe–S cluster biogenesis are
sensed by IRP and whether trafﬁcking of iron through mitochondria is
an obligate process through which IRP senses iron.
The impact of impaired cytosolic Fe–S cluster biogenesis on IRP1 has
also been examined [54–58]. Reduction of NUBP1 andNAR1 speciﬁcally
impairs cytosolic Fe–S proteins, including c-acon and others [56–58].
Concomitant with this is the activation of IRP1 along with an increase
in TfR1 and a reduction in ferritin expression. Interestingly, IRP2 is not
affected suggesting that the response of IRP2 observedwhenmitochon-
drial Fe–S biogenesis is impaired is a secondary response to the maldis-
tribution of cellular iron. Thus, as is the case when the cytosolic Fe–S
cluster biogenesis system is inhibited in yeast, inhibition of the cognate
proteins in mammalian cells has a selective impact on cytosolic Fe–S
proteins. The ﬁnding that IRP2 is stabilized in ABCB7-deﬁcientmamma-
lian cells may reﬂect a feedback effect on mitochondrial Fe–S cluster
formation or iron metabolism [55]. Deletion of the yeast homolog of
ABCB7, Atm1p, also leads to an abnormal distribution of iron [51].
Taken together, these studies suggest that unlike IRP1, IRP2 does not
sense the ﬂux of iron through the cytosolic Fe–S biogenesis pathway.
Investigations of the etiology of FA provide the most clearly
understood example linking a human disease of Fe–S cluster biogenesis
and alterations in IRP function (reviewed in [59–61]). FA is the most
common inherited ataxia in humans. It is primarily caused by formation
Fig. 3. Iron-dependent and iron-independent mechanisms for regulating IRP1. IRP1 can
be regulated through mechanisms dependent or independent of the [4Fe–4S] cluster. In
the cluster-dependent pathway, IRP1 has dual roles either as a high afﬁnity IRE-binding
protein when devoid of the [4Fe–4S] cluster or as a c-aconitase when the [4Fe–4S] cluster
is assembled. The c-aconitase formdoes not bind RNA. The [4Fe–4S] cluster is accessible to
lowmolecular cluster perturbants, including reactive oxygen species (ROS), such as O2•−,
H2O2 or reactive nitrogen species (RNS), such as NO• or ONOO−. Hypoxia stabilizes
the c-aconitase form by reducing the level of oxygen or ROS. IRP1 can be phosphorylated
at S138. IRP1 phosphomimetic mutants indicate that the Fe–S cluster can be assembled
and the protein exhibits aconitase activity; however, the Fe–S cluster is more sensitive
to disruption by oxygen and hydrogen peroxide. Iron stimulates the FBXL5-mediated
degradation of IRP1 S138 phosphomimetic mutants and non-phosphorylated IRP1 when
Fe–S cluster biogenesis is impaired.
Modiﬁed fromWallander et al. [4].
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of triplet expansion repeats in the frataxin gene leading to reduced
expression of this small acidicmitochondrial protein althoughmissense
mutations of frataxin are also a cause. Frataxin binds to a complex
containing the Fe–S scaffold protein ISCU and the cysteine desulfurase
NFS1 and its partner ISD11, and in this process is believed to function
as an iron chaperone [27–29,62]. One study reported that a small por-
tion of frataxin also functions in the cytosol where it interacts with
IRP1 and facilitates conversion to c-acon [42]. At the cellular level, FA
is characterized by a loss of activities of mitochondrial, cytosolic, and
presumably nuclear Fe–S proteins. Similar to what has been observed
with the knockdown of other participants inmitochondrial Fe–S cluster
biogenesis pathway, FA is associated with mitochondrial iron overload
and signs of cytosolic iron deﬁciency [27,63,64]. Both IRPs are activated,
and this is associated with a reduction in ferritin and increase in TfR1
expression. Furthermore, expression of the iron exporter ferroportin is
reduced further contributing to the abnormal iron distribution, and
presumably to oxidative stress observed in FA [64]. Interestingly,
frataxin deﬁciency is associated with a reduction of other components
of the mitochondrial Fe–S cluster machinery, including ISCU and NFS1,
along with defects in heme synthetic enzymes [64]. The fact that
frataxin expression is itself reduced in iron deﬁciency suggests that
the induction of cytosolic iron deﬁciency due to impairedmitochondrial
Fe–S cluster biogenesis could be ampliﬁed by a downstream impact of
reduced frataxin expression [27]. An interesting area for further investi-
gation concerns the extent towhich enhanced accumulation of IRE RNA
binding activity, especially that provided by the large latent pool of IRP1
RNA binding activity in the form of c-acon, coupled with impaired
ability to down-regulate IRP due to inhibition of the iron-dependent
SKP1–CUL1–FBXL5 (S-phase kinase-associated protein 1-Cullin 1-F-
box-leucine rich repeat protein 5) E3 ubiquitin ligase further exacerbates
disease etiology. This issue likely has relevance to numerous diseases
of Fe–S cluster biogenesis (reviewed in [46,59]).
3.2. Fe–S cluster disassembly in c-acon facilitates sensing reactive oxygen
and nitrogen species
The discovery that IRP1 RNA binding activity could be generated
from c-acon raised a key issue of how, and under what conditions,
could the Fe–S cluster be removed. Iron deﬁciency per se was not
believed to be sufﬁcient to promote loss of the cluster on its own. How-
ever, aconitases have long been known to sense ROS and RNS because
their [4Fe–4S] cluster is solvent accessible and these reactive species
can initiate cluster loss (reviewed in [65]). In fact, for one isoform of
aconitase in Escherichia coli, the ease with which it was inactivated by
superoxide anion appears to function as a feedback mechanism to
modulate an overactive electron transport chain [66]. This only requires
conversion to the [3Fe–4S] cluster species that, in the case of c-acon, is
not sufﬁcient to generate RNA binding activity. A further important
fact is that aconitases differ in their sensitivity to ROS and RNS, where
c-acon is more resistant [67–69]. Thus, although the Fe–S switch
mechanism was accepted as a bonaﬁde means for iron regulation of
IRP1, the mechanistic basis through which it occurred was not clear.
Insight into this problem came from early studies showing that
tumor cell aconitase was a target of NO generated by activated
macrophages (reviewed in [70]). On this basis, a large number of
studies were initiated demonstrating that NO and its reactive product
ONOO− can facilitate conversion of c-acon to IRP1 (reviewed in [71]).
NO also inﬂuenced IRP2, but the mechanism for this regulation and
the impact on iron metabolism was unclear [72,73]. Recent studies
using mice lacking IRP1 or IRP2 have assessed the role of each IRP in
the NO-dependent regulation of macrophage iron metabolism. These
studies demonstrated that IRP1 was solely responsible for alterations
in macrophage iron metabolism in response to NO [74]. Furthermore,
NO-dependent activation of IRP1 could ameliorate abnormal iron
storage in Irp2−/− bone marrow macrophages ex vivo by repressing
ferritin expression. Similarly, activation of IRP1 by the pharmacological
nitroxide Tempol prevented the neurodegenerative symptoms in
Irp2−/−mice [75]. Tempol is best known as a free radical scavenger;
however, in Irp2−/− mice Tempol appeared to promote cluster loss
from c-acon through the direct action of RNS.
While the ability of NO to activate IRP1 may be necessary for mac-
rophage activation or action, the physiological role of ROS is less clear.
Loss of the Fe–S cluster from aconitases can be initiated by superoxide
leading to the generation of the [3Fe–4S] non-RNA binding form and
H2O2 generates IRP1 from c-acon although the mechanism through
which this occurs is not clear (reviewed in [76,77]). Increased conver-
sion of c-acon to IRP1 by H2O2 may enhance iron uptake while
impairing storage and export, leading to iron overload. However a re-
cent report suggests a mechanism to partially evade IRP action under
these conditions [78]. Perhaps the physiological role of ROS involves
the constant conversion of a small fraction of c-acon into IRP1.
Depending on the cellular iron status, IRP1 could then be converted
back to c-acon or remain in the RNA binding form to regulate IRE-
containing mRNAs. In other words, physiological generation of ROS
may be necessary for iron sensing by IRP1.
An additional, but not necessarily alternative view is that the
sensitivity of c-acon to ROS and RNS can be regulated allowing for the
existence of pools of protein with a stable versus unstable Fe–S cluster.
Previous studies demonstrated that two protein kinase C phosphoryla-
tion sites exist in IRP1, S138 and S711. S138 phosphomimetic mutants
of c-acon are much more oxygen labile compared to the wildtype pro-
tein and are also at least 10-foldmore sensitive to NO in terms of cluster
disassembly [79,80]. Furthermore, these phosphomutants undergo
spontaneous disassembly of the Fe–S cluster even in the absence of a
perturbant [80]. Another study showed that IRP1 activation by H2O2
requires a signaling pathway possibly involving phosphorylation
[81]. Taken together, these studies show that rapid recruitment of
IRE-binding activity can be achieved by cluster perturbants or phos-
phorylation induced alterations in Fe–S cluster stability.
3.3. Iron regulation of IRP1 protein degradation
Early studies on themechanismof IRP1 regulation by iron suggested
that protein degradationwas the primarymechanism for inactivation of
RNA binding [82]. With the demonstration that IRP1 is the cytosolic
isoform of aconitase, and that insertion and loss of the [4Fe–4S] cluster
regulated RNA binding, the “Fe–S switch” mechanism was widely
accepted as the dominant mechanism for controlling IRP1 RNA binding
activity [83]. This view was further advanced by the observation that
total levels of IRP1/c-acon protein did not change as a function of iron
status. Inmany cases, however, the c-acon pool is in vast excess relative
to IRP1 [84,85]. Thus, the much larger and more stable c-acon pool
would mask iron-dependent changes in abundance of IRP1. Liver pro-
vides a case in point as c-acon exceeds IRP1 by more than 100-fold.
Severe dietary iron deﬁciency results in an increase of IRP1 RNAbinding
activity of no more than 4-fold, indicating that a small portion of the c-
acon pool was recruited [84]. Hence, iron-mediated degradation of IRP1
would not be routinely observed using immunoblots. Some evidence
indicated that IRP1 could be regulated through protein degradation
during iron overload or through phosphorylation [86,87]. The role of
protein degradation in controlling IRP1 was examined anew using
models where the Fe–S switch was disrupted either by mutation of
cluster-ligating cysteines or through genetic manipulation of Fe–S clus-
ter assembly or disassembly [54,88]. In this manner, regulation of IRP1
can be examined without c-acon. Under these conditions, IRP1 stability
was clearly iron-regulated, and led to the view that iron-mediated IRP1
degradation was a compensatory mechanism to prevent excess RNA
binding activity when the Fe–S cluster switch mechanism is not active,
which can be lethal [19,54]. The relevance of this mechanism to IRP1
function was further substantiated with the ﬁnding that the FBXL5 E3
ligase that targets IRP2 for degradation also acts on IRP1 [89–91].




Given these ﬁndings, it is of interest that studies where Fe–S cluster
biogenesis is impaired, IRP1 protein levels dropped signiﬁcantly
[25,41,44,47,48,54–58,92]. Under these conditions, IRP1 protein can be
stabilized by iron chelation, suggesting that the loss of IRP1 is not mere-
ly due to instability of an apoprotein but instead is part of a second iron
dependent mechanism to control accumulation of IRP1 RNA binding
activity [54]. Impaired mitochondrial Fe–S biogenesis leads to cytosolic
iron deﬁciency, presumably reducing FBXL5 activity as evidenced by
increased IRP2 protein levels [23,27,39,44,47,48,55]. The mechanism
by which IRP1 is degraded while IRP2 is stabilized under these condi-
tions remains undetermined. Relative to normal cells, a reduction in
FBXL5 activity in response to impaired mitochondrial Fe–S biogenesis
could lead to increased IRP2 accumulation but still be sufﬁcient to
degrade excess IRP1 arising from an inability to accumulate c-acon.
FBXL5 independent mechanisms may also account for this paradox,
but further studies are required to determine FBXL5 function in re-
sponse to impaired mitochondrial Fe–S cluster biogenesis. Regardless
of themechanism, the extent towhich IRP1 and IRP2 RNAbinding activ-
ity rises to pathological levels when Fe–S cluster formation is impaired
is likely to be inﬂuenced by the abundance of c-acon and the extent to
which FBXL5 is inactivated. These factors will likely be strong predictors
of the extent to which IRP1 and IRP2 RNA binding activity rise to unac-
ceptable levels in pathological states involving impaired Fe–S cluster
formation or accelerated cluster disassembly.
3.4. S138 phosphorylation and the mechanism of IRP1 regulation by iron
The Fe–S switch and protein degradation mechanisms for control-
ling IRP1 function could each have unique uses in modulating iron
metabolism in order to meet cellular needs. Hence, issues such as sen-
sitivity to Fe–S biogenesis activity or the level of ROS or RNS may
meet the distinctive iron requirements of speciﬁc cell types or physi-
ological scenarios. A mechanism that could serve these needs involves
S138 phosphorylation of IRP1 by protein kinase C because it leads to
accumulation of the RNAbinding form [93]. The ﬁnding that S138 phos-
phomimetic mutants of IRP1 could be converted to a form of c-acon
with a highly unstable Fe–S cluster suggested an altered set-point for
iron regulation [79]. Surprisingly, the S138E phosphomutant was still
subjected to iron regulation but as a consequence of iron-stimulated
protein degradation reminiscent of IRP2 regulation [87]. In order to
determine if enhanced oxidative damage of IRP1 as a consequence of
increased Fe–S cluster cycling in IRP1S138E promoted its degradation,
the cluster-ligating cysteine residues were mutated to serine, blocking
cluster insertion in S138E and wildtype IRP1 (IRP1S138E/3C>3S and
IRP13C>3S). While this failed to block iron-dependent degradation of
IRP1S138E, the more surprising result was that the protein level of
IRP13C>3S and another cluster mutant were iron-regulated [54,88].
These observations were conﬁrmed by the subsequent demonstration
that IRP1 is a substrate for the FBXL5 E3 ligase [89,90]. Recent studies
indicate that IRP1S138E can be regulated either by protein degradation
or Fe–S cluster insertion depending on the level of ROS or RNS [80].
These studies suggest that S138 phosphorylation of IRP1 is a mecha-
nism to rapidly increase IRP1 RNA binding activity and to facilitate
formation of a pool of c-acon that is sensitive to cluster perturbants
and cellular iron levels. Coupled with the iron-mediated degradation
of IRP1 by FBXL5, inducible phosphorylation broadens the physiological
scenarios of IRP1 action.
3.5. IRPs and oxygen sensing
The discovery of a functional IRE in the 5′ UTR of the mRNA
encoding HIF-2α suggested new roles for IRPs in the adaptive re-
sponse to hypoxia and iron deﬁciency [10]. A recent study reported
that HIF-2α mRNA is translationally repressed in liver from iron-
deﬁcient rats, and is associated with increased IRP1 and IRP2 activity
[94]. Other studies have provided evidence that the HIF-2α IRE is
preferentially targeted by IRP1 [11,95]. HIF-2α is primarily regulated
by protein stabilization in response to hypoxia and iron deﬁciency
(reviewed in [96,97]). Under these conditions, HIF-2α stimulates eryth-
ropoiesis through activation of erythropoietin (EPO) and intestinal iron
absorption through the activation of DMT1 and ferroportin [98–101],
providing a mechanism to coordinate iron uptake with red cell produc-
tion. IRP-dependent translational regulation of HIF-2αmRNA has been
proposed as a mechanism to reduce EPO production during hypoxia
resulting from impaired erythropoiesis in iron deﬁcient anemia, there-
by ensuring that microcytic hypochromic red blood cells are not
produced [10]. Given the preferential regulation of HIF-2α mRNA by
IRP1, this suggests that under hypoxic iron sufﬁcient conditions IRP1
would exist in its c-acon form, and unable to bind RNA, ensuring that
HIF-2α mRNA is translated and EPO is produced. The signiﬁcance of
the preferential regulation of the HIF-2α IRE by IRP1 requires further
investigation.
3.6. Hierarchical regulation of IRE-containing mRNA
Vertebrate mRNAs containing consensus IREs encode proteins of
widely varying function, from those with a direct role in iron metab-
olism to proteins involved in the regulation of citrate metabolism (m-
acon), cell proliferation, cytoskeletal dynamics (MRCKα), cell cycle
(CDC14A), and in the adaptive responses to hypoxia (HIF-2α). The
broad functional spectrum of proteins encoded by IRE-containing
mRNAs suggests that they are not identically regulated by IRPs. A
comparison of the binding afﬁnity of 5′ IRE-containing mRNAs to
IRP1 provides a basis for determining the extent to which IRPs may
act hierarchically in mammals.
One example of differential regulation of IRP target mRNAs is
expression of ferritin and eALAS during erythroid differentiation.
Erythroid precursors have a high iron requirement given the large
quantity of heme and hemoglobin they produce. Thus, in erythroid pre-
cursors producing hemoglobin, iron would be diverted tomitochondria
for heme formation and away from storage in ferritin. With regard to
IRPs, the evidence indicates that eALASmRNA ismoreweakly regulated
than ferritin mRNA [9]. In primary murine erythroid progenitors upon
differentiation, ferritin mRNA translation is tightly repressed with less
than 5% of the mRNA polysome bound, whereas translation of eALAS
mRNA is more efﬁciently translated with 40% of this mRNA associated
with polysomes [102]. This 8-fold relative difference in translatability
of these mRNAs occurred under conditions when IRPs are activated
and TfR1 mRNA levels are enhanced. The higher afﬁnity of the ferritin
IRE for IRPsmay in part explain its selective repression under these con-
ditions [103]. It remains to be determined if the polysome bound eALAS
mRNA present during normal erythroid differentiation has escaped IRP
action due to its low-afﬁnity IRE or because variants of the eALASmRNA
exist that lack the IRE. Regarding this point it is of interest that at least
two studies indicate that both IRPs are critical for red cell heme forma-
tion. First, in Irp2−/−mice, eALAS biosynthesis is increased in erythroid
bone marrow precursor cells, leading to inappropriate synthesis of
protoporphyrin IX and anemia [104]. These mice also display reduced
TfR1 and increased ferritin expression, indicating erythroid precursors
are iron deﬁcient. Although Irp1−/− mice do not develop microcytic
anemia, the anemia is more severe in Irp2−/− Irp1+/−mice, indicating
that IRP1 has a role in erythroid function [105]. Second, in zebraﬁsh
and humans, defects in glutaredoxin 5 lead to impairment of mitochon-
drial Fe–S biogenesis and cytosolic iron depletion that activates IRP1,
and reduces eALAS expression [19,43]. Taken together, these studies
suggest that differential targeting of 5′ IRE-containing mRNAs by IRPs
is essential for optimal coordination of heme formation and iron storage
during erythropoiesis.
Another example of differential regulation of IRP target mRNAs is
the expression of ferritin andm-acon [84,106]. Dietary iron deﬁciency
leads to a reduction of liver ferritin to undetectable levels. The decline
of m-acon protein levels under these conditions is signiﬁcant, but
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reﬂects only about a 50% decrease. Thus, in response to the same sig-
nal, proteins encoded by 5′ IRE-containing mRNAs, are selectively
regulated. These differences in expression can be attributed to the
selective regulation of these proteins at the translational level, as
observed in cultured cells and in cell-free protein synthesis systems
programmed with IRP1 or IRP2 [84,106,107] and the ﬁnding that
IRP1 binds less well to the m-acon versus L-ferritin IRE [108,109].
Consistent with these ﬁndings, genetic ablation of both IRP1 and
IRP2 in mice leads to a substantial enhancement not only of ferritin,
but also ferroportin expression in intestine, while there was a smaller
fold increase in m-acon expression [110]. These studies support the
view that m-acon mRNA is less efﬁciently repressed in tissues com-
pared with other 5′ IRE-containing mRNAs.
A third example of differential regulation of 5′ IRE-containing
mRNAs in mammals comes from a comparison of HIF-2α and L-ferritin
mRNA translation in liver [94]. In iron-replete rat liver, about 3-fold
more HIF-2α mRNA was found associated with polysomes compared
with L-ferritin mRNA. Iron deﬁciency leads to increased IRP RNA binding
activity and a further translational repression of bothmRNAs, yet HIF-2α
mRNA remained more highly polysome associated. Finally, the compar-
ison of succinate dehydrogenase iron protein subunit and ferritin expres-
sion inDrosophila further indicates that IRP hierarchically regulatemRNA
translation in vivo [111]. Thus, differential translational control of 5′ IRE-
containingmRNAby IRPs is essential for adaptive changes in ironmetab-
olism and in other metabolic processes.
What dictates the differential translational control of 5′ IRE-
containing mRNAs? To determine how mRNAs containing functional
5′ IREs are differentially regulated, the afﬁnity of IRP1 for six 5′ IRE-
containing mRNAs was determined [108]. These IREs bound to IRP1 in
a hierarchical manner that related to the function of the encoded pro-
tein, such that ferritin IREs had the highest afﬁnity while m-acon had
the lowest. IRP1 bound to 5′ IREs over a 9-fold range: L-ferritin,
H-ferritin, ferroportin, HIF-2α, eALAS and m-acon (Fig. 4A). Similar re-
sults were reported for IRP1 binding afﬁnities for ferritin and m-acon
IRE using an alternative binding assay [109]. Given the high afﬁnity of
IRP1 for binding the IRE (pM afﬁnity), a valid concern is whether the
9-fold difference in afﬁnity is sufﬁcient to alter regulation. To address
this, the afﬁnity of IRP1 with a L-ferritin mutant IRE observed in a case
of hereditary hyperferritinemia–cataract syndrome (HHCS) was exam-
ined. The afﬁnity of themutant L-ferritin IRE differed from thewildtype
by only 1.9 fold yet this was sufﬁcient to produce L-ferritin dys-
regulation in vivo [108,112]. A more striking evaluation of this is seen
when the afﬁnities of a large number of HHCS IRE mutants were com-
pared to the rise in serum ferritin due to mRNA derepression [113]
(Fig. 4B). The plot of serum ferritin as a function of Krel (relative binding
afﬁnity) revealed that the steepest slope occurred over the ﬁrst 10-fold
loss of afﬁnity. Similar results were obtained for IRP2 [113]. This is
essentially the same range of afﬁnity differences observed for the
binding of natural 5′ IREs to IRP1 (Fig. 4A). These ﬁndings indicate
that small changes in IRP1 or IRP2 binding afﬁnity lead to physiological
and pathologically signiﬁcant changes in the synthesis of proteins
encoded by 5′ IRE-containing mRNAs.
How are these changes in afﬁnity of interaction between IRP1 and
IRE established? Binding afﬁnity is dependent on the number and
strength of bonds between receptor and ligand, and biologically sig-
niﬁcant differences in afﬁnity are usually assumed to involve a loss
or gain of multiple bonds. In the case of IRP1, however, it can be in-
ferred that the 9-fold difference in binding afﬁnity would arise due
to small differences in binding energy equivalent to a single H-bond
[108]. Consequently, Goforth, et al. proposed that the difference in
bond strength and/or in an induced ﬁt mechanism, but not bond
number, may give rise to the regulatory binding hierarchy [108]. In-
deed, the recent report of the crystal structure of IRP1 bound to the
TfR1 B IRE indicated that overall the number of bonds in this complex
was essentially the same as observed in the complex of IRP1 and the
H-ferritin IRE [114]. Thus, subtle differences in binding of IREs to IRP
or in the pathway of binding are likely to be an important contributor
to the hierarchical regulation of IRE-containing mRNA. A recent study
reported that the ferritin IRE, but not the m-acon IRE directly
binds ferrous iron, leading to a weakened interaction of IRP1 [109],
suggesting an additional mechanism that contributes to the hierar-
chical regulation of IRE-containing mRNAs. There are also mecha-
nisms to evade IRE action, such as mRNA isoforms that lack the IRE
or those that contain internal ribosome entry sites [78,115].
3.7. What constitutes an IRE?
A key factor in the discovery of the IRE was the strong sequence
identity of a short ~28–30 nt sequence in the 5′ UTR of both H- and
L-ferritin mRNAs. Importantly, the sequence identity between these
IREs (~90%) was substantially greater than that of the coding region
(~50%) amongst vertebrate H- and L-ferritin mRNAs [116]. Of further
signiﬁcance were the accompanying “functional” discoveries of IRPs
and that the IRE conferred iron regulation of translation when trans-
ferred to the 5′ UTR of a heterologous mRNA [117–119]. Shortly
thereafter, multiple IREs were identiﬁed in the 3′ UTR of TfR1 mRNA
where they served to control RNA stability yet could modulate trans-
lation if transferred to a 5′ UTR [120]. The conserved secondary struc-
ture of IREs established the concept that the canonical IRE was an
RNA stem loop with a terminal hexanucleotide CAGUG(N) loop and
Fig. 4. Altered afﬁnity of IRP1 for mutant and natural IREs. A) The afﬁnity of interaction
of IRP1 for six vertebrate 5′ IREs as determined by electrophoretic mobility shift assays
(EMSA) [108]. The KD for these IREs varied over a 9-fold range. B)Mutations in the human
L-ferritin IREwere identiﬁed in seven patientswith hereditary hyperferritinemia–cataract
syndrome. The afﬁnity of interaction of IRP1 with mutant human L-ferritin IREs was
determined by EMSA and related to serum ferritin values reported for each patient
on different occasions (open circles) [113]. Maximal serum ferritin for each patient (closed
circles). Results on the x-axis are expressed as Krel which is KD,mutant/KD,wildtype and higher
values for Krel indicate lower binding afﬁnity of themutant IREwith IRP1. Note the steeper
slope of the relationship between serum ferritin and Krel over the range 1 to 10 for Krel.
A similar observation was made for IRP2 [113].




an unpaired C (C8) in the stem, 5′ of the loop [121] (Fig. 5). Structural
and biochemical studies indicated that formation of the AGU
pseudotriloop, as a consequence of base pairing of the ﬁrst and ﬁfth
nucleotides of the CAGUGN sequence, occurs in solution and is critical
for the binding of IRP1 [122–127]. Molecular and in silico studies
identiﬁed IREs with the same canonical loop sequence and overall
secondary structure in multiple metazoan mRNAs, and demonstrated
key roles of the terminal loop and unpaired C stem in IRP binding
[108,128,129].
The high resolution crystal structures of IRP1 bound to the ferritin
IRE and the TfR1 B IRE provide key insights into the nature of this un-
usually high afﬁnity RNA:protein interaction [114,130] (reviewed in
[128]) (Fig. 6). IRP1 binds to the IRE through two sets of interactions
separated over about 30 Å. IRP1 makes the majority of its bonds with
the IRE in a sequence speciﬁc manner and involves canonical features
of known functional IREs. Thus, the exposed nucleotides, including
AGU of the terminal pseudotriloop and the unpaired C8 residue in the
IRE stem, make 15 of 22 contacts with IRP1. The additional seven
bonds are largely with sites in the phosphodiester backbone of the
IRE stem. The two-site binding mode of IRP1, which bears strong simi-
larities with the recognition of tRNA by tRNA synthetases, allows for
enhanced speciﬁcity of RNA recognition, and likely contributes to the
unusual high afﬁnity of interaction [130]. When bound to IRP1, the
ferritin IRE exhibits signiﬁcant additional bending and twisting of the
RNA helix as a consequence of the larger inter-helical junction around
C8 and due to the presence of the unpaired U6 in ferritin IRE compared
with the TfR1 B IRE. This causes a signiﬁcant difference in the degree to
which the lower stem of the IRE approaches the so-called stem-binding
domain (domain 4) of IRP1 [114] (Fig. 6). Deviations in structure of the
lower stem of IREs have been proposed to make key contributions to
regulation [131].
Signiﬁcant large scale structural changes occur in c-acon, particular-
ly in domains 3 and 4, in order to accommodate the IRE [130] (Fig. 6). In
comparing this structure to that of c-acon [132], Walden et al. provide
unique insight into how structural plasticity of one polypeptide can
support two widely different functions [130]. They proposed that resi-
dues within IRP1/c-acon that inﬂuence the ability to interconvert be-
tween these activities may dictate the ability of why some aconitases
bind RNA but others do not. Importantly, this study establishes a struc-
tural framework from which to evaluate how the different canonical
IREs as well as proposed IRE-like elements may make use of subtle
differences in bonding or require major differences, possibly including
additional binding partners, in order to allow for their unique regulation
by IRPs.
The ﬁrst indication of structural differences amongst the known IREs
that suggested altered ability to regulatemRNA fate came from studies of
the ferritin IRE [122]. Initial computer predictions had suggested that the
highly conserved unpaired C8 formed a single nucleotide bulge and gave
rise to the canonical view of IRE secondary structure (Fig. 5). However,
secondary structure mapping with small chemical probes conﬁrmed
other in silico predictions of a more complex stem structure compared
to the canonical IREs [103,122,124]. Vertebrate ferritin IREs contain an
unpaired U two base pairs 5′ of C8 (Fig. 5) as conﬁrmed in both NMR
and X-ray crystallography [124,130,133]. This contrasts with all other
known functional IREs and even with ferritin IREs in lower organisms
that appear to only have the single C8 bulge [134]. Interestingly, deletion
of U6 from the ferritin IRE substantially diminishes the afﬁnity of interac-
tion with IRPs, particularly IRP2 [103,108,109,133,135]. Chemical prob-
ing studies suggested that this “double bulge” feature of vertebrate
ferritin IREs is dynamic and may interconvert with a larger UGC/C inter-
nal loop perhaps facilitating direct binding of ferrous iron [103,109].
These additional features likely facilitate structural alterations that may
underlie the stronger regulatory role of the IRE in ferritin relative to
other mRNAs. Indeed, the recent structural studies comparing a single
C-bulge IRE from TfR1 with the H-ferritin IRE bound to IRP1 revealed a
substantial difference in the bend-angle and helical twist of the IRE
stem and the degree to which the lower stem approaches IRP1 [114].
Since these two IREs bind IRP1 with similar afﬁnities [114], it appears
that signiﬁcant plasticity of the RNA and protein allows for the accom-
modation of IREs with different structures. It will be of interest to deter-
mine if alternative structural alterations provide a mechanistic basis for
the substantially weaker binding of the m-acon IRE, and to determine
the impact of unpaired nucleotide(s) in the upper stem, such as observed
for DMT1 and HIF-2α IREs (Fig. 5) [18].
Given the observations that U6 enhances the interaction of both IRPs
with the ferritin IRE, one question is what is the role for bulge nucleo-
tides in other IREs? While structures of IREs other than H-ferritin and
TfR1 B have not been determined, secondary structure predictions sug-
gest that several IREs possess additional unpaired nucleotides in the
stem, especially on the 3′ side (Fig. 5). The HIF-2α and DMT1 each con-
tain a single IRE with an additional 3′ unpaired nucleotide for which
protein expression and RNA binding data are available (Fig. 5). In the
case of both IREs, there is evidence suggesting that they are preferen-
tially regulated by IRP1 [10,11,136]. Given the critical role of hypoxia
in regulating intestinal absorption and erythropoiesis, the possibility
that IRP1 may preferentially regulate these mRNAs is intriguing. A sec-
ond issue of interest concerns whether unpaired nucleotides in differ-
ent IREs program speciﬁc changes in regulation. Deletion of U6 lowers
the afﬁnity of IRP1 for the ferritin IRE and may have an even stronger
effect on IRP2 binding [108,109,133]. In the case of HIF-2α and DMT1
IREs, the impact of the 3′ unpaired nucleotidesmay bias binding toward
IRP1 not IRP2. In addition, the presence of this feature in the HIF-2α and
DMT1 IREs may be critical for limiting the strength of IRP1 binding in
order to ﬁne tune regulation. Finally, a recent transcriptome-wide
examination of mRNAs that interact with IRPs in vitro identiﬁed novel
mRNAs containing canonical IREs, and demonstrated that IRPs may
bind RNAs with differences in the location of unpaired nucleotides or
in upper stem base pairing capacity [18]. Similarly, a recent in silico
study has pointed to additional potential IREs in previously unidentiﬁed
mRNAs [129]. Thus, the reach of the IRP–IRE network may extend into
new areas of cellular function.
3.8. Roles for non-canonical IREs in IRP action
Test-tube RNA evolution experiments (SELEX) provided the ﬁrst
indication of the sequence and structure requirements for IRP recog-
nition of IRE elements [125,126,137,138]. In this regard, one of the
Fig. 5. Comparison of the proposed secondary structure of IREs. The key structural
elements required for recognition of the IRE by IRP1 include the unpaired C (C8)
in the IRE stem and the A16G17U18 nucleotides of the pseudotriloop. The canonical
IRE secondary structure is represented by one of the ﬁve TfR1 IREs (TfR1 B), where
the RNA helix is interrupted by only the unpaired C8. The L-ferritin IRE secondary
structure showing the conserved unpaired U at position 6 (arrow). This additional
unpaired nucleotide has been observed in the NMR of the ferritin IRE and the crystal
structure of IRP1 bound to the ferritin IRE [124,130,133]. Proposed secondary structures
of DMT1 and HIF-2α IREs. Note the additional unpaired nucleotides (arrows).
IRE residue numbering is according to Walden et al. [130].
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more intriguing results came from studies where the entire IRE se-
quence was randomized and IRP1 was used to select high afﬁnity
RNA ligands. Intriguingly, an IRE-like RNA was identiﬁed that pos-
sessed a larger terminal loop (CAGUGUCA) along with a somewhat
more complex pattern of unpaired nucleotides in the C8 region of
the stem [138]. On this basis, studies on amyloid precursor protein
(APP) and α-hemoglobin stabilizing protein (AHSPα) mRNAs, and
the recent transcriptome-wide study potentially identifying a wide
array of new IRP targets are of clear interest [18,139,140]. The evidence
strongly suggests that both APP and AHSPα mRNAs are targets of IRP
action. However, the proposed IRE-like element in these mRNA differs
substantially from the canonical IRE, raising questions regarding the
structural basis of their binding to IRP1. It is of interest in this regard
that for the novel RNAs identiﬁed by SELEX that bind tightly to IRP1,
this IRE contains the CAGUGU consensus sequence in a larger eight
nucleotide terminal loop. This IRE is also proposed to have an unpaired
pyrimidine on the 5′ side of the stemwith the correct spacing from the
critical AGU binding site in the terminal loop. In contrast, the APP and
AHSPα IRE-like elements do not have these structural elements. Thus,
while the evidence is strong that IRP1 associates with APP and AHSPα
mRNAs in cells, the question as to whether IRP1 binds these elements
indirectly or whether they require the assistance of protein partners re-
mains to be determined. The recent transcriptome-wide analysis [18]
suggested that IRPsmay bindmanynon-canonical IRE RNAs, suggesting
the presence of an expanded IRP-dependent post-transcriptional
regulon.
4. Recent advances in IRP2 regulation
The last decade has seen major advances in IRP2 regulation. The
identity of FBXL5 as the E3 ligase responsible for the iron-mediated
degradation of IRP2 was discovered. New insights into the role of
IRP2 in cell proliferation have been deﬁned, and mouse models of
IRP2 deﬁciency have provided mechanistic insight into its role in
regulating cellular iron homeostasis.
4.1. Iron-mediated regulation of IRP2 stability
IRP2 is primarily regulated by protein stability: iron depletion and
hypoxia stabilize IRP2, whereas iron promotes IRP2 ubiquitination
and proteasomal degradation [141–144]. One early study reported
that a cysteine rich 73-amino acid domain was required for iron-
mediated degradation of IRP2 [144]. Several models were proposed
whereby iron or heme oxidized speciﬁc cysteine residue(s) within
the 73-amino acid domain, triggering the ubiquitination and degrada-
tion of IRP2 [145,146]. A protein designated heme-oxidized IRP2 Ub
ligase (HOIL-1) was identiﬁed and shown to bind to heme-oxidized
residues within the 73-amino acid domain [147,148]. Subsequent
studies from several groups showed that mutation of cysteine resi-
dues within the 73-amino acid domain or deletion of the entire 73-
amino acid domain did not affect iron-mediated degradation of IRP2
[149–151]. Furthermore, HOIL-1 silencing or overexpression in cul-
tured cells had no effect on the degradation of IRP2 by iron [152].
These studies prompted investigation into other mechanisms to ac-
count for IRP2 degradation by iron.
Recently, a novel E3 ligase complex, SKP1–CUL1–FBXL5, was iden-
tiﬁed as the E3 ligase responsible for iron-mediated IRP2 degradation
[89,90] (Fig. 7). FBXL5 was independently identiﬁed by two groups
using different approaches. Vashisht et al. [90] used multidimensional
protein identiﬁcation technology (MUDPIT) to identify proteins that
interact with epitope-tagged FBXL5. Salahudeen et al. [89] used a
small interfering RNA (siRNA) screen to identify proteins that altered
IRP2 degradation. FBXL5 is a member of the F-box family of adaptor
proteins that confer substrate speciﬁcity to SCF E3 Ub ligases
(reviewed in [153,154]). FBXL5 is conserved in vertebrates, and con-
tains an N-terminal hemerythin domain, a F-box domain that medi-
ates its association with SKP1 and four leucine-rich repeats that
likely function in IRP2 binding. Hemerythrins are oxygen carrier pro-
teins in marine organisms that bind to oxygen through a diiron L cen-
ter [155]. Hemerythrin-like domains have been identiﬁed in bacterial
proteins where they are thought to function as oxygen sensors
[156,157]. FBXL5 represents the ﬁrst eukaryotic protein to contain
this domain.
Several experiments showed that FBXL5 regulates IRP2 stability
[89,90,158]. First, FBXL5 forms a SCF complex that interacts with IRP2
in vitro. The region of IRP2 that binds FBXL5 is not yet known, but the
73-amino acid domain is not involved. A study showed that sequences
in the C-terminal region of IRP2 are necessary, but not sufﬁcient for
IRP2 degradation [159]. Because IRP1 is a FBXL5 substrate, it is likely
that IRP1 and IRP2 share a similar degron. Second, FBXL5 silencing
stabilized IRP2,whereas FBXL5overexpression promoted IRP2 degrada-
tion. Third, FBXL5 is stabilized in iron-replete cells, and destabilized by
iron depletion and hypoxia. The hemerythrin domain is required for
FBXL5 stability asmutations in speciﬁc histidine and glutamate residues
within this domain reduced FBXL5 abundance and iron-dependent
stability. Finally, reduced stability of FBXL5 during iron depletion or
hypoxia provides an explanation for IRP2 accumulation during hypoxia
[150,160,161]. Similarly, the enhanced degradation of IRP2 by antioxi-
dants and stabilization of IRP2 by oxidants is also likely explained by
changes in FBXL5 stability [88,161]. It should be noted that oxidative
stress can also inactivate IRP2 RNA binding independent of changes
in IRP2 protein levels [162–164], and in one study this was shown to
be due to oxidation of cysteines that are predicted to lie in the RNA-
binding cleft [164].
Fig. 6. Crystal structure of c-aconitase and the IRP1:IRE complex. The crystal structures of c-aconitase [132] and the IRP1:IRE complex [121,130] are shown. A) Cytosolic aconitase
structure showing domain 1 (yellow), domain 2 (green), domain 3 (blue) and domain 4 (red) with the [4Fe–4S] cluster in the center (orange balls). B) IRP1:IRE complex structure
shown with domains 1 to 4 as in (A). The ferritin IRE helix (purple) is shown with the two major contact sites of C8 (left) and the A16G17U18 bases of the pseudotriloop shown (right)
as enlarged balls.
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5. Pathological consequences of IRP and FBXL5 deﬁciencies
in mice
Over the past decade, the generation of global and conditional
mouse models of IRP2 and IRP2/IRP1 deﬁciency has demonstrated
their importance in cellular iron metabolism. These studies have
also underscored their critical role in mitochondrial iron metabolism.
5.1. Total body ablation of IRP1 and IRP2
Genetic inactivation of both Irp1 and Irp2 in mice leads to embry-
onic lethality at the blastocyst stage indicating a critical role for the
IRP–IRE network during early development [110,179,180]. Irp1−/−
mice lack an overt phenotype, despite mild ferritin dysregulation in
kidneys and in brown fat [179]. The lack of an overt phenotype is sur-
prising as c-acon is a highly conserved protein found in many diverse
organisms and that c-aconitase is the principal form present in tissues
of the body [160]. The function of c-acon is still not well understood,
but apparently it is not required for normal physiology.
Two distinct strains of Irp2−/−mice have been generated. One strain
was generated by the insertion of a PGK-neomycin gene into exon 3/4
of the Irp2 gene [181] and the other strain was generated by Cre–Lox
technology [182]. Both Irp2−/− mouse strains develop mild microcytic
anemia and altered body iron distribution [104,183]. Iron content is
elevated in intestine and liver and is associated with increased ferritin
expression and decreased TfR1 expression, and is reduced in splenic
macrophages and is associated with decreased ferritin expression.
Microcytic anemia in Irp2−/− mice is associated with normal
transferrin saturation and serum iron parameters, and is thought to
be due to cellular iron deﬁciency in erythroid precursors as a conse-
quence of reduced TfR1 levels and increased ferritin levels [104,183].
Because erythroid precursors are dependent on transferrin-bound iron
for heme synthesis, increased iron sequestration in ferritin and reduced
iron uptake would lead to a reduction in the cellular labile iron pool,
impairing heme synthesis. Mice lacking IRP2 in enterocytes, hepato-
cytes or macrophages do not develop microcytic anemia suggesting
that microcytic anemia in Irp2−/− mice is an intrinsic defect of iron
homeostasis in erythroid precursors [184]. Irp2−/− mice also develop
erythropoietic protoporphyria characterized by increased proto-
porphryin IX in bone marrow, serum and liver [104]. Erythroid ALAS
synthesis is upregulated in Irp2−/− erythroid precursors likely due to
loss of IRP2 translational repression. The heme precursor protoporphy-
rin IX accumulates in erythroid precursors due to reduced iron availabil-
ity required to complete heme synthesis.
The Irp2−/− strain generated by LaVaute et al. [181] develop a late
onset neurodegenerative disorder characterized by abnormal gait,
hind-limb weakness and tremors, and by reduced grooming and neu-
romuscular performance assayed by the hanging wire test. The cere-
bellum, substantia nigra, hippocampus and caudate putamen among
other brains areas displayed elevated levels of ferric iron and ferritin
that correlated with axonopathy and neuronal loss [105]. The onset
and severity of neurodegeneration is exacerbated in Irp2−/− Irp1+/−
mice, demonstrating a gene dosage effect with the IRPs [75,105]. Neu-
rodegenerative symptoms in both Irp2−/− and Irp2−/− Irp1+/− mice
were alleviated by Tempol, a membrane-permeable radical scaven-
ger, where it reduced ferritin levels and lower iron content in cerebel-
lar white matter tracts [75]. Tempol was shown to convert the c-acon
form of IRP1 to the RNA binding form that stabilized TfR1 mRNA and
repressed ferritin synthesis, and thus restored iron homeostasis. More
recently, Irp2−/− mice were reported to have lower motor neuronal
degeneration and spinal cord axonopathy that was more severe in
Irp2−/−Irp1+/− [185]. Lumbar spinal sections in Irp2−/−mice showed
the accumulation of myelin dense bodies, which are hallmarks of neu-
rodegeneration, in the ventral and lateral white matter. Mitochondria
in the lumbar spinal cord were swollen, and displayed disrupted
and vacuolized cristae. Ferritin and TfR1 levels were increased and
decreased, respectively, in motor neurons, and total iron content was
reduced in the spinal cord, consistent with cellular iron deﬁciency in
motor neurons of Irp2−/−mice. Respiratory complexes I and II activities
were reduced in lumbar spine mitochondria in Irp2−/− mice. As com-
plexes I and II contain Fe–S clusters and heme prosthetic groups essen-
tial for activity, this suggested that cellular iron deﬁciency in motor
neurons might impair mitochondrial function, leading to neuronal de-
generation. This hypothesis was tested by treating Irp2−/− mice with
Tempol and by crossing Irp2−/− or Irp2−/−Irp1+/− mice into a Fth−/+
background [186]. Motor neuron survival improved using both ap-
proaches consistent with the notion that cellular iron deﬁciency has a
role in motor neuronal degeneration in Irp2−/−mice.
In contrast to Irp2−/− mice generated by LaVaute et al. [181],
Irp2−/− mice generated by Galy et al. [187] did not display an abnor-
mal gait, hind-limb weakness and tremors or neuropathological
changes at 13–14 months of age. Perls' and TUNEL staining did not re-
veal signs of iron deposition or cellular degeneration in the brain, and
electron microscopy showed no evidence of ultrastructural defects or
mitochondriopathy. Irp2−/−mice also did not show impaired muscle
strength when tested by the forepaw grip strength test (analogous to
the hanging wire test used by LaVaute et al. [181]). In agreement with
LaVaute et al. [181], the Irp2−/− strain generated by Galy et al. [187]
displayed motor coordination and balance defects and reduced
grooming activity when assayed by the rotarod and the modiﬁed-hole
board tests. In addition, both strains displayed decreased TfR1 and
increased ferritin expression in the brain [187]. Whether differences
in severity of clinical and pathological signs of neurodegeneration be-
tween the two Irp2−/− strains are due to targeting strategies, genetic
backgrounds or technical issues is not known.
5.2. Macrophage/monocyte ablation of IRPs
Splenic and bone marrow macrophages of Irp2−/− mice have re-
duced ferric iron stores with repressed levels of ferritin and ferroportin
[104,183,184]. Interestingly, these mice have a slight increase in serum
ferritin and normal hepcidin levels [104,183,184]. Ferritin secretion en-
sues when cellular ferritin synthesis occurs during iron depletion, and
may explain reduced ferritin levels and splenic iron deposition seen in
these animals [188]. A conditional deletion of IRP2 from macrophages/
monocytes using LysozymeM-Cre did not recapitulate the splenic phe-
notype seen in Irp2−/− mice [184], suggesting that splenic iron mis-
management may be a result of IRP2 deﬁciency in another cell type or
the combined effect of IRP2 deﬁciency in multiple tissues.
5.3. Intestinal ablation of IRPs
The function of IRPs in iron absorption was investigated by speciﬁc
deletion of IRP2 alone or both IRP1 and IRP2 in intestinal epithelial
cells [184]. Mice lacking IRP2 in the duodenum recapitulated the
intestinal phenotype of duodenal iron loading and increased ferritin
expression in Irp2−/− mice. Duodenal iron content and ferritin levels
were not affected in mice lacking IRP2 in hepatocytes or in macro-
phages, suggesting that dysregulated iron homeostasis in IRP2 deﬁ-
cient duodenum is likely cell autonomous.
Mice lacking both IRP1 and IRP2 in intestinal epithelial cells were
generated by breeding mice homozygous for ﬂoxed Aco1 and Ire2
alleleswithmice expressing Cre-recombinase under control of theVillin
promoter [110]. These mice displayed severe growth defects 7 days
post-partum, and 80% of the animals died shortly after weaning likely
due to dehydration, with the remaining 20% reaching adulthood due to
incomplete IRP deletion. IRP deﬁcient enterocytes from mice displayed
less structured duodenal crypts and villi, and intestinal enterocytes
exhibited mitochondriopathy along with increased apoptosis. Ferritin
and ferroportin levels were profoundly increased, and TfR1 and DMT1-
IRE isoform mRNAs and protein were decreased. The increase in
ferroportin levels occurred without changes in mRNA levels and despite
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increased hepcidin levels. Increased hepcidin levels could not be
accounted by increased hepatic iron loading, and was postulated to be
due to decreased erythropoiesis or inﬂammation. Surprisingly, blood
parameters revealed no signs of systemic iron defects given the profound
changes in cellular iron homeostasis in mice with IRP deﬁcient
enterocytes. It is possible that increased iron export by ferroportin equal-
izes reduced iron uptake and increased iron sequestration in ferritin. This
study demonstrated that dysregulation of iron uptake, storage and
export in IRP deﬁcient enterocytes is consistentwith cellular iron starva-
tion as a possible cause for mitochondriopathy and impaired enterocyte
function.
The importance of ferritin in iron absorption was demonstrated in
micewith a speciﬁc deletion of H-ferritin subunit in intestinal epithelial
cells [189]. Thesemice showed increased body iron stores and transfer-
rin saturation, and as expected, increased hepatic hepcidin mRNA
levels. Further analysis showed reduced levels of DMT1, DYCTB and
TfR1 mRNAs, while ferroportin and L-ferritin subunit increased. IRP2
levels were reduced, suggesting an increase in the cellular labile iron
pool, which would lead to the destabilization of DMT1 and TfR1
mRNAs and increased synthesis of ferroportin and L‐ferritin subunit.
DMT1 and DCYTB mRNAs are transcriptionally activated by HIF-2α in
iron-deﬁcient mice [98,99]. Whether reduced DMT1 and DCYTB
mRNAs in H-ferritin deﬁcient enterocytes are in part due to reduced
HIF-2α accumulation is not known.
5.4. Hepatic ablation of IRPs
Conditional deletion of IRP2 in hepatocytes recapitulated the
hepatic phenotype in Irp2−/− mice where iron loading was associated
with ferritin derepression. In these mice, expression of TfR1 and
DMT1 was unchanged, and the mechanism for increased hepatic iron
loading is not clear. Mice lacking IRP2 in enterocytes or macrophages
showed no evidence of iron loading in hepatocytes, showing that
dysregulated iron homeostasis in hepatocytes in IRP2 deﬁcient mice
is intrinsic to hepatocytes.
The deletion of both IRP1 and IRP2 in hepatocytes has provided
insight into IRP function in vivo [190]. Hepatocyte IRP deﬁciency causes
mice to die between 8 and 12 days post-partum. Profound liver damage
as characterized by internal bleeding, hepatic steatosis and increased
apoptosis was apparent in these animals. Despite reduced hepcidin
levels, there were no overt signs of systemic iron dysfunction. Analysis
of IRP-target mRNAs showed that levels of ferritin and ferroportin
were elevated, whereas levels of TfR1 and the DMT1-IRE mRNAs
and protein are decreased. Zip14 (SLC39A14, iron transporter) and
mitoferrin 2 (SLC25A28, mitochondrial iron transporter), which are
not IRP regulated, were also downregulated. Total liver nonheme iron
and mitochondrial nonheme iron were reduced 50% compared with
control mice. The reduction in iron uptake coupled with increased
iron sequestration in ferritin and increased iron export by ferroportin
is consistent with severe cellular iron starvation in IRP deﬁcient
hepatocytes.
Mitochondrial dysfunction is a deﬁning feature of many fatty liver
diseases [191]. Consistent with this, mitochondriopathy is the major
pathological consequence of hepatocyte IRP deﬁciency [190]. Mito-
chondria appear swollen, and contain hypodense matrices and abnor-
mal cristae architecture, consistent with iron and copper deﬁciency in
rodents [192]. Interestingly, the expression of the mitochondrial iron
transporter mitoferrin 2 is reduced in IRP deﬁcient hepatocytes and
correlates with a reduction in mitochondrial nonheme iron. Mito-
chondria are responsible for the synthesis of Fe–S clusters and heme
that are required by complexes I, II and III and by TCA cycle enzymes.
IRP deﬁcient hepatocytes display markedly reduced activities of
complexes I, II and III and ferrochelatase, as well as the cytosolic Fe–S
cluster containing protein xanthine dehydrogenase. It is likely that
defects in the electron transport chain and TCA cycle are major
contributing factors to the mitochondrial abnormalities seen in IRP
deﬁcient hepatocytes.
5.5. Mouse models of FBXL5 and FBXL5-IRP2 deﬁciencies
The importance of IRP2 in cellular iron metabolism was further
highlighted by FBXL5 ablation in mice [91]. Total body ablation of
FBXL5 inmice resulted in embryonic lethality at E8.5, andwas associated
with iron overload and oxidative stress in embryos. Embryonic lethality
was prevented by simultaneous ablation of IRP2. Fbxl5−/−Irp2−/− mice
developed normally and were physically indistinguishable from lit-
termate controls. Mice with hepatocyte speciﬁc ablation of FBXL5
were viable, but developed hepatic steatosis and mitochondriopathy
in hepatocytes. Increased IRP levels were associated with increased
TfR1 levels and ferrous iron in hepatocytes. Unexpectedly, L-ferritin
protein and mRNA levels increased in FBXL5 deﬁcient hepatocytes
compared with control mice despite increased IRP expression. The
most likely explanation for increased ferritin expression is transcrip-
tional activation of the L-ferritin gene induced by oxidative stress in
hepatocytes [193]. Mice lacking hepatocyte FBXL5 displayed reduced
hepcidin mRNA expression as a consequence of reduced BMP signal-
ing. These mice also showed reduced survival when fed a high iron
diet. Taken together, this study showed that embryonic lethality in
Fbxl5−/−mice is primarily due to dysregulation of IRP2 degradation,
which leads to increased cellular iron and oxidative stress, and show
that FBXL5 regulation of IRP2 is critical for regulation of cellular iron
homeostasis.
5.6. IRP–IRE network in human disease
To date there are no reports of mutations in IRP1 or IRP2 that cause
human disease, but mutations in IREs or in coding sequences of IRE-
encoded genes have been linked to human disorders. Mutations in
L‐ferritin subunit mRNA cause autosomal dominant hereditary
hyperferritinemia–cataract syndrome (HHCS) that is characterized by
juvenile bilateral cataracts and high levels of serum ferritin without
iron overload. These mutations reduce IRP binding to the 5′ IRE and
lead to abnormal L‐ferritin subunit accumulation in tissues and serum
[194–196]. A point mutation in the 5′ IRE of H‐ferritin subunit that
increases its afﬁnity for IRPs causes autosomal dominant iron overload
disorder [197]. Coding region mutations in L‐ferritin subunit cause he-
reditary ferritinopathy or neuroferritinopathy characterized by abnor-
mal ferritin inclusion aggregates and iron in the globus pallidus [198].
These mutations alter the amino acid sequence at the C-terminus of
L-ferritin subunit, reducing its stability and ability to incorporate iron
[199,200]. The neurodegeneration and iron overload phenotype was
replicated in mice expressing a mutant L-ferritin subunit form [201]. A
missense mutation in the L‐ferritin subunit coding sequence was iden-
tiﬁed that leads to high levels of serum ferritin without iron overload
[202]. Kannengiesser and colleagues [188] postulated that thismutation
may modify a signal sequence that increases secretion of L‐ferritin sub-
units, and a subsequent study in cell culture shows that secretion of this
mutant ferritin is increased as compared to wildtype ferritin [188]. Mu-
tations have been reported in other IRE-encoded genes, such as eALAS
(sideroblastic anemia) [203–205], ferroportin (hereditary hemochro-
matosis) [206,207] and DMT1 [208–210]. These studies show that
abnormal expression of proteins encoded by IRE-containing mRNAs
disrupts systematic and cellular ironmetabolism and leads to iron over-
load and neurodegeneration.
A genome wide association study (GWAS) has associated various
IRP2 polymorphisms with Alzheimer's disease (AD) [211]. A poten-
tially functional single nucleotide polymorphism (SNP) in the IRP2
promoter region was located within a consensus binding site for the
AP-1 and SP1 transcription factors, and could possibly explain altered
IRP2 expression seen in AD patients. This is of interest as a study
showed IRP2 co-localization with pathological features of AD, including
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neuroﬁbrillary tangles and senile plaques [212]. An additional link be-
tween IRP2 and neurodegenerative disease involves the regulation of
amyloid precursor protein (APP). Studies have shown APP to be a func-
tional ferroxidase that interacts with FPN in mediating iron export,
and inhibition of ferroxidase activity leads to neuronal iron accumu-
lation consistent with AD [213]. Similarly, neurons of Tau deﬁcient
mice retain iron and mislocalize APP, thus disrupting iron export by
FPN [214]. More importantly, iron chelation with Clioquinol alleviated
cognitive deﬁcits seen in these Tau deﬁcient mice. These observations
highlight the importance of iron metabolism in maintaining proper
neurological function, and provide therapeutic opportunities for treating
neurodegenerative diseases such as Alzheimer's and Parkinson's. More
recent GWAS have found strong associations between IRP2 and patients
with chronic obstructive pulmonary disease (COPD) [215]. Three SNPs
in IRP2 were found to correlate with reduced forced expiratory volume
(FEV), a prominent feature of COPD [216]. It is known that IRP2 expres-
sion is altered in lung tissue from COPD patients, and iron deposition is
increased in the lungs of smokers [215]. Further studies are needed to
conﬁrm a role for IRP2 in AD and COPD.
6. Outlook
Since their discovery over 20 years ago, IRPs still remain an active
ﬁeld of research. Iron-dependent and iron-independent mechanisms
regulating IRP1 and IRP2 function have been identiﬁed and the physio-
logical consequences of these mechanisms determined. The crystal
structure of IRP1 bound to RNA has provided a basis to study the selec-
tivity of IRE binding. Mouse models of IRP deﬁciency have shown the
importance of IRPs in regulating cellular iron metabolism. The elusive
E3 ligase mediating IRP2 degradation by iron has been identiﬁed, and
the identiﬁcation of novel IREs has broadened our vision of the IRP–
IRE network.
At a mechanistic level, many questions regarding IRP function re-
main unanswered. One question regards the pathways of Fe–S cluster
biogenesis that are directly sensed by IRPs and whether trafﬁcking of
iron through mitochondria is an obligate process through which IRPs
sense iron. Additionally, the extent to which Fe–S cluster removal
from c-acon versus de novo synthesis of IRP1 contribute to its role in
homeostatic regulation of iron in animals needs attention. Another
question is to determine how canonical and non-canonical IREs bind
IRP1 to allow for their linkage to processes uniquely sensed by IRP1
(e.g. cytosolic Fe–S biogenesis). The discovery of novel IREs that prefer-
entially bind to IRP1 or IRP2 is an opportunity to study links between
iron homeostasis and other cellular or organismal processes. For exam-
ple, what is the physiological signiﬁcance of the preferential regulation
of HIF-2α IRE by IRP1? The identiﬁcation of FBXL5 E3 ligase raises the
question whether other substrates are also targeted by FBXL5. The
role of the IRP2 73-amino acid domain and Ser157 phosphorylation in
cell proliferation requires further investigation. A better understanding
of how iron contributes to neurodegeneration is neededwith the goal of
developing safer and effective therapies to treat these disorders.
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Abstract 
Iron regulatory protein 2 (Irp2) is a key regulator of cellular iron metabolism in 
vertebrates.  Irp2 controls the posttranscriptional expression of the iron uptake protein 
transferrin receptor 1 (TfR1) and the iron storage protein ferritin. Previous studies have 
shown that mice with a targeted deletion of the Irp2 gene develop microcytic anemia, 
erythropoietic protoporphyria and neurobehavioral impairments.  Here, we show that 
Irp2-/- mice develop fasting hyperglycemia, glucose intolerance and impaired glucose-
stimulated insulin secretion from pancreatic β cells, all of which have been implicated in 
the pathogenesis of diabetes mellitus. Impaired glucose-stimulated insulin secretion in 
Irp2 deficient β cells is not due to reduced β cell mass or reduced insulin expression, but 
rather due to the accumulation of proinsulin in β cells and reduced mature insulin content 
caused by defective processing of proinsulin to mature insulin.  Iron homeostasis is 
dysregulated in Irp2 deficient β cells as evidenced by decreased TfR1 expression and iron 
content, and increased ferritin expression and iron sequestration causing cellular iron 
deficiency.  This is associated with reduced activity or levels of mitochondrial and 
cytosolic Fe-S proteins, suggesting that iron-sulfur (Fe-S) cluster biosynthesis is impaired 
in Irp2 deficient β cells.  Increasing cellular iron in Irp2 deficient β cells restored 
proinsulin and insulin content to normal levels, and improved glucose-stimulated insulin 
secretion.  These studies reveal a previously unidentified link between insulin processing 
and cellular iron homeostasis, and show that Irp2 is required for normal β cell function 




Type 2 diabetes (T2D) develops when insulin target tissues become resistant to 
insulin, and pancreatic β cells are unable to fully compensate for reduced insulin 
sensitivity (Ashcroft and Rorsman, 2012; Kahn et al., 2009; Muoio and Newgard, 2008).  
Important factors contributing to reduced insulin secretion in T2D is the gradual decline 
of β cell function and the eventual loss of β cell mass. The mechanisms leading to β cell 
dysfunction are not fully understood, but defects in glucose sensing, mitochondrial 
function and endoplasmic reticulum (ER) stress are involved (Ashcroft and Rorsman, 
2012; Scheuner and Kaufman, 2008; Kahn et al., 2009; Muoio and Newgard, 2008).  
Evidence has accumulated revealing a role for proinsulin misfolding in the ER and 
ensuing ER stress as early events in the pathogenesis of T2D (Sun et al., 2015; Weiss, 
2013). Consistent with these findings, elevated circulating proinsulin is associated with 
the development of T2D in humans (Pradhan et al., 2003; Zethelius et al., 2003).   
 Evidence has revealed a role for iron in the pathogenesis T2D.   Excess body iron 
stores, as measured by serum ferritin, are associated with an increased risk of T2D in 
patients with the genetic iron-overload disease hemochromatosis and in healthy 
individuals (Rajpathak et al., 2009; Simcox and McClain, 2013). The molecular 
mechanisms through which excess iron contributes to development of T2D are not 
completely understood, but likely involves insulin resistance as well as iron-induced 
oxidative β cell death (Cooksey et al., 2004; Hansen et al., 2012; Ristow et al., 2003; 
Simcox and McClain, 2013).  Less is known about the consequence of iron deficiency in 
β cell function. Iron is required for the mitochondrial synthesis of Fe-S clusters and heme 
that are cofactors for electron transport complexes (ETCs), the TCA enzyme aconitase 
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and for the maturation of extramitochondrial Fe-S proteins involved in DNA metabolism, 
ER function and nucleotide metabolism (Maio and Rouault, 2015; Netz et al., 2014). 
Consequently, cellular iron deficiency can lead to mitochondrial dysfunction and cell 
death (Lill et al., 2012; Silva and Faustino, 2015). The importance of optimal Fe-S cluster 
biosynthesis is underscored by studies showing that mutations in Fe-S cluster biogenesis 
genes in humans cause neurological and metabolic diseases (Rouault, 2015; Stehling et 
al., 2014).   
 Cellular iron content must therefore be maintained within a narrow range to avoid 
the adverse consequences of iron depletion or excess. Maintaining cellular iron content 
within this physiologic range requires precise mechanisms for regulating its uptake and 
storage.  In vertebrates, cellular iron homeostasis is controlled posttranscriptionally by 
iron-regulatory protein 2 (Irp2) (Anderson et al., 2012; Hentze et al., 2010; Rouault, 
2006). Irp2 is a cytosolic protein that binds to RNA stem-loops known as iron-responsive 
elements (IREs) in the mRNAs of proteins involved in iron uptake (transferrin receptor 1 
(TfR1, Tfrc)) and sequestration (ferritin), and regulates the stability or translation of these 
mRNAs.  In iron-deficient cells, Irp2 binds to an IRE in the 5’ untranslated region (UTR) 
of ferritin mRNAs to inhibit translation and to the IREs in the 3’ UTR of the TfR1 
mRNA to prevent its degradation. In iron-sufficient cells, Irp2 is targeted for proteasomal 
degradation (Salahudeen and Bruick, 2009; Vashisht et al., 2009), increasing ferritin 
translation and iron sequestration, and promoting TfR1 mRNA degradation and reducing 
iron uptake. Irp2 regulation of ferritin and TfR1 precisely coordinates iron uptake and 
sequestration in response to fluctuations in cellular iron concentration, ensuring that cells 
acquire sufficient iron for their needs without causing toxicity. Irp2-/- mice develop 
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microcytic anemia and erythropoietic protoporphyria and exhibit neurological and 
behavioral impairments. Studies have shown that iron deficiency in neurons of Irp2-/- 
mice impairs the activity of several Fe-S containing ETCs and other Fe-S proteins 
causing mitochondrial dysfunction and neuron degeneration (Jeong et al., 2011).  Taken 
together, these studies emphasize the importance of Irp2 in maintenance of optimal 
cellular iron homeostasis to avoid mitochondrial dysfunction and cell death (Cooperman 
et al., 2005; Galy et al., 2005b; Jeong et al., 2011; LaVaute et al., 2001; Zumbrennen-
Bullough et al., 2014).   
 Here, we demonstrate that Irp2 is required for β cell function, and more 
specifically for the processing and secretion of insulin. A role for Irp2 in β cell function 
was demonstrated in Irp2-/- primary islets and recapitulated using the rodent insulinoma 
cell line INS-1 832/13 depleted of Irp2.   Irp2 deficiency leads to increased proinsulin 
content and reduced insulin content and secretion. Cellular iron content is reduced due to 
decreased TfR1 expression, and increased iron sequestration in ferritin, leading to 
functional iron deficiency and impaired mitochondrial function. Our data suggest that 
defective proinsulin processing arises in part from mitochondrial dysfunction due to 
impaired biosynthesis of Fe-S clusters. Together, our results identify a mechanism that 
links iron homeostasis to the processing and secretion of insulin.  
 
Materials and methods 
The generation of mice with global deficiency of Irp2 has been previously 
described (Zumbrennen-Bullough et al., 2014). Briefly, Irp2-/- mice were generated by 
inserting a self-excision cassette containing neomycin (Neor) linked to cre-recombinase 
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(Cre) into exon 3 of the mouse Irp2-/- gene as previously described (Zumbrennen-
Bullough et al., 2014.) This cassette (pACN) contains the Cre gene (driven by the testes-
specific angiotensin-converting enzyme (tACE promoter) linked to Neor (driven by the 
polymerase II promoter) and is flanked by loxP sites allowing for excision of Neoras it 
passes through the male germ line. Irp2-/- mice were generated on a C57BL/6J and 
129/Sv background and backcrossed with C57BL/6J for five generations. Irp2-/- and WT 
littermates were obtained from intercrosses from Irp2+/- parents.  Male mice at 2- to 18-
months of age were used for this study.  Mice were kept in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Utah (Protocol Number: 13-02012).  
All mice were housed in a pathogen free environment with water and fed mouse breeder 
diet containing 270 mg Fe/kg (Teklad 8626) provided ad libitum.  Mice were euthanized 
according to AVMA Guidelines for the Euthanasia of Animals.  At the German Mouse 
Clinic (GMC; Neuherberg, Germany), mice were maintained in IVC cages with free 
access to water and standard mouse chow containing 183 mg Fe/kg (Altromin no.1324).  
All experiments and housing of the animals in the GMC were performed according to the 
German Law on the Protection of Animals (regulation 209.1/211-2531-70/07 by the 
Government of Upper Bavaria (Regierung von Oberbayern).  
The rat insulinoma β INS1 832/13 β-cell line was kindly provided by Dr. Chris 
Newgard (Duke University). Cells were cultured in RPMI-1640 medium supplemented 
with 10% fetal calf serum, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 
0.05 β-mercaptoethanol (β-ME) and 5.0 ug/mL puromycin, grown at 37 oC with 5% CO2 
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as described (Hohmeier et al., 2000).  INS1 832/13 cells were stably transduced with 
empty vector (pLentiLox3.7puro) or an Irp2 shRNA (pLentiLox3.7puro::IRP2-4) 
(Zimmer et al., 2008) kindly provided by Dr. Othon Iliopoulos (Massachusetts General 
Hospital Cancer Center). Cells were treated with 50 ug/ml ferric ammonium citrate 
(FAC) or desferrioxamine DFO (50 um) for 24 - 48 h and lysates prepared for western 
blot analysis.   
For glucose tolerance tests, animals were fasted for 16-17 h and baseline blood 
glucose was determined from tail-vein blood (Ascencia Elite XL Glucometer, Bayer 
Corp.).  Conscious animals were then challenged with an intraperitoneal (ip) injection of 
glucose (2g/kg body weight, Sigma-Aldrich) and blood glucose levels were determined at 
15-, 30-, 60-, 90-, and 120-min postinjection. For insulin tolerance tests, random-fed 
conscious animals were injected with human recombinant insulin (0.75U/kg body weight, 
Novalin R, Novo Nordisk). Tail-vein blood samples were taken before and 15-, 30-, 60-, 
90-, 120-, and 150-min postinjection. 
For plasma insulin analysis, 100 µl of tail-vein blood were collected from 
overnight fasted mice for baseline insulin measurements, and 30 min post-i.p. glucose 
injection (2g/kg body weight).  Plasma insulin was measured using the Sensitive Rat 
Insulin RIA Kit (Linco Research, Inc.). For pancreatic insulin and proinsulin content, 
freshly harvested pancreata were incubated overnight in acid-ethanol mixture (1.5% HCl 
in 70% EtOH) at -20 °C.  Tissue was homogenized and incubated overnight at -20 °C.  
Samples were centrifuged at 3000 x g for 15 min at 4 °C. Supernatant was neutralized 
with equal volume of 1 M Tris-HCl pH 7.5 and centrifuged at 15,000 x g for 10 min at 4 
°C.  Insulin was quantified using a Mouse Insulin ELISA (ALPCO) and proinsulin was 
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quantified using a Rat/Mouse Proinsulin ELISA (Mercodia) and normalized to total 
protein determined by Coomassie Plus Protein Assay Reagent (Thermo).  
Mice were anesthetized using Avertin (0.015 ml/g body weight) and sacrificed by 
cervical dislocation.  The pancreas was perfused through the common bile duct with 6 
mL of Hanks balanced salt solution (HBSS, Invitrogen) containing 0.1 mg/mL DNase I 
(Roche), 25 mM HEPES and 0.3 mg/ml Liberase RI Purified Enzyme Blend (Roche).  
Pancreata were extracted and incubated in a 37 °C water bath for ~12 min in 
HBSS/Liberase RI solution. Pancreatic tissue was disrupted by vigorous shaking for 10 s 
and washed twice with HBSS containing 0.1 mg/mL DNase I and 10% heat inactive fetal 
bovine serum (FBS, Invitrogen).  Islets were handpicked twice from exocrine tissue. For 
GSIS assays, 10 islets were size-matched and handpicked to a 96-well plate and 
incubated in Krebs-Ringer bicarbonate HEPES buffer (10 mM HEPES pH 7.35, 140 mM 
NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 
10 mM HEPES, 0.1% bovine serum albumin (BSA), 2.6 mM glucose) for 1 h at 37°C.  
Islets were then treated with 16.7 mM glucose for an additional 1 h at 37 °C.  Islets were 
sonicated in 1 ml HBSS at settling 4 with 10 x 1 s bursts (Brinkmann Sonic 
Dismembrator, Fisher Scientific).   
For glucose-stimulated insulin and proinsulin secretion assays in EV and shIrp2 
expressing INS1 832/13 cells, approximately 0.05 x 106 cells were plated onto a 24-well 
plate an grown to 100 % confluency. The standard culture medium containing 11 mM 
glucose was changed to medium containing 5 mM glucose 18 h before performing 
secretion assays.  Cell were washed and preincubated for 2 h in HBSS (20 mM HEPES, 
pH 7.2 with 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 2.5 mM 
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CaCl2, 25.5 mM NaHCO3, and 0.2% BSA.  Insulin secretion was measured by static 
incubation in 0.8 mL of HBSS containing 3 mM or 15 mM glucose for a 2-h period. 
Insulin (ALPCO) and proinsulin (Mercodia) were assayed by ELISAs and normalized to 
total lysate protein using Coomassie Plus Protein Assay Reagent (Thermo). 
Metal content was determined by digesting pancreas (20-30 mg) or isolated islets 
(100-200 islets) in 40% metal-free nitric acid at 95°C. Samples were diluted in water and 
analyzed by PerkinElmer Optima 3100XL inductively-coupled plasma optical emission 
spectrometer. Metal concentrations were corrected for dilution and normalized to total 
mg or number of islets.   
Isolated islets (150-200) were lysed in Triton Lysis Buffer (10 mM Tris-HCl pH 
7.4, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 1 mM DTT and Cocktail Protease 
Inhibitor (Roche)) using a micro-dounce. Lysates were cleared by centrifugation and 
protein concentration was determined using Coomassie Plus Protein Assay Reagent. Islet 
lysates were boiled in lithium dodecyl sulfate (LDS) sample buffer (Invitrogen) 
containing 2.5% β-mercaptoethanol (β-ME) boiled in lithium dodecyl sulfate sample 
uPAGE 4-12% Bis-Tris gels (Invitrogen) with MES SDS-running buffer.  INS1 832/13 
cells expressing EV or shIrp2 were treated with FAC or DFO for 24 h and lysed in Triton 
Lysis Buffer.  Cell lysates (30 ug protein) were analysis by 4-12% Bis-Tris gels as 
described above.  Proteins were transferred to a Hybond-ECL nitrocellulose membrane 
(Amersham) and probed with the following antibodies: chicken anti-Irp1 polyclonal 
antibody (PAb) (Guo et al., 1994); rabbit anti-Irp2 PAb antibody (Yu et al., 1992); rabbit 
antiferritin-H PAb (H-53 Santa Cruz Biotechnology); mouse anti-TfR1 monoclonal 
antibody (MAb) (Zymed clone H68.4), rabbit anti-ferritin PAb (UT106) (Schneider and 
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Leibold, 2003; Zumbrennen-Bullough et al., 2014), rabbit antiCisd1 PAb (Proteintech 
16006-1-AP) and beta-actin MAb (AC-15, Ambion). Horseradish peroxidase-conjugated 
secondary antibodies were bound and proteins were visualized using Western Lighting 
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences). Membranes were 
stripped for 10 min at 65 °C in stripping buffer (62.5 mM Tris-HCl, pH 6.8, 100 mM β-
ME and 2% SDS).  
Pancreata were fixed with 4% buffered formalin immediately after dissection and 
embedded in paraffin. Pancreas sections (5 um) were rehydrated with xylene followed by 
decreasing concentrations of ethanol and antigen retrieval was performed using Dako 
Target Retrieval Solution at 90 oC for 30 min followed by cooling at room temperature 
for 20 min.  For islet morphometric analysis, sections were taken at 120 um intervals for 
insulin staining using guinea pig antiinsulin PAb (Dako, 1:200) for 16 h followed by 
incubation with donkey antiguinea pig secondary antibody (Jackson ImmunoReseach, 
1:500) for 1 h and visualization by 3’3’-diaminobenzidine (DAB).  Images (4x) spanning 
the entire pancreas were acquired using Nikon Widefield CCD/Spinning Disk 
microscopes that were automatically stitched together to generate a compound image.  
Image J software was used to quantify islet area and the fraction of insulin-stained tissue 
area in four sections per pancreas for 2.5-, 7.5- and 18-month old mice (n = 3 - 6 mice per 
genotype). Five cell clusters were considered to be an islet. β cell mass was calculated by 
multiplying the fraction of insulin-stained tissue area by pancreas weight.  
 For immunofluorescence studies, pancreas sections were incubated in TBST 
blocking solution (Tris-buffered saline containing 0.1 % Tween) for 1 h at room 
temperature and then incubated with the following antibodies in TBST overnight at 4 oC: 
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rabbit antirat ferritin PAb (UT106 1:100) (Schneider and Leibold, 2003; Zumbrennen-
Bullough et al., 2014), mouse antiTfR1 MAb (Zymed clone H68.4, 1:200), mouse 
antiinsulin MAb (Millipore clone E11D7, 1:100), rabbit antiGlut2 PAb (Millipore 07-
1402, 1:200) and mouse anti-proinsulin Mab (Developmental Studies Hybridoma Bank, 
GS--9A8, 1:100).  Sections were washed in PBS and then incubated with Alexa FluorTM 
488 or Alexa FluorTM 567 antirabbit or antimouse IgG secondary antibodies in TBST for 
1 h at room temperature.  Images were acquired using an Olympus FV1000 confocal 
microscope at the same time using identical camera settings.  
Total RNA was extracted from islets isolated from 39-49 week old WT and Irp2-/- 
mice using TRIzol reagent (Invitrogen). cDNA synthesis was performed with total RNA 
(0.5 ug - 1 ug) using SuperScript III First-Strand synthesis SuperMix for qRT-PCR 
(Invitrogen).  qRT-PCR was performed on an ABI Prism 7900HT Sequence Detection 
System using TaqMan master mix and TaqMan Gene Expression Assays.  The ΔΔCT 
method was used to determine mRNA-fold change. All experiments were performed 
using 5-6 mice per genotype and fold changes were normalized to actb levels. 
Complex I and IV activities were measured in EV and shIrp2 expressing INS1 
832/13 cells using Complex I and IV Enzyme Activity Dipstick Assay Kits 
(Mitosciences) following the manufacturer’s protocol.  Aconitase activity was assessed in 
mitochondrial and cytosolic extracts using an Aconitase Enzyme Activity Microplate 
Assay Kit assay (Abcam).  Enriched mitochondrial and cytosolic fractions were prepared 
using Triton Lysis Buffer and 0.01% digitonin (Schneider and Leibold, 2003).  ATP 
content measurements were performed on cell lysates from INS1 832/13 cells expressing 
EV and shIrp2.  Cells were preincubated at 37 oC for 60 min in HBSS (secretion buffer) 
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containing 2.5 mM glucose and then incubated in either 5.0 mM glucose or 20 mM 
glucose for an additional hour. ATP content was measured in triplicate samples using the 
ATP Determination Kit (Molecular Probes).  
Data are expressed as average mean ± standard errors of the means (SEM). For 
two-group comparison, a two-tailed Student’s-t test was used.  For multiple group 
comparisons, two-way analysis of variance (ANOVA) was used followed by Tukey’s 
multiple comparison test. For all hypotheses the significance level was p < 0.05.   Prism 
6.0 (Graphpad) was used for statistical analysis.    
 
Results 
Mice with global deletion of Irp2-/- were generated by inserting a self-excision 
cassette containing neomycin (Neor) linked to cre-recombinase (Cre) into exon 3 of the 
mouse Irp2-/- gene as previously described (Zumbrennen-Bullough et al., 2012).   
Previous studies showed that Irp2-/- mice displayed dysregulation of ferritin and TfR1 in 
tissues and altered body iron distribution and developed mild microcytic anemia and 
neurodegenerative disease (Cooperman et al., 2005; Galy et al., 2005a; Galy et al., 2006; 
LaVaute et al., 2001; Zumbrennen-Bullough et al. 2014). In the GMC primary screen, 
plasma glucose concentrations were elevated in both random-fed and fasted 12-month old 
male Irp2-/- mice compared to WT (random-fed: Irp2-/-, 211.2 ± 13.6 mg/dl versus WT, 
150 ± 13 mg/dl glucose, n = 9-10, p < 0.01; fasted: Irp2-/-, 118 ± 7.1 mg/dl versus WT, 
95.0 ± 5.3 mg/dl; n = 7-10, p < 0.05). Glucose concentration showed a tendency to be 
elevated in random-fed 3-month old male Irp2-/- mice, and significantly elevated in 
female Irp2-/- mice. The observed changes in glucose homeostasis in 3-month old mice 
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were not attributable to alterations in lipid homeostasis as plasma total cholesterol, 
triglycerides, nonesterified fatty acids, and electrolytes were similar in Irp2-/- and WT 
mice. The determination of body composition by dual-energy X-ray absorptiometry 
(DEXA) showed a decreased lean mass in Irp2-/- mice and suggested an increased body 
fat content. No further differences in energy metabolism especially regarding food intake 
and energy expenditure were detected.  
Next, to assess whole body glucose metabolism, intraperitoneal glucose tolerance 
tests (ipGTTs) were performed on overnight fasted 5-month old Irp2-/- and WT male 
mice.  After glucose injection, Irp2-/- mice exhibit an increased peak glucose 
concentration and reduced glucose clearance compared to WT mice (Figure 5.1).  
Increased Area Under Curve (AUC) values indicate that Irp2-/- mice had developed 
glucose intolerance already at an age of 2-months without worsening over time in mice at 
12- and 18-months of age (Figure 5.1B).  Irp2-/- female mice (10- and 20-weeks of age) 
display significant, but less pronounced glucose intolerance (Figure S5.1) compared to 
males, and therefore, subsequent studies were performed solely in male mice.   At all 
ages, Irp2-/- mice had significantly higher elevated fasting glucose levels compared to WT 
mice (Figure 5.1C).  
To determine whether impaired glucose clearance in Irp2-/- mice is due to insulin 
resistance, insulin tolerance tests were performed in 5- and 18-month old Irp2-/- and WT 
mice.  Comparable glucose disposal rates suggest glucose intolerance in Irp2-/- mice was 
not a consequence of insulin resistance (Figure 5.2A).  We next performed euglycemic-
hyperinsulinemic clamps in order to analyze whole-body and organ-specific insulin 
action in more detail. When exogenous insulin is administered to Irp2-/- mice, they 
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display increased insulin sensitivity evident by higher glucose infusion rates (GIR) 
compared to age and body composition-matched WT mice (Figure 5.2B and 5.C).  
Comparable whole body glucose turnover rates (Rd, Figure 5.2D) in both genotypes 
suggest improved insulin sensitivity in Irp2-/- mice is not caused by peripheral alterations 
in insulin action, but rather a more pronounced suppression of hepatic glucose production 
by insulin (Figure 5.2E). There were also no genotypic changes in whole body glycolysis 
rates (Figure 5.2F).  Taken together these data suggested that glucose intolerance in Irp2-
/- mice is primarily related to impaired β cell function. 
 In the fasted state (0 min), basal insulin levels tended to be lower in 5- and 18-
month old Irp2-/- mice compared to WT. Intraperitoneal glucose injection in 5-month old 
Irp2-/- mice is followed by a comparable relative increase in plasma insulin 
concentrations from baseline levels compared to WT mice, but in contrast was weaker in 
18-month old animals suggesting an age-dependent effect.  
 To measure pancreatic β cell sensitivity in response to elevations in plasma 
glucose hyperglycemic clamps were carried out in overnight fasted 7-month old Irp2-/-
and WT mice.  Irp2-/- mice showed fasting hyperglycemia (Irp2-/-, 7.17 ± 0.39 versus 
WT, 6.06 ± 0.23 mmol glucose/L; p = 0.02; Figure 5.3A) and reduced basal plasma 
insulin concentrations (Irp2-/-, 75.37 ± 15.80 versus WT, 281.12 ± 119 pmol insulin/L; p 
< 0.05; Figure 5.3B). Insulin secretion in response to hyperglycemia (~18 mM) is blunted 
in Irp2-/- (Figure 5.3A and 5.B).  Calculation of the AUC during the first phase (0-15 min 
of the clamp) and steady state phase (60-105 min of the clamp) of the clamp showed that 
insulin secretion was reduced by 62% (p < 0.05) and 67% (p < 0.05), respectively, in 
Irp2-/- mice compared to WT mice (Figure 5.3B and 5.C). These results indicated that 
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glucose intolerance in Irp2-/- mice is due to impaired insulin secretion from β cells. 
 To determine the basis of abnormal insulin secretion in Irp2-/- mice, pancreatic 
insulin content was quantified in WT and Irp2-/- mice.  Total pancreatic insulin was 
reduced by 22% in 2.5-month old Irp2-/- mice, and further reduced by 50% and 41% in 
7.5- and 18-month old Irp2-/- mice, respectively, compared to age-matched WT mice 
(Figure 5.4A).  By contrast, pancreatic proinsulin content and the proinsulin-to-insulin 
ratio increased in all Irp2-/- mice compared to WT mice (Figure 5.4B and C).  Reduced 
insulin content in Irp2-/- mice was not due to reduced insulin transcription as the 
transcript levels of the two insulin genes, Ins1 and Ins2, were not changed in Irp2-/- islets 
(Figure 5.4D).  Morphometric quantification of insulin-stained paraffin-embedded 
pancreatic sections showed that islet area and β-cell mass were unaffected in 2.5- and 7.5-
month old Irp2-/- mice; however, islet area and β-cell mass tended to be reduced in 18-
month old Irp2-/- mice (Figure 5.4E and F).  Insulin and glucagon immunostaining of 
Irp2-/- islets revealed normal morphology with insulin positive β cells uniformly 
distributed within the islet core and glucagon positive alpha cells on the periphery (Figure 
S2A).  Glucagon expression was unaffected in Irp2-/- islets (Figure S5.2).  As proinsulin 
is cleaved and processed by prohormone convertase 1/3 (PC1/3, Psk1), the expression of 
PC1/3 was evaluated in Irp2-/- islets. No change in PC1/3 expression was observed, 
suggesting that the defective insulin processing was not due to reduced PC1/3 expression 
(Figure S5.3).  No change in expression or subcellular localization of the glucose 
transporter Glut2 was observed in Irp2-/- islets, indicating that defective insulin 
processing was not caused by a general defect in ER protein maturation in Irp2-/- β cells. 
Together, these results suggested that processing of proinsulin to mature insulin is 
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impaired in Irp2-/- β cells. 
We next assessed glucose-stimulated insulin secretion (GSIS) in islets isolated 
from WT and Irp2-/- mice.  Irp2-/- islets displayed reduced insulin content, increased 
proinsulin content and an increased proinsulin-to-insulin ratio compared to WT islets 
(Figure 5.4G-I).  The secretory responses of WT and Irp2-/- islets under basal (2.5 mM) 
glucose and high (16.7 mM) glucose were assessed in a 1-h static assay.  Insulin secretion 
was blunted in Irp2-/- islets under high glucose compared to WT islets, and tended to be 
lower under basal glucose (Figure 5.4J).  When the amount of insulin secretion was 
calculated as a percentage of total islet insulin content, no significant difference in GSIS 
was observed between WT and Irp2-/- islet (Figure 5.4K).  Together, these data 
demonstrated that reduced insulin secretion in Irp2-/- islets is caused at least in part by 
reduced insulin content.  
Irp2 deficiency in mice is associated with destabilization of TfR1 mRNA and 
derepression of ferritin synthesis that causes abnormal iron content in tissues such as 
brain, liver, intestine, and red cells (Cooperman et al., 2005; Galy et al., 2005b; LaVaute 
et al., 2001; Zumbrennen-Bullough et al., 2014).  We thus assessed the consequence of 
Irp2 deficiency on iron content, and ferritin and TfR1 expression in WT and Irp2-/- islets.  
Total iron content was reduced by 47% in Irp2-/- islets compared to WT islets, while the 
content of Cu, Mn, and Zn was unaffected.  Western blot analysis showed increased 
ferritin and reduced TfR1 expression in Irp2-/- islets compared to WT islets, while Irp1 
levels were unaffected (Figure 5.5A). Consistent with reduced TfR1 protein levels, TfR1 
mRNA levels were also downregulated in Irp2-/- islets (Figure 5.5B).  Ftl1 mRNA levels 
were unchanged in Irp2-/- islets, although Fth1 mRNA levels were unexpectedly 
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decreased, suggesting a transcriptional response to low iron levels (Figure 5.5B).  We 
also assessed divalent metal transporter 1 (Dmt1) mRNA levels as it contains a 3’-IRE 
and its increased expression in mouse β cells causes iron overload (Hansen et al., 2012).  
Dmt1 mRNA levels were unchanged in Irp2-/- islets, suggesting that reduced iron content 
in Irp2-/- islets was not due to Dmt1-dependent iron uptake (Figure 5.5B).  
Consistent with western blot analysis, immunofluorescence studies revealed 
prominent costaining of ferritin with insulin in Irp2-/- β cells and reduced TfR1 staining 
compared to WT β cells (Figure 5.5C and 5.5D).  These results showed that loss of Irp2 
leads to reduced TfR1 expression and iron uptake, and increased ferritin expression and 
iron sequestration, which in turn, leads to functional cellular iron deficiency.    
The role of Irp2 in insulin production and secretion was further studied in the rat 
insulinoma cell line INS1 832/13 depleted of Irp2 by stable expression of a shIrp2 RNA.  
Western blot analysis confirmed reduced Irp2 expression, concomitant increased ferritin 
and a modest reduction in TfR1 levels compared to cells expressing empty vector (EV) 
(Figure 5.6A).  Treatment of cells with the iron chelator desferrioxamine (DFO) 
stabilized Irp2 and reduced ferritin levels, while ferric ammonium citrate (FAC) reduced 
Irp2 levels and increased ferritin levels in both EV and shIrp2 cells (Figure 5.6A), as 
previously reported for other cell types (Salahudeen and Bruick, 2009; Vashisht et al., 
2009).  Irp2 RNA-binding activity, as assessed by RNA electrophoretic mobility shift 
assays (RNA-EMSA), was reduced in shIrp2 cells, whereas Irp1 RNA-binding activity 
increased consistent with reduced iron in these cells (Figure 5.6B-C).  In agreement with 
Irp2-/- islets studies, shIrp2-INS1 cells displayed reduced insulin content, increased 
proinsulin content and impaired GSIS compared to EV cells (Figure 5.6D-F).  In 
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addition, glucose-stimulated proinsulin secretion increased by ~ 2-fold in shIrp2-INS1 
cells compared to EV cells (Figure 5.6G).  These results showed that shIrp2-INS1 cells 
recapitulate the abnormal proinsulin phenotype observed in Irp2-/- islets and that the 
proinsulin processing defect is likely in part cell-autonomous.  
We next questioned whether iron supplementation normalizes proinsulin and 
insulin content, and insulin and proinsulin secretion in shIrp2-INS1 cells. FAC increased 
insulin and proinsulin content, and glucose-stimulated insulin and proinsulin secretion in 
shIrp2-INS1 cells to levels observed in EV cells (Figure 5.6D-G).  When the amount of 
secreted insulin was normalized to insulin content, the increase in secretion seemed to 
result mostly, but not completely, from reduced insulin content. Collectively, our data 
showed that iron is required for normal insulin production and secretion from β cells.   
Iron is required for the mitochondrial synthesis of Fe-S clusters that are cofactors 
for the electron transport complexes I, II, and III and for the TCA enzyme aconitase 
within mitochondria, as well as for the maturation of nuclear and cytoplasmic Fe-S 
proteins (Netz et al., 2014).  Previous studies have shown that complex I, II, and III 
activities are reduced in neurons of Irp2-/- mice (Jeong et al., 2011) and is associated with 
mitochondrial dysfunction.  We therefore assessed Fe-S biosynthesis in shIrp2-INS1 cells 
by measuring complex I activity (contains eight Fe-S clusters), complex IV activity 
(lacks Fe-S clusters but contains heme), and mitochondrial and cytosolic aconitases (each 
contain one Fe-S cluster).  Complex I activity was reduced by 33% in shIrp2-INS1 cells 
compared to EV cells, while complex IV activity was unchanged (Figure 5.7A and B).  
FAC supplementation restored complex I activity in shIrp2-INS1 cells to levels in EV 
cells (Figure 5.7A).  Mitochondrial and cytosolic aconitase activities were also reduced in 
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shIrp2-INS1 cells (Figure 5.7C).  The reduction in cytosolic aconitase activity is 
consistent with increased Irp1 RNA-binding activity in shIrp2-INS1 cells (Figure 5.7C 
and Figure 5.6B). We also assessed the abundance of the extramitochondrial Fe-S 
proteins Cisd1 (MitoNEET) and Cisd2 (Naf-1, Miner1) in EV and shIrp2-INS1 cells 
treated with FAC or DFO (Figure 5.7D). Cisd1 is a mitochondrial outer membrane 
protein that is destabilized in HeLa cells after treatment with iron chelators (Ferecatu et 
al., 2014), while Cisd2 is predominately localized to the ER membrane with the Fe-S 
cluster facing the cytoplasm (Wiley et al., 2013). Cisd1 and Cisd2 levels were reduced in 
shIrp2-INS1 cells, and were further reduced in shIrp2-INS1 cells treated with DFO.  
Cisd1 and Cisd2 levels were restored in shIrp2-INS1 cells to EV levels (Figure 5.7D).  
These results suggested that iron deficiency due to loss of Irp2 impairs Fe-S biosynthesis 
as evidenced by reduced activity or levels of mitochondrial and extramitochondrial Fe-S 
proteins.   
Reduced activity of mitochondrial respiratory complexes and the TCA enzymes 
can lead to energy deficiency and increase reactive oxygen species (ROS) production 
(REF). To determine whether changes in Fe-S protein activity or levels are associated 
with changes in energy production, ATP content was assessed in EV and shIr2p-INS1 
cells. Cellular ATP content was reduced by 50% in shIrp2-INS1 cells compared to EV 
cells (Figure 5.7E).  Basal ROS levels as measured by the cell-permeable indicator 
carboxy-H2DCFDA fluorescence were similar in EV and shIrp2-INS1 cells, but were 
elevated in shIrp2-INS1 cells after exposure to H2O2 (Figure 5.7F), indicating that shIrp2-





Our lab has shown that Irp2-/- mice develop fasting hyperglycemia and glucose 
intolerance in addition to perturbations in iron homeostasis that results in microcytic 
anemia and protoporphyria, which are consistent with other models of IRP2 deficiency.  
The link between iron homeostasis and diabetes mellitus is well established.  Individuals 
with the iron overload disorder hemochromatosis are prime examples of this association 
(Fleming and Ponka, 2012).  Increased bodily iron stores and elevated serum ferritin in 
these individuals are risk factors for the development of T2D.  The mechanisms that 
account for T2D risk in cases of excess iron are not fully understood, but likely involve 
peripheral insulin resistance and β-cell damage from increased oxygen radicals.   In 
contrast, little is known about glucose metabolism and iron deficiency.  The prevalence 
of iron deficiency in obesity is considerably high compared to individuals with a normal 
body mass index, and obesity is the number one risk factor for T2D (Jehn et al., 2004).   
Irp2-/- mice exhibit reduced GSIS as a consequence of pancreatic insulin 
deficiency.  Low insulin levels are associated with elevated proinsulin, which suggests a 
defect within the biogenesis of insulin.  Studies that perturb processing enzymes, ER 
homeostasis, and Zn2+ transport (required for insulin hexamer formation in golgi vesicles) 
have resulted in reduced mature insulin and accumulation of proinsulin.  The mechanisms 
in these studies are somewhat obvious due to known functions of mutated genes, however 
our case is not as straightforward.  There is no apparent reduction in prohormone 
convertase levels or ultrastructural defects of the ER.    
IRP2 knockdown in INS-1 β-cells recapitulates the insulin defects seen in Irp2-/- 
mice, in addition to reduced Complex 1 activity and ATP content.  Our data showing 
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reduced activity or levels of Fe-S cluster containing proteins; Complex I, CISD1, CISD2, 
and IRP1 support a model of defective Fe-S cluster biogenesis or transfer of Fe-S clusters 
into apo-proteins.  Given that iron supplementation can rescue the insulin defect in 
shIRP2 INS-1 β-cells, we conclude that cellular iron deficiency due to loss of IRP2 
results in a reduction of Fe-S clusters.   
This poses an important question.  What role do Fe-S clusters play in diabetes, 
and how would reduced Fe-S cluster biogenesis affect insulin processing?  Insight into 
these questions comes from studies of the Fe-S cluster assembly protein Frataxin.  
Mutations in frataxin cause the neurodegenerative disorder Friedrich’s Ataxia (FA) that is 
marked by abnormal gait, scoliosis, heart disease, and diabetes.  Mice with β-cell specific 
deletion of Frataxin are glucose intolerant and develop diabetes (Ristow et al., 2003).  
This was a consequence of increased ROS and loss of β-cell mass due to apoptosis.   In 
our model however, we did not observe any loss of β-cell mass and no substantial 
elevation in ROS even though there appears to be increased sensitivity to oxidative stress. 
Another Fe-S cluster containing protein has been associated with diabetes.   Cdk5 
regulatory associated protein 1-like 1 (CDKAL1) is one of the most reproducible genes 
linked to diabetes across ethnic populations, and encodes a mammalian 
methylthiotransferase (Dehwah et al., 2010).  CDKAL1 is responsible for the addition of 
2-methylthio-N6-threonylcarbamoyladenosine (ms2t6A) to tRNALys (UUU) that is 
required for proper translation of AAA and AAG codons.  Mice with β-cell specific 
deletion of CDKAL1 have reduced insulin secretion and become glucose intolerant (Wei 
et al., 2011).  This study showed that β-cells in these mice fail to correctly translate 
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proinsulin that results in inability to recognize the C-peptide and A-chain cleavage site.  
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Figure 5.1.  Fasting hyperglycemia and glucose intolerance in Irp2-/- mice  
(A) Glucose tolerance test for 5-month old male WT and Irp2-/- mice.  Glucose area 
under the curve (AUC) calculated from ipGTTs performed in WT and Irp2-/- mice at ages 
2-, 5-, 12- and 18-months.  (B) Plasma glucose concentrations of fasted Irp2-/- and WT 
mice. Data are expressed as means ± SEM and were compared by two-tailed Student’s t-
test. *p < 0.05, **p < 0.01, ***p < 0.001 relative to WT mice.  Number of mice is 




































































Figure 5.2. Glucose intolerance in Irp2-/- mice is not due to impaired peripheral and 
hepatic insulin action .  (A) Insulin tolerance tests were performed in random-fed 5-
month old male WT and Irp2-/- mice. Glucose AUC calculated from ITT is shown.  (B) 
Percent body mass, (C) glucose infusion rate, peripheral glucose utilization rate , (D) 
insulin-mediated suppression of hepatic glucose production, (E) whole body glucose 
turnover and (F) whole body glycolysis from euglycemic-hyperinsulinemic clamp 
experiments conducted in fasted 7-month old male WT and Irp2-/- mice. Data are 
expressed as means ± SEM and were compared by two-tailed Student’s t-test.  *p < 0.05 



















































































































































































Figure 5.3. Impaired glucose-induced insulin secretion in Irp2-/- mice in vivo.  
Hyperglycemic clamps were performed in 7-month old, fasted male WT and Irp2-/- mice. 
(A) Glucose and (B) insulin levels were measured at the indicated times. (C) Insulin AUC 
corresponding to the first phase (5 min and 7.5 min) and second phase (60-110 min) of 
insulin secretion are shown. Data are expressed as means ± SEM and were compared by 


















































































Figure 5.4.  Accumulation of pancreatic proinsulin is associated with reduced insulin 
content and secretion in Irp2-/- islets,  (A) Pancreatic insulin and (B) proinsulin content 
and (C) proinsulin-to-insulin ratio (P/I) in 2.5-, 6.5- and 18-month old WT and Irp2-/- 
mice.  (D) qRT-PCR analysis shows no difference in Ins1 and Ins2 expression in islets 
from 10-month old WT and Irp2-/- mice. Values were normalized to β-actin mRNA and 
are expressed as fold change relative to WT.  (E) Quantification of islet area and (F) β 
cell mass in insulin-stained paraffin-embedded pancreatic sections from 2.5-, 7.5- and 18-
month old WT and Irp2-/- mice.  Mass was calculated by multiplying the fraction of 
insulin-positive β cell area by pancreatic wet weight.  Total insulin content (G), 
proinsulin content (H) and (I) proinsulin-to-insulin ratio quantified in islets from 7.5-
month old WT and Irp2-/- mice. (J) Static incubation of islets from WT and Irp2-/- mice 
under basal (2.5 mM) glucose followed by stimulation with high (16.7 mM) glucose for 1 
h and normalized to total islet protein. (K) Insulin secretion in (J) was normalized to total 
islet insulin content. Insulin and proinsulin content were assayed using ELISAs and 
normalized to total pancreatic or total islet protein. Data are means ± SEM and were 
compared by two-tailed Student’s t-test; *p < 0.05, **p < 0.01 and ***p < 0.001. Number 
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Figure 5.5.  Dysregulated iron metabolism in Irp2-/- islets.  (A) Western blot analysis 
shows IRP2, IRP1, ferritin and TFR1 levels in islets isolated from 8-month old WT and 
Irp2-/- mice (n = 3 mice per genotype). β-actin is a loading control.  (B) qRT-PCR of 
Ftl1, Fth1, Tfr1 and Dmt1 in WT and Irp2-/- islets.  The Dmt1 TaqMan assay detects both 
-IRE and +IRE Dmt1 mRNA variants. Values were normalized to β-actin mRNA and 
expressed as relative fold change to WT (n = 6 mice per genotype).  Data are expressed 
as mean ± SEM and were compared using two-tailed Student’s t-test.  *p < 0.05, ***p < 
0.001.  (C and D) Paraffin-embedded pancreatic sections from 8-month old WT and Irp2-
/- mice were immunostained with antibodies to ferritin (green) or TfR1 (green) and 
costained with insulin antibodies (red). The insulin antibody detects both insulin and 
proinsulin. Nuclei are stained with DAPI (blue).  Arrows in D show β cells costained 
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Figure 5.6.  Iron improves insulin content and secretion in Irp2 deficient INS1 β-cells.  
(A) Western blot analysis of IRP2, ferritin and TFR1 levels in INS1 832/13 insulinoma 
cells expressing a shIrp2 or empty vector (-).  Cells were grown with or without DFO (50 
uM) or FAC (50 ug/ml) for 18 h. β-actin is a loading control.  (B) EV- and shIrp2-INS1 
cell lysates were analyzed by RNA-EMSA using a 32P-labeled ferritin-IRE. Irp1- and 
Irp2-RNA complexes are indicated. (C) Cellular labile iron pool in EV- and shIrp2-INS1 
cells measured by the calcein method.  (D) Total insulin content and (E) proinsulin 
content in EV and shIrp2-INS1 cells grown with or without FAC.  F) Glucose-stimulated 
insulin and (G) proinsulin secretion in EV- and shIrp2-INS1 cells grown with our without 
FAC. Insulin and proinsulin were assayed in cells under low (5 mM) glucose and after 
stimulation with high (15 mM) glucose for 1 h and were normalized to total cellular 
protein. (H) Insulin and (I) proinsulin secretion in F and G normalized to total insulin 
content or proinsulin content.  The assays in (C-I) were performed in triplicate from three 
independent experiments.  Data are expressed as means ± SEM and were compared by 
two-tailed Student’s t-test or two-way ANOVA.  *p< 0.05; **p < 0.01; ***p < 0.001; 
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Figure 5.7.  Cellular iron deficiency reduces the activity or abundance of Fe-S proteins in 
Irp2 deficient INS1 β-cells.  (A) Complex I activity in lysates from EV and shIrp2-INS1 
cells in the presence of FAC (50 ug/ml) for 18 h normalized to total lysate protein. (B) 
Complex IV activity in EV- and shIrp2-INS1 cell lysates normalized to total protein 
content. (C) Cytosolic and m-aconitase activity in EV and shIrp2-INS1 cells normalized 
to total lysate protein. Western blot analysis shows enrichment of c-aconitase (Irp1) and 
m-aconitase in cytosolic and mitochondrial fractions, respectively. (D) Western blot 
analysis of the Fe-S proteins CISD1 and CISD2 in EV- and shIrp2-INS1 cell lysates 
grown in DFO (50 uM) or FAC (50 ug/ml) for 18 h. Irp2 and β-actin are shown.  (E) ATP 
content was measured in lysates of EV and shIrp2-INS1 cells grown in the presence of 
FAC for 18 h and normalized to total protein. (F) Accumulation of basal ROS levels over 










































































































































Figure S5.1.  Glucose intolerance in female WT and Irp2-/- mice.  Glucose tolerance tests 
were performed on female (A) 10-week-old and (B) 20-week-old WT and Irp2-/- mice. 
Glucose AUC for the data are shown.  Data are expressed as mean ± SEM and compared 











































































Figure S5.2.  Islet morphology and glucagon expression is normal in Irp2-/- mice.  
Paraffin-embedded pancreatic sections from 12-month-old WT and Irp2-/- mice (n = 3 
mice per genotype) were costained with antibodies to insulin (red) and glucagon (green).  







Figure S2.  Glucagon and insulin staining of islets 






Figure S5.3. Glut2 expression and localization in Irp2-/- islets.  Immunostaining of 
paraffin-embedded pancreatic sections from 7.5-month old WT and Irp2-/- mice (n = 3 
mice per genotype) using Glut2 antibodies (green) revealed no difference in Glut2 
expression or subcellular localization in Irp2-/- mice. This suggests that processing of a 
membrane localized protein that is process in the secretory compartment is normal in 









Paraffin-embedded pancreatic sections from 7.5-month-old WT and Irp2-/-mice (n=3 
mice/genotype) were stained with Glut2 antibodies (green).  Nuclear DNA was detected 
by DAPI stain (blue).  No change in Glut2 expression levels or subcellular localization 
was observed in Irp2-/- islets




Figure S5.4. Gene expression analysis of HIF-1 targets in Irp2-/- islets.  qRT-PCR 
analysis of HIF-1 transcriptional targets from 7.5-month old WT and Irp2-/- mice (n = 3 
mice per genotype) using Taqman Gene Expression probes for the indicated targets.  Data 
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 The dual nature of iron has far reaching implications in both healthy and 
pathological states.  In this regard, organisms have evolved elaborate mechanisms to 
maintain iron levels within a physiological window that is optimal for life.  Importantly, 
these mechanisms are highly conserved throughout Metazoa, underscoring the 
importance of regulating iron homeostasis.  Defective iron regulation can have drastic 
health consequences ranging from iron deficient anemia to severe organ failure from the 
iron overload disease hemochromatosis.  In this dissertation, we used two distinct models 
to study mechanisms of iron homeostasis to better understand the role of iron and its 
regulation in key biological processes.   
 In the nematode C. elegans, we discovered a novel pathway that integrates 
nuclear receptor and insulin signaling to regulate intestinal iron uptake that is important 
for the innate immune response.  Using a suppressor screen that rescued growth in low 
iron conditions we identified NHR-14 to be a potent inhibitor of iron import through the 
iron importer SMF-3.  The mechanism by which this occurs relies on the nuclear 
localization of the newly identified transcription factor PQM-1.  Specifically, we found 
that NHR-14 prevents nuclear localization of PQM-1 resulting in its cytoplasmic 
retention.  Mutant worms lacking NHR-14 have significantly more PQM-1 localized to 
the nucleus, thus causing drastic changes in gene expression.  Importantly, smf-3 
expression is highly induced in these mutants in a manner that is partially dependent on 
PQM-1.  Future studies will need to address the molecular mechanisms behind the 
regulation of PQM-1 by NHR-14.  Specifically how NHR-14 inhibits nuclear localization 
of PQM-1.  Protein-protein interactions, posttranslational modifications, and indirect 
transcriptional regulation are all reasonable hypotheses.   
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In addition to increased iron uptake, these mutants have a primed innate immune 
response that enhances resistance to the pathogens Pseudomonas aeruginosa and 
Salmonella enterica.  This response consists of the upregulation of numerous genes 
involved in the C. elegans immune response.  Among this repertoire, we consider smf-3 
regulation a critical component of innate immunity by regulating iron availablitly.  This is 
a significant finding in the context of nutritional immunity and the molecular arms race 
between host and pathogen to aquire or sequesters iron.  Given that NHR-14 is rapidly 
degraded in response to bacterial infection suggests a novel pathway used to sense and 
respond to pathogens.  It is an interesting possibility that NHR-14 senses pathogen 
associated molecular patterns through its ligand-binding domain to initiate a cascade of 
events that ends with a robust transcriptional immune response.      
 We also identified NHR-14 to be a homolog of the mammalian HNF4α, a 
transcription factor that is critical for development and many metabolic processes.  
Similar to what we observed in C. elegans, mice lacking HNF4α specifically in intestinal 
cells had a significant increase in the expression of the mammalian iron importer DMT-1.  
Considering the importance of HNF4α in the development and function of the intestine, 
combined with its associated risk in chronic inflammatory diseases, it is interesting to 
speculate potential therapeutic interventions that focus on iron management.  Signifcant 
evidence has also emerged highlighting the importance of the gut microbiome for proper 
intestinal function.  Recent data have shown that oral iron administration to combat 
anemia in infants adversely affects the gut microbiome, leading to enhanced pathogen 
colonization and intestinal inflammation.  Whether HNF4α plays a role in regulating iron 
bioavailabilty for the gut microbiome remains to be determined.      
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 This dissertation also examines the role of IRP2 in pancreatic β-cell function and 
its impact on whole body glucose metabolism.  We observed that mice lacking IRP2 have 
impaired glucose homeostasis that is highlighted by fasting hyperglycemia and 
hypoinsulinemia reminiscent of type 1 diabetes.  Cellular iron homeostasis in β-cells of 
these mice is defective rendering them functionally iron deficient.  Notably, iron uptake 
by TfR1 is significantly reduced while iron storage by ferritin is elevated.  We found that 
hypoinsulinemia is associated with an accumulation of proinsulin, suggesting a defect in 
the insulin biosynthesis pathway.  Given that we could rescue this defect in a clonal β-cell 
model by increasing iron levels provides strong evidence that insulin processing is iron-
dependent.  
 Insulin production and secretion are the primary functions of pancreatic β-cells, 
and these processes rely heavily upon healthy mitochondria and ER function.  We found 
that IRP2 deficient β-cells have defective mitochondria characterized by a reduction in 
Complex 1 activity and total ATP levels.  Similarly we found these cells to have 
increased ER stress that is associated with sensitivity to reactive oxygen species.  It has 
recently become appreciated that ER function is tightly linked to Fe-S cluster 
biosynthesis in the mitochondria, such that many key ER associated proteins utilize these 
cofactors.  Here we speculate that iron deficiency in β-cells due to loss of IRP2 results in 
impaired Fe-S cluster biogenesis, negatively affecting Fe-S cluster containing proteins of 
the ER.  This disruption is likely contributes to the observed defects in insulin processing.  
These findings are significant in the context of global health, where billions of 




 deficiency and diabetes is warranted, with the potential for significant contributions to 
how we treat and manage diabetes.      
 
